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CYTOPLASMIC CYCLIN E MEDIATES RESISTANCE TO AROMATASE INHIBITORS IN 
BREAST CANCER 
 
Iman Doostan, M.D. 
Supervisory Professor: Dr. Khandan Keyomarsi, Ph.D. 
 
Almost seventy percent of patients with breast cancer have tumors that express hormone 
receptors and need hormonal therapy. Aromatase inhibitors (AIs) block estrogen 
biosynthesis and are considered as the first line hormonal therapy for ER+ post-menopausal 
patients. However, resistance to these drugs remains a major challenge in clinic and the 
biology of such resistance is not completely understood. Cyclin E is deregulated in breast 
cancer through generation of low molecular weight isoforms that renders patients to a poor 
survival. Herein, we show that HR+ patients with LMW-E expressing tumors show 
diminished early response to neo-adjuvant AIs as well as poor recurrence-free survival. In 
addition, xenografts with LMW-E expression are unresponsive to letrozole. Using LMW-E 
inducible model system, we show that LMW-E expression bypasses cell cycle inhibition of 
AIs through up-regulation of CDK2, Rb, and phospho-Rb in a reversible manner. Lastly, we 
show that LMW-E expressing breast cancer cells respond to dinaciclib but not palbociclib. 
Taken together, this study suggests that targeting CDK2 by inhibitors such as dinaciclib in 
combination with AIs is a potential therapeutic strategy for HR+ postmenopausal breast 
cancer patients with LMW-E expressing tumors.  
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CHAPTER 1: INTRODUCTION TO USE OF ANTIESTROGEN THERAPIES  
IN BREAST CANCER 
1-1 EPIDEMIOLOGY OF BREAST CANCER  
        Cancer follows cardiovascular diseases as the cause of death in the US (1). In women, 
breast cancer (BC) comprises the top site of cancer diagnosed each year excluding skin 
cancer (30% of all cancers). Lung and bronchus cancer includes only 12% of all the new 
cancer cases in women. About 252,710 of breast cancer cases are estimated in US in 2017 
(1). In addition, only lung cancer precedes breast cancer in terms of mortality from a 
malignancy in women (1). These statistics show the significance of breast cancer and 
highlight the need for new therapeutic strategies to better control this devastating disease. 
 
1-2 SUBTYPES OF BREAST CANCER AND TREATMENT OPTIONS  
        Breast cancer is a heterogeneous disease. Historically, breast cancer was classified 
according to the histopathology of the tumor. Staining of breast cancer tissue samples for 
estrogen, progesterone, and Her-2 receptors was the mainstay for this type of classification. 
Based on the positivity of each receptor, breast cancer is divided into four subtypes, i.e., 
hormone receptor positive (express ER or PR but lack Her-2), hormone and Her-2 positive 
(express both ER/PR and Her-2), Her-2 positive (express Her-2 but not ER/PR) and triple 
negative (deficient in three receptors, also called basal like) (2, 3). Perou and colleagues 
used cDNA microarray analysis to examine gene expression profile of normal and tumor 
tissues from 42 individuals (including breast cancer tissues, DCIS and normal breast tissue) 
(4). Based on similarity and variation of gene expression in these samples, they identified 
four different subtypes of BC known as “ basal-like, ER positive/luminal, Erb-B2 positive, and 
normal breast subtypes” (4). Further studies suggest that such classification based on gene 
expression profile has prognostic value (5). Sotiriou et al used microarray analysis to 
examine gene expression profile of 99 breast tumors from patients (both node negative and 
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positive) with available clinical and histopathological data (5).  Hierarchical clustering of 
these tumors identified two main groups including luminal (mainly ER positive) and basal 
(mainly ER negative) with some minor subgroups including luminal subtype A, luminal 
subtype B (or possibly C), normal breast-like, and ERBB2 positive subtypes (5). Correlation 
of the subtype clustering with outcome revealed that patients with ER negative tumors 
(basal/ERBB2) relapsed earlier and had worse survival in comparison to patients with 
luminal-subtype tumors (5). Luminal A tumors express hormone receptors but lack Her-2 
and show low expression of Ki67 as proliferation marker. These tumors tend to grow slower 
and have the best prognosis of all subtypes. In contrast, luminal B subtypes, overexpress 
Her-2 receptor with high Ki67 expression, and tend to have lower survival rates compared to 
luminal A (6). Her-2 subtype is detected in younger women compared to luminal types and 
have fairly poor prognosis. Finally, tumors with basal-like gene expression profile account for 
the majority of the triple negative breast cancer (TNBC) and show aggressive behavior. In 
addition, this subtype is more prevalent in African American women and has the worst 
prognosis of all subtypes with higher tendency to relapse (7, 8). Analysis of these TNBC 
tumors reveals a heterogeneous pattern (9). Lehmann and colleagues analyzed gene 
expression profile of 386 triple negative tumors (used as training set) and 201 other TN 
tumors (used as validation set) from 21 data sets (9). They clustered these tumors according 
to differential gene expression into 6 subtypes including “mesenchymal, mesenchymal 
stem–like, immune-modulatory, luminal androgen receptor, basal-like 1, and basal-like 2 
subtypes” (9). Each distinct subtype has enrichment of specific sets of genes that can be 
clustered into specific pathways. For example, basal like 1 subtype showed enrichment of 
genes that are clustered into cell cycle and DNA replication regulatory pathways, while 
luminal androgen subtypes were enriched in androgen metabolism pathways (9). This 
suggests that although all these tumors are considered as triple negative, they rely on 
different pathways and hence individual targeted therapies could have beneficial therapeutic 
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value. As a proof of concept, the authors showed that representative cell lines for each 
subtype show better response to specific molecularly targeted therapy (9). For example, cell 
lines representative of luminal androgen subtype expressed higher androgen receptor both 
at mRNA and protein level and these cell lines responded to a lower dose of bicalutamide 
(androgen receptor antagonist) (9). Novel therapeutic approaches using targeted therapies 
in triple negative population of breast cancer are discussed in further detail in this section.  
 
1-2a Hormone receptor positive breast cancer and treatment options 
        Hormonal therapies are the main treatment strategies for HR+ cancer subtypes (10). In 
early stage hormone receptor positive patients, it is necessary is to recognize patients with 
low possibility of recurrence in order to avoid the use of aggressive treatments such as 
chemotherapy in this subpopulation. Genomic tools that measure gene expression profiles 
with the goal to estimate the benefit of adding chemotherapy to anti-hormonal therapies are 
now commonly incorporated into decision-making regarding selection of treatment for HR+ 
breast cancer patients. Mammaprint and Oncotype DX are examples of these tools that 
have been validated for estimation of recurrence of breast cancer (11, 12). Using gene 
expression profile, van 't Veer and colleagues identified a signature of poor prognosis in 
early stage breast cancer patients (T1 or T2 and N0) (13). The authors performed 
microarray analysis on 98 tumors from early stage patients and identified a 70-gene 
signature that significantly correlated with 5-year breast cancer relapse (13). Patients with 
poor prognosis signature showed up-regulation of genes that play role in biologic processes 
such as angiogenesis, invasion and metastasis (13). In this dataset, tumors marked as poor 
prognosis signature had 28-fold higher change of metastasis within 5-year in comparison to 
tumors with good prognosis signature (13). The same team incorporated this 70-gene 
signature in prognostication of 295 stage I/II breast cancer patients including both ER+/ER- 
patients with or without lymph node involvement (11). Results from this study revealed 10-
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year survival rate of 94.5% (±2.6%) in patients who were considered “good-prognosis” 
based on the gene expression signature (11). In contrast, only 54.6% (±4.4%) of patients 
with poor-prognosis signature survived within the same period of time. In addition, patients 
with poor-prognosis signature had approximately five times higher chance of metastasis 
compared to ones with good-prognosis signature (11). This suggests that gene expression 
profiles of the initial tumor can inform about the possibility of metastasis during the course of 
disease progression. In a similar study, the authors examined the correlation between gene 
expression and recurrence in 668 node negative ER+ patients who underwent tamoxifen 
treatment (12, 14). RT-PCR was performed on paraffin embedded tissue samples to 
measure expression of 21 cancer related genes (OncotypeDX) including genes involved in 
proliferation (Ki67, CCNB1 expressing cyclin B1), invasion (matrix metallopeptidase 11), 
hormone receptors (ER and PR) and Her-2 to mention a few. They classified patients 
according to the score of gene expression into low-risk, intermediate-risk, or high-risk group 
(12). Statistical analysis showed that 51% of patients were considered as low-risk and only 
6.8% of these patients had distant recurrence within 10 years. This recurrence rate was 
significantly lower compared to 30.5% recurrence in the high-risk category (12). Taken 
together, these studies show that molecular profile of the tumor at early stage is a valuable 
tool for estimation of prognosis in the early stage cancer and thus avoid aggressive 
treatment such as chemotherapy in patients who will not benefit from such treatment. 
        Generally, in the early stage disease, hormone receptor positive patients will receive 
anti-estrogen therapy either tamoxifen for premenopausal or aromatase inhibitors in the 
post-menopausal settings for five years (15). However, a few studies propose longer 
treatment regimens in these patients. For example, a double-blind study examined the 
extension of treatment using letrozole in patients who have finished five-year tamoxifen 
treatment. The results showed improved disease-free survival by 48% in the letrozole arm 
compared to placebo control group (16). Similarly, extension of tamoxifen therapy after five 
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years in premenopausal patients significantly reduced recurrence and mortality from breast 
cancer (17). However, this benefit should be balanced against the expected side effects 
from anti-hormonal therapy such as enhanced risk of endometrial cancer using tamoxifen 
and joint pain and fracture with aromatase inhibitors (16, 17). Besides hormonal therapies, 
bisphosphonates have shown beneficial effects in breast cancer patients (18, 19). 
Bisphosphonates inhibit the activity of osteoclasts and decrease bone resorption (20). In 
addition, studies have shown that bisphosphonates have anti-tumor activity by inhibition of 
adhesion molecules (21), exert anti-proliferative activity (22), and show pro-apoptotic activity 
(23). A meta-analysis of bisphosphonates in breast cancer patients showed that 
bisphosphonates not only decrease bone recurrence of breast cancer but also improve 
outcome in the post-menopausal patients (24). In contrast to early stage disease, patients 
with advanced disease often show inherent (de novo) resistance to anti-estrogen treatments 
or advance in spite of early initial response (25). In these situations, addition of other 
treatment options such as inhibitors of cyclin dependent kinase 4/6 is needed (See section 
cyclin D and CDK4/6 inhibitors in breast cancer). Fulvestrant, which down-regulates and 
inhibits ER protein (26), is often used in the metastatic setting alone or in combination with 
other hormonal therapies.  
 
1-2b HER-2 positive breast cancer and treatment options 
        Approximately one fifth of breast cancer patients overexpress the Her-2 receptor (27). 
Her-2 is a trans-membrane receptor and part of the EGFR family that can be overexpressed 
or amplified in breast cancer (28). Therapies targeting the HER2 pathway are currently used 
in the early stage as well as advanced stage of the disease and have improved survival of 
Her-2 positive breast cancer patients (29). These inhibitors of the pathway include herceptin, 
lapatinib, pertuzumab and T-DM1 (30, 31). Trastuzumab (herceptin) is an antibody that can 
recognize and inhibit Her-2 receptor by binding to the extracellular portion of the receptor 
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(Figure 1). Clinical trials using the combination of trastuzumab and chemotherapy showed 
that addition of trastuzumab to chemotherapy delayed progression of breast cancer by 
approximately three months in patients with metastatic disease who overexpress Her-2. In 
this study, half of the 235 patients who received combination of chemotherapy and herceptin 
showed objective response versus only 32% in the chemotherapy alone group (32). Similar 
to other therapies, resistance to herceptin develops overtime limiting its benefit (33). One 
such mechanism of resistance is the loss of the extracellular domain of the receptor such 
that the receptor can not be detected and inhibited by the antibody (34). Another possible 
mechanism of resistance to herceptin is the heterodimer complex formation between Her-2 
and Her-3 receptors (35, 36). Clinically, Her-3 expression is detected in a subset of Her-2 
expressing breast cancer tumors and overexpression of both receptors is linked with poor 
survival (37). Mechanistically, this dimerization process results in continued tyrosine kinase 
activity of the intracellular domain of the receptor in spite of herceptin treatment leading to 
activation of downstream signaling pathways (36). Pertuzumab is another monoclonal 
antibody capable to bind to extracellular domain of Her-2 but at a different site compared to 
herceptin. Unlike herceptin, pertuzumab prevents the dimerization between Her-2/Her-3 
(38). Preclinical models showed additional antitumor activity of pertuzumab in combination 
with herceptin suggesting the complementary action of these two antibodies (39). A phase 
III trial in Her-2 positive metastatic breast cancer patients showed that addition of 
pertuzumab to herceptin and docetaxel is an effective combination strategy to be used as 
first line treatment (40, 41). Another class of Her-2 receptor targeting drugs is tyrosine 
kinase inhibitor lapatinib. Since lapatinib blocks the intracellular domain of the receptor, any 
modification of the extracellular domain can still be inhibited by the drug (42). Therefore, it is 
predicted to be effective in breast cancer tumors resistant to herceptin (43). Combination of 
lapatinib with trastuzumab in an in vivo model showed enhanced antitumor activity 
compared to individual drugs (44). Another class of Her-2 targeting drug isTDM-1, which 
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consists of two components, emtansine (a microtubule inhibitor) linked to trastuzumab. Her-
2 positive cancer cells are recognized by the Her-2 antibody resulting in uptake and release 
of the chemotherapy drug only in the cancer cells while sparing the normal cells.  A 
preclinical model using the combination of pertuzumab and T-DM1 showed enhanced anti-
proliferative effect in vitro and prolonged control of tumor volume in vivo (45).   
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Figure 1. Anti-Her-2 targeted therapies in breast cancer.  Her-2 is a member of the 
EGFR tyrosine kinase receptor that can activate intracellular transduction pathways such as 
PI3K and MAPK resulting in proliferation and survival of breast cancer cells. Trastuzumab 
(herceptin) and pertuzumab block Her-2 by recognizing the extracellular domain the 
receptor. Lapatinib binds to intracellular domain and inhibit the tyrosine kinase activity of the 
receptor. TDM1 is composed of trastuzumab (antibody) and emtansine (cytotoxic). 
Emtansine is released inside the cells when herceptin binds to Her-2 receptor on the surface 
of breast cancer cells. 
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1-2c Triple negative breast cancer and treatment options 
        Fifteen to twenty percent of all breast cancers have tumors without expression of ER, 
PR and HER-2, considered as triple negative breast cancer (TNBC). Therefore, anti-
estrogen and Her-2 targeting drugs are ineffective in this subpopulation while chemotherapy 
is the major therapeutic option for these patients (46). TNBC patients have the worst 
prognosis among all breast cancer patients (7, 47). However, these tumors tend to respond 
better to chemotherapies compared to hormone receptor positive tumors in the short term 
(48). Lymph node positive TNBC patients will require chemotherapy to control the disease. 
Generally, these patients are treated with adjuvant chemotherapy using taxanes and 
anthracyclines (7). Retrospective studies have compared these regimens in different 
settings. As an example, a randomized trial including early stage node positive breast 
cancer patients showed that a regimen including cyclophosphamide, epirubicin and 
fluorouracil (CEF) is superior to cyclophosphamide, methotrexate and fluorouracil (CMF). 
Follow up for 10 years showed that CEF regimen increased relapse-free survival in 
comparison to CMF regimen, 52% versus 45%, respectively (49). TNBC patients who did 
not achieve complete eradiation of tumors in their breast and axilla (pathologic complete 
response) after chemotherapy have higher relapse rate. In contrast, TNBC patients with a 
small tumor (less than 0.5 cm) without lymph node involvement have very good prognosis 
and may not benefit much from chemotherapy. Cytotoxic chemotherapy remains the 
mainstay treatment in advanced TNBC patients. There is a great interest in the use of novel 
targeted therapies in the metastatic settings as described in the next paragraphs (50-52). 
        Poly ADP ribose polymerase (PARP) inhibitors are examples of such targeted 
therapies that have been investigated in recent years in patients harboring TNBC tumors 
with BRCA1/BRCA 2 mutations. BRCA-1 mutation is detected in about 10-15% of TNBC 
patients and is associated with high-grade tumor and basal like subtype (53). Germline 
inheritance of a mutation in the BRCA1 or BRCA2 genes increases the risk of breast and 
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ovarian cancer, in a cancer predisposition syndrome known as hereditary breast and 
ovarian cancer syndrome (54, 55) and increases oncogenesis in contralateral breast (56). 
Sixty percent of individuals having BRCA1 mutation and 55% of those harboring BRCA2 
mutation are expected to have breast cancer by the age 70 (56). BRCA1 codes for a protein 
with tumor suppressive function that is involved in DNA repair particularly the homologous 
recombination pathway (57). Brca1−/− cells were not capable of activating the double strand 
break repair mechanisms indicating the important role for BRCA1 function in suppressing 
tumorigenesis (57). PARPs are a family of proteins with conserved domains that are able to 
bind to DNA at the site of single-strand breaks and recruit other enzymes that play critical 
role in DNA repair (58, 59). PARP-deficient mice are very susceptible to DNA damaging 
agents and are prone to genomic instability (60). Most xenografts derived from BRCA2-
deficient cell lines responded to PARP inhibitor (AG14361) as a single agent suggesting that 
PARP inhibitors are beneficial in BRCA mutant breast cancer patients (61, 62). Similarly, 
PARP inhibitors induce genomic instability, apoptosis, and synthetic lethality in cell lines 
deficient in BRCA1/2 repair pathway (63). Further preclinical work using the Brca1−/−, 
p53−/− mouse model (representing TNBC tumors) shows that BRCA deficient tumors 
respond to PARP inhibitor (64). In this model, breast cancer tumors generated in Brca1−/−, 
p53−/− were implanted in wild type mice and treated with vehicle, PARP inhibitor 
(AZD2281), cisplatin, or combination of both drugs (64). Results revealed the arm that 
received PARP inhibitor showed improved survival compared to vehicle treated arm. 
Moreover, the best survival curve was detected in the arm that received combination of 
PARP inhibitor with cisplatin suggesting synthetic lethality (64). PARP inhibitor (olaparib) 
was shown to have therapeutic benefit in BC patients with advanced recurrent disease who 
harbor mutation in BRCA1 or BRCA2 (65). Patients were selected to receive two different 
doses of olaparib, high dose (400 mg two times a day) or low dose (100 mg two times a 
day) (65). Forty one percent of patients who received high dose and 22% of those with low 
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dose of olaparib showed objective response (65). The most common adverse effects 
included fatigue, nausea, and anemia (65). In addition, combination of PARP inhibitor with 
standard chemotherapy is beneficial for TNBC patients (50). Addition of PARP inhibitor 
(veliparib) plus carboplatin to standard neoadjuvant chemotherapy doubled the rate of 
pathologic complete response, 52% vs 26% respectively (50). Taken together, these 
preclinical and clinical studies show that targeting DNA damage repair pathways using 
PARP inhibitors is an important treatment strategy in TNBC patients.  
        Besides from PARP inhibitors, other strategies such as blocking angiogenesis and 
inhibiting cell surface receptors (such as EGFR) are under investigation in TNBC patients 
(52, 66). Immunostaining of a panel of invasive breast cancer samples revealed higher 
expression of EGFR receptor in TNBC patients compared to non-TNBC patients (67). A 
phase II study examined the efficacy of EGFR inhibitor (cetuximab) compared to 
combination of cetuximab with carboplatin in stage IV TNBC patients. Results from this 
study revealed that only 6% of patients who received cetuximab and 16% of those who 
underwent combination treatment responded to therapy (68). Examination of post-treatment 
tissue revealed that the majority of patients showed active EGFR pathway possibly through 
parallel activation (68). However, more promising results were found in another study in 
which a combination of cetuximab and cisplatin increased response rate to 20% compared 
to 10% (cisplatin arm) in metastatic TNBC patients and prolonged time to progression, but 
increased the rate of severe adverse events (52). Similarly, using quantitative immunoassay 
higher level of VEGF is detected in tumor specimens of TNBC patients compared to non-
TNBC patients suggesting significance of VEGF in TNBC patients (69). Vascular endothelial 
growth factor (VEGF) is a strong stimulator of new blood vessel formation secreted by tumor 
tissues and can be blocked by monoclonal antibodies such bevacizumab (70, 71). A phase 
III study combining bevacizumab to docetaxel in recurrent or metastatic Her2-negative 
patients showed delayed progression of breast cancer without significant addition in the 
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toxicity profile (51). In the neoadjuvant setting, bevacizumab increased the rate of pCR 
when combined with cyclophosphamide plus docetaxel regimen for TNBC patients (66). 
Taken together, these studies demonstrate that addition of targeted therapies to standard 
chemotherapy regimens in a personalized approach opens new hopes for the treatment of 
TNBC patients. 
 
1-3 ESTROGEN AND ESTROGEN RECEPTOR IN BREAST CANCER  
        The discovery of estrogen hormone goes back to almost 80 years ago by Adolf 
Butenandt when he isolated crystalized estrogen from urine of pregnant women (72). 
Nowadays, it is evident that estrogen is mainly produced by ovaries in premenopausal 
women. After menopause however, estrogen is produced by conversion of testosterone 
through the activity of the aromatase enzyme, which is present in adipose and other tissues 
(73, 74). The level of estrogen in plasma influences functions of multiple organs in the body. 
In brain, estrogen fluctuation throughout the menstrual cycle affects cognition (75). Hormone 
replacement therapy in women decreases the risk of Alzheimer disease suggesting that 
estrogen has protective role against Alzheimer (76). Moreover, estrogen treatment 
decreased depressive symptoms in post-menopausal women possibly through 
enhancement of the serotonergic activities in the brain (77). In cardiovascular system, 
estrogen regulates vascular tone, blood pressure, and decreases atherosclerosis formation 
in the vessels (78, 79). It regulates turnover of the adult bone and stimulates the growth and 
maturity of the skeletal system (80, 81). More importantly in reproductive system and breast 
tissue, estrogen stimulates proliferation of the uterus endothelium as well as mammary 
epithelial cells (82, 83). 
        Epidemiologic studies have shown a link between estrogen and breast cancer 
formation. A study by Trichopoulus and colleagues found that among 3,887 patients with 
long-term follow up, those who underwent surgical ovariectomy had lower risk of breast 
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cancer in comparison to individuals who did not undergo surgery (84). In addition, lifetime 
exposure to estrogen is associated with higher risk of tumorigenesis in breast tissue (85, 
86). In a prospective study, about 10000 women, aged 40 to 65, were included and followed 
at least once a year for any possible breast cancer diagnosis (86). Women filled out 
questionnaires regarding their age at menarche, history of pregnancies, breastfeeding and 
other information during 1990 and 1991 and updated their information annually. A total of 
1718 women were diagnosed with invasive breast cancer during the follow up of the study 
until 1997 (86). Statistical analysis revealed the correlation between total number of 
menstrual cycles in a woman’s lifetime (and before first pregnancy) and increased risk of 
breast cancer (86). Similar epidemiologic studies have indicated that premature menarche, 
late menopause, and nulliparity are linked with increased chance of developing breast 
cancer suggesting the link between estrogen and breast cancer formation (84, 85). Similar 
epidemiologic studies highlight the association between estrogen and breast cancer in 
postmenopausal women (87, 88). Misser and colleagues measured estrogen and androgen 
serum levels in 322 postmenopausal breast cancer patients and matched controls. Higher 
levels of both hormones were detected in breast cancer patients compared to controls (87). 
In a similar study, Kaaks and colleagues measured the level of different estrogen forms and 
androgen in postmenopausal women before they develop breast cancer and compared that 
to their matched controls. In their analysis, women with higher serum level of estrogens as 
well as androgens had higher rate of breast cancer formation (88).  
         Estrogen pathway is activated upon binding of the hormone with two different estrogen 
receptors known as ERα and ERβ, which are produced from two distinct genes. Estrogen 
receptor is mainly localized to the nucleus and interaction with estrogen further enriches 
nuclear localization of the receptor (89). Following interaction of these receptors with the 
ligand, they become phosphorylated and form a dimer with another receptor, translocate to 
the nucleolus, and bind to DNA to activate ER mediated gene expression (90). This is 
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considered as classical ligand-dependent process in which ER functions in concert with 
other proteins as a transcription factor. Several regulatory proteins known as coactivators 
and corepressors interact with estrogen receptor and influence gene transcription (table 1). 
In addition to this classical function, signaling pathways such as MAPK can phosphorylate 
ER receptor and activate the pathway in the absence of estrogen (91, 92). Due to significant 
role of estrogen pathway in breast cancer, different drugs have been developed and used in 
clinic to block this pathway. These anti-estrogen medications are discussed in further detail 
in the next section. 
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Table 1- Coactivators/corepressors of ERα and their role in breast and other cancers 
 
Name Coactivator 
or 
Corepressor 
Other name Comment/Role Reference 
SRC-1(steroid 
receptor 
coactivator–1) 
Coactivator  Recruits 
chromatin-
modifying 
enzymes, link to 
prognosis of 
Her2+ BC 
(93, 94) 
TIF2(transcriptional 
intermediary factor–
2) 
Coactivator GRIP1(glucocorticoid 
receptor–interacting 
protein 1) 
Fusion with MOZ 
in AML, 
coactivation of 
PR 
(95-97) 
NCO2(nuclear 
receptor coactivator 
2) 
 
Repressor of 
tamoxifen 
activity 
 Overexpressed 
in prostate 
cancer, 
translocated in 
sarcoma 
(98-100) 
AIB1(Amplified in 
Breast Cancer) 
Coactivator RAC3(receptor-
associated 
coactivator 3) 
Overexpressed, 
prognostic value 
and EMT in BC 
(101-103) 
CBP(CREB binding 
protein) 
Coactivator P300 Interact with 
BRCA and NF-
kappaB in BC, 
mutated in 
ovarian cancer 
(104-106) 
TRAP220(thyroid 
hormone receptor–
associated protein) 
Coactivator DRIP205 Link between 
ERα and RNA 
polymerase II, 
interact with 
BRCA1, cell 
cycle role 
through aurora 
kinase A 
(107-109) 
CARM1(coactivator-
associated arginine 
methyltransferase 
1) 
Coactivator PRMT4(protein 
arginine N-
methyltransferase 4) 
Overexpressed 
in BC, role in 
growth and 
metastasis of BC 
(110, 111) 
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Table 1 (continued)-coactivators/corepressors of ERα and their role in breast and 
other cancers  
Name Coactivator or 
corepressor 
Other name  Comment/role Reference 
NCoR (nuclear 
receptor 
corepressor) 
Corepressor TRAC-1 
(thyroid-
hormone- and 
retinoic-acid-
receptor-
associated co-
repressor 1) 
Represses ER 
gene 
transcription, 
recruits 
deaetylases 
(112, 113) 
hPR-A (human 
progesterone 
receptor A 
isoform) 
Corepressor  Inhibits NF-
kappaB 
signaling 
(114) 
SMRT 
(silencing 
mediator of 
retinoid and 
thyroid 
hormone 
receptors) 
Corepressor  Prevents 
stimulated 
growth by 
tamoxifen, 
regulates ERα 
induced 
transcription 
(115, 116) 
REA (repressor 
of estrogen 
action) 
Corepressor  Competes with 
SRC-1 to 
repress ERα 
transcription 
(117, 118) 
SHP (short 
heterodimer 
partner) 
Corepressor NR0B2 
(nuclear 
receptor 
subfamily 0 B2) 
Interacts with 
and inhibits ERα 
directly, 
competitive 
inhibitor of AR 
coactivators 
(119, 120) 
RIP140 
(receptor-
interacting 
protein 140) 
Corepressor NRIP1 
(Nuclear 
receptor-
interacting 
protein 1) 
(NRIP1) 
Interacts with 
HDACs, 
regulates 
activity of 
glucocorticoid 
receptor 
(121, 122) 
DAX-1 
(dosage-
sensitive sex-
reversal) 
Corepressor  Mutated in 
congenital 
adrenal 
hyperplasia, 
represses ERα 
and AR 
(123-126) 
RTA (repressor 
of tamoxifen 
activity) 
Corepressor  Interacts and 
represses ERα 
(127) 
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1-4 ANTIESTROGEN TREATMENT OPTIONS IN BREAST CANCER  
        More than 70% of breast cancer tumors express hormone receptors, thus these 
patients may potentially benefit from therapies targeted against estrogen pathway. There 
are three main options available to tackle against estrogen pathway by targeting different 
mechanisms (Figure 2 and table 2). The first anti-estrogen treatment developed in the field 
is known as Tamoxifen, considered as selective estrogen receptor modulator (SERM). 
Tamoxifen binds to estrogen receptor and inhibits binding of the receptor to its ligand 
estrogen (128). The other class of these drugs is known as selective estrogen receptor 
downregulator (SERDs) such as Fulvestrant. Fulvestrant is a competitive inhibitor of ER that 
not only binds to and blocks the receptor but also degrades it (129, 130). The third class of 
antiestrogen treatments is aromatase inhibitors. Aromatase is the rate-limiting enzyme that 
is responsible for conversion of androgens to estrogen. In contrast to the other two classes 
of drugs that target ER, aromatase inhibitors inhibit generation of estrogen (131). Letrozole, 
anastrozole and exemestane are three FDA approved AIs that are currently used in the 
clinic in post-menopausal breast cancer patients (132, 133). In spite of improved survival 
using anti-estrogen therapies in HR+ patients, some patients do not respond to these 
medications (see resistance to aromatase inhibitors section). In addition, patients often 
develop acquired resistance after initial therapy. Therefore, it is important to understand the 
resistance mechanisms to each of these anti-estrogen treatments. The next sections will 
describe the development, clinical use and resistance mechanisms of these drugs 
individually in more detail. 
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Table 2- Structure and classification of available anti-estrogens in breast cancer  
Name Class Chemical structure 
 
 
exemestane 
 
 
aromatase inhibitors 
(steroidal inactivator) 
 
 
 
anastrozole 
 
 
aromatase inhibitors 
(nonsteroidal inhibitor) 
 
 
 
 
letrozole 
 
 
 
aromatase inhibitors 
(nonsteroidal inhibitor) 
  
 
 
tamoxifen 
 
 
SERM 
(selective estrogen receptor 
modulator) 
 
 
 
fulvestrant 
 
SERD 
(selective estrogen receptor 
downregulator) 
 
 
References: (134-136) 
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Figure 2. Estrogen production and hormonal therapies in ER+ breast cancer patients. 
Estrogen (E) is mainly produced by ovaries in pre-menopausal women and through 
aromatase activity in post-menopausal ones. Fulvestrant binds to and degrades estrogen 
receptor (ER) while tamoxifen (T) blocks ER from binding to estrogen. AIs reduce estrogen 
level by inhibiting converting enzyme known as aromatase.  
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1-4a Tamoxifen in breast cancer and resistance mechanisms 
        Estrogen plays a significant role in breast cancer tumorigenesis. One of the first 
approaches (in the 1970s) to control breast cancer was to irradiate ovaries in patients with 
advanced breast cancer in order to block hormone production (137). Later on, tamoxifen 
was developed which has revolutionized the field of breast cancer treatment. The first trial 
using ICI 146474 (later known as tamoxifen) was reported in 1971 when 10 out of 46 breast 
cancer patients showed response to the drug (138). Binding of Tamoxifen to ER receptor 
may induce both agonistic and antagonistic activity depending on the target tissue. While 
tamoxifen acts as an ER-antagonist in breast cancer cells, it stimulates estrogenic effect in 
bone tissue leading to prevention of osteoporosis (139, 140). In addition, tamoxifen 
decreases cholesterol level and decreases morbidity from myocardial infarction (141-143). 
In contrast to these beneficial effects, tamoxifen shows agonistic effect on uterus and results 
in higher incidence of endometrial cancer in patients who receive long-term tamoxifen with a 
rate of 1.2 per 1000 patients annually (144). Xenograft model systems have been 
established to study the beneficial role of Tamoxifen in vivo (145). In these animal models, 
nude mice are subcutaneously implanted with HR+ breast cancer cells (such as MCF7 or 
T47D) in the presence of estrogen (daily injection or subcutaneous pellets). Once tumors 
are formed and reach a certain size, animals are treated with daily dose of tamoxifen (for 
example 100mcg/day) and tumor volumes are measured regularly until the end of the 
experiment when tumors are analyzed (145). Using this animal model with implantation of 
endometrial and breast cancer, the authors show that tamoxifen stimulates endometrial 
tumor growth while it shows anti-tumor activity in breast (146). In addition to increased rate 
of cancer in uterus, volunteers who were enrolled in tamoxifen prevention studies suffered 
from higher rate of hot flashes, vaginal discharge as well as menstrual irregularities 
compared to placebo treated ones (147). One other major concern with tamoxifen is the 
development of resistance as expected for any targeted agent with long-term use (148). 
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Research studies in this field have identified different mechanisms of resistance to 
tamoxifen (149, 150). Mutation in the ER receptor, interaction of ER with other signaling 
pathways, and loss of ER expression are among such resistance mechanisms (150, 151). 
Understanding these resistant mechanisms will allow scientists to find new therapies 
available to patients who show limited response to tamoxifen.  
         ERα loss is one strategy that breast cancer cells adopt in order to become resistant to 
tamoxifen (149, 152). Examination of ER in clinical tissue samples taken before and after 
development of resistance has confirmed ER loss in 15% to 30% of resistant tumors (149, 
151, 153). In theory, restoration of ER is considered a potential therapeutic approach in 
tamoxifen resistant patients harboring tumors with loss of ER expression upon treatment 
(154). Since the main mechanism of action of tamoxifen is direct binding to ER, the cells 
become unresponsive to the drug as a result of ER loss. Epigenetic modification of the ER 
gene is involved in silencing of the gene (155, 156). Cancer cells silence ER receptor by 
methylation at the CpG islands. Yang and colleagues treated two ER-ve cell lines (MDA-MB-
231, MDA-MB-435) with inhibitor of the DNA methyltransferase (DNMT) and examined ER 
expression in these cell lines (157). DNMTs are enzymes that catalyze methylation of the 
DNA such as promoter regions of cancer suppressor genes leading to underexpression or 
silencing of these genes (158, 159). Aberrant activity of DNMTs is detected in many human 
cancers including colon (160, 161), pancreas (162, 163), and breast (164, 165). In addition, 
inhibitors of DNMTs have shown promise in hematologic malignancies (166, 167). Following 
treatment with the DNMT inhibitor these ER− cell lines were able to express ER mRNA as 
well as ER protein. Combination of DNMT with HDAC inhibitors in this study resulted in ER 
expression to almost 50% level of ER detected in MCF7 (ER+) cell line. Taken together, 
these studies suggest that ERα loss contributes to resistance to Tamoxifen and restoring ER 
may be a beneficial approach to re-sensitize the cells to anti-estrogen treatment.  
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        Besides ER loss, mutation of the estrogen receptor may play role in mediating 
resistance to tamoxifen (148, 150). Fuqua et al reported a Lys to Arg mutation in ER 
(K303R) in 20 out of 59 hyperplasia tissues (150). In addition to this premalignant tissue, the 
mutation was also found in the adjacent normal tissue. This alteration was not detected in 
blood sample suggesting a somatic mutation. In addition, exogenous expression of mutant 
ER in MCF7 cells resulted in hypersensitivity to very low levels of estrogen (150). Generally, 
ER mutations are often selected for during endocrine therapy rather than being present in 
tumors isolated from newly diagnosed patients (148). Mutated ER is able to dimerize 
independent of ligand and activates the downstream estrogenic signaling pathway. Under 
this condition, development of novel anti-ER medications that can block mutated ER would 
be a potential therapeutic option for patients who have ER mutation. 
        The interaction between estrogen receptor and growth factor signaling pathway is 
another mechanism contributing to tamoxifen resistance. Her-2 and EGFR tyrosine kinase 
receptors can become activated through interaction with estrogen receptor at the cell 
membrane (168). Alternatively, PI3K and MAPK signaling pathways can lead to 
phosphorylation of estrogen receptor in the absence of estrogen (169, 170). Activation of 
these signaling pathways can promote cancer cell proliferation and survival in spite of anti-
estrogen treatment (171, 172). Clinically, when patients become resistant to tamoxifen, one 
strategy is to switch to a second line of hormonal therapy either to aromatase inhibitors or 
Fulvestrant (173). For example, a randomized multi-center study examined switching from 
tamoxifen to anastrozole in patients who underwent antiestrogen treatment with tamoxifen 
for two years (173). Results this study indicated that patients who received anastrozole had 
significantly better overall survival compared to those who remained on tamoxifen (173). 
Another feasible approach in the treatment of patients with tamoxifen resistance is to 
combine tamoxifen with inhibitors of the growth factor signaling pathways such as herceptin, 
or lapatinib. Preclinical models show that her-2 pathway can mediate resistance to 
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tamoxifen (174). For example, Benz et al injected Her-2 overexpressing MCF7 cell line 
(ER+) and parental cell line into nude mice in order to generate tumors followed by 
tamoxifen treatment to assess response to treatment (174). Results revealed that the control 
tumors showed tumor regression in response to tamoxifen treatment while her-2 
overexpressing tumors continue to grow suggesting resistance (174). Massarweh and 
colleagues examined her-2 expression in xenograft tumors that were generated from ER+ 
MCF7 cell lines treated with tamoxifen (175). Western blot analysis revealed higher level of 
EGFR/her-2 expression in tamoxifen resistant tumors compared to sensitive ones (175). In 
addition, treatment of the mice with an EGFR inhibitor (gefitinib) delayed emergence of 
resistance to tamoxifen (175). Mechanistic studies show that gefitinib inhibits downstream 
signaling pathway of her-2 as shown by decreasing phospho-AKT and phospho-MAPK 
(175). Clinical studies are in line with these finding suggesting that her-2 pathway inhibition 
has beneficial role under tamoxifen resistant conditions (176). For example, A phase III trial 
on metastatic breast cancer patients (including previous tamoxifen therapy) who were 
randomized to receive trastuzumab in combination with anastrozole showed improved 
progression-free survival by 2.4 months in comparison to those who received anastrozole-
alone treatment (176). Collectively, these studies show that mechanisms of resistance to 
tamoxifen are diverse and suggest that understanding and identifying the underlying 
resistance mechanism in each patient would guide a personalized therapeutic approach.  
 
1-4b Fulvestrant and breast cancer 
        Fulvestrant is an analogue of 17β-estradiol, structurally different from AIs. Fulvestrant 
selectively interacts with estrogen receptor and prevents binding of ER to estrogen (177). 
Binding of fulvestrant to ER prevents dimerization and nuclear localization of the receptor 
(130, 178). In addition, this process induces degradation of ER receptor resulting in 
inhibition of the pathway (129). Fulvestrant, in contrast to tamoxifen, does not have agonistic 
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activity on endometrial tissue (179). Early clinical trials showed efficacy in breast cancer 
patients resistant to other therapies (180). Howell and colleagues used monthly 
intramuscular injection of fulvestrant in 19 breast cancer patients who progressed in spite of 
treatment with tamoxifen. Seven patients showed partial response and six patients had no 
change in tumor size suggesting that fulvestrant can extend duration of response to anti-
estrogens (180). In clinical studies, two different doses of fulvestrant have been used; high 
dose (500 mg) versus low dose (250 mg). In a phase III study, a higher dose was 
associated with longer progression-free survival compared to low dose without increased 
toxicity (181). Early studies have focused on use of fulvestrant in patients who failed prior 
tamoxifen or AI therapy (182). Subsequent studies however, have compared fulvestrant in 
treatment-naive patients to other therapies (183). A phase II study compared high dose 
fulvestrant versus anastrozole in locally advanced or metastatic HR+ post-menopausal 
breast cancer patients. Clinical benefit rate was not statistically significant in fulvestrant 
versus anastrozole arm (36% versus 35.5% respectively) (183). However, time to 
progression was longer in fulvestrant treated patients without any additional side effect 
profile suggesting that fulvestrant is at least as good as AIs in the early phase of treatment 
(183). Results recently published from a phase III study comparing these two treatments in 
HR+ advanced breast cancer patients also support an improved progression free survival for 
2.8 months in patients who received fulvestrant (184). Fulvestrant side effects of are similar 
to those of AIs including pain in joints, hot flashes and nausea (184). In summary, 
fulvestrant is an effective anti-estrogen medication used in ER+ breast cancer patients 
specifically in the metastatic setting. 
 
1-4c Aromatase Inhibitors in breast cancer   
        The third classes of drugs that inhibit estrogen pathway are known as aromatase 
inhibitors. According to their structure (Table 2), aromatase inhibitors are divided into two 
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different classes. Class I drug, also known as steroidal group, consists of formestane and 
exemestane, which covalently bind to and inhibit the enzyme in an irreversible manner (33). 
Both drugs resemble in structure to androstenedione as the substrate for estrogen 
conversion (131). Formestane was the first drug developed by Dr. Brodie’s lab and later 
substituted by exemestane, which is FDA approved and is currently being used in clinic for 
postmenopausal HR+ BC patients (185). The second class of AIs, known as non-steroidal 
AIs, includes letrozole and anastrozole that are also FDA approved and used clinically as 
the standard of care for ER+ post-menopausal patients (132). These inhibitors are 
derivatives of anti-fungal azole drugs, bind to the enzyme non-covalently, and inhibit 
aromatase in a competitive reversible manner (186). Many clinical studies have shown 
advantage of AIs over tamoxifen in post-menopausal BC patients (132, 133, 187). For 
example, in a phase III trial (ATAC), HR+ postmenopausal patients were treated with 
adjuvant anastrozole (arimidex), tamoxifen, or in combination (132). Results from this study 
showed significant improvement in disease-free survival, time to recurrence, and distant 
metastasis in the anastrozole group compared to tamoxifen (132). The arm receiving 
combination of anastrozole and tamoxifen was discontinued early due to lack of benefit 
compared to tamoxifen-alone arm. In addition, more recent studies propose the use of AIs in 
the neoadjuvant setting in selected patients before they undergo surgery as discussed in the 
next paragraph. 
        Another similar phase III trial (Breast International Group 1–98), randomized 8010 HR+ 
BC patients to either letrozole or tamoxifen treatment (133). Results from this study showed 
that patients who were treated with letrozole had higher disease-free survival and lower 
recurrence of breast cancer at distant sites in comparison to tamoxifen (133). In the letrozole 
group, 4.1% of patients died from disease whereas 4.8% of patients died in the tamoxifen 
arm (P value did not reach significant level) (133). A higher percentage of patients 
developed endometrial cancer on tamoxifen compared to letrozole arm (0.3% versus 0.1% 
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respectively, p=0.18) and the thromboembolism rate was higher in tamoxifen arm compared 
to letrozole arm (3.5% vs.1.5% respectively, P<0.001) (133). However, letrozole-treated 
patients experienced higher arthralgia compared to tamoxifen treated ones (20.3% vs. 
12.3%, p<0.001) (133).  
         Aromatase inhibitors are also shown to be favorable in stage III and IV post-
menopausal patients than tamoxifen (187). In a phase III study, 907 advanced breast cancer 
patients (Stage IIIB, metastatic, or recurrent patients not candidate for surgery or radiation 
therapy) with HR+ (or unknown status) were assigned to letrozole or tamoxifen as first line 
therapy (187). Follow up of these patients revealed that letrozole increased median time to 
progression and time to treatment failure by 15 weeks in comparison to tamoxifen. 
Moreover, letrozole treated patients showed higher rate of objective response compared to 
tamoxifen arm (30% versus 20%) indicating the benefit of letrozole over tamoxifen in the 
advanced stage of the disease (187). In a similar study, 353 HR+ (or unknown status) 
postmenopausal BC patients with locally advanced/metastatic disease received either daily 
anastrozole or tamoxifen (188). Anastrozole treatment improved time to progression by 5.5 
months in comparison to tamoxifen and was associated with fewer thromboembolic events 
(188). Similar to anastrozole, a phase III trial compared exemestane to tamoxifen in a cohort 
of locally advanced or metastatic HR+ postmenopausal patients (189). A total of 371 
patients were treated with either tamoxifen or exemestane daily until they progressed on 
treatment (defined by 25% increase in tumor size, or new lesion) or developed toxicity. 
Analysis of the follow up data revealed that patients in exemestane arm had significantly 
longer progression-free survival compared to tamoxifen arm, 9.9 months versus 5.8 months, 
respectively (189). Patients on exemestane had higher rate of overall response compared to 
tamoxifen, 46% compared to 31% respectively. However, exemestane did not change 
overall survival of patients in comparison to tamoxifen (189). Taken together, these studies 
revealed the beneficial role of aromatase inhibitors in post-menopausal BC patients.  
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1-4d Aromatase inhibitors in the neoadjuvant setting 
        One feasible clinical approach in treatment of post-menopausal setting using AIs is 
treatment in the neoadjuvant setting before patients undergo surgery. An advantage of this 
approach is to induce tumor shrinkage such that an inoperable tumor becomes operable. 
Consequently, neoadjuvant treatment increases the chance of breast conserving surgery in 
patients that were initially considered suitable for total mastectomy. Similar to studies using 
AIs in the adjuvant setting, neoadjuvant studies have also shown superiority of aromatase 
inhibitors to tamoxifen in HR+ postmenopausal patients. For example, letrozole was 
compared to tamoxifen in a neoadjuvant setting study including 337 newly diagnosed post-
menopausal HR+ patients (190). Clinical response (complete or partial response by 
palpation) was higher in the letrozole arm compared to tamoxifen arm, 55% versus 36% 
respectively. While none of the patients were eligible for breast conserving surgery (BCS) 
pretreatment, 45% of patients became BCS eligible with letrozole and 35% in the tamoxifen 
group after neoadjuvant treatment. Higher efficacy of letrozole compared to tamoxifen in 
post-menopausal patients was also confirmed in another neoadjuvant study (191). Another 
neoadjuvant study examined response to anastrozole in comparison to tamoxifen during the 
12-week neoadjuvant treatment (Pre-Operative Arimidex Compared to Tamoxifen 
(PROACT). Higher objective response was detected in the anastrozole arm compared to 
tamoxifen arm as measured by ultrasonography, 39.5% versus 35.4%, respectively (192).  
         Collectively, these adjuvant and neoadjuvant studies highlight the significance of AI 
use in treatment of HR+ patients. Unfortunately, resistance is a major obstacle facing these 
medications and in this section different mechanisms of AI resistance are discussed in more 
detail.  
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1-5 RESISTANCE TO AROMATASE INHIBITORS 
       In spite of favorable response with AIs compared to tamoxifen in BC patients, 
resistance to AIs is considered a clinical challenge. Two forms of resistance are detected 
clinically in breast cancer patients including primary (de novo or intrinsic) or secondary 
(acquired) resistance. In the primary resistance setting, the tumors show innate resistance to 
the drugs and patients do not respond to the initial treatment. Results recently published 
from non-metastatic HR+ patients undergoing neoadjuvant aromatase inhibitor therapy 
suggest primary resistance in almost 20% of patients (193). Forty nine out of 245 (20.8%) 
HR+ treatment-naive patients showed primary resistance to AIs as defined by Ki67 more 
than 10% in the sample taken after two weeks of treatment (193). Thirty five of these AI 
resistant patients were treated with neoadjuvant chemotherapy before undergoing surgery 
and analysis of tumors at the time of surgery showed pathologic complete response (pCR) 
in only 5.7% of these patients suggesting that these patients are also resistant to 
chemotherapy (193). Another neoadjuvant trial revealed only 55% objective response to 
letrozole in newly diagnosed breast cancer patients (190). In the newly diagnosed 
metastatic setting, the response rate is much lower and almost all patients eventually 
succumb to the disease (187). In a phase III trial, only 8% (34 out of 453) of patients with 
advanced disease who were randomized to receive letrozole showed complete response 
and 23% showed partial response (30% objective response) (187). Similarly, results from 
another randomized trial showed overall response to anastrozole in only 20% of patients 
with advanced disease (188). Secondary resistance is defined when patients respond to 
initial therapy but fail after a long-term initial response. For example, five-year follow up of 
HR+ postmenopausal patients showed that more than 10% of patients recurred while on 
anastrozole treatment (132). Mechanisms of resistance to these drugs are distinct but 
sometimes overlap as described in more detail separately in the next few sections of this 
dissertation. 
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1-5a Aromatase enzyme and resistance to anti-estrogens 
         CYP19 (aromatase) is located on chromosome 15 and is responsible for catalyzing the 
last step in the conversion of androgens to estrogen (194). Aromatase enzyme is expressed 
in many different tissues including brain, placenta, adipose tissue, breast and bone (195). 
Tissue specific promoters tightly regulate expression of aromatase in each tissue (196). For 
example in placenta, aromatase expression is under control of a promoter that is located 
more than 40kb upstream of the translation start site (196). However, in ovaries another 
promoter located upstream of the second exon regulates expression of aromatase (197). In 
the reproductive system, aromatase is abundant in ovaries and regulates the reproductive 
cycle through local production of estrogen in ovaries (198, 199). In males, local production 
of estrogen in testis by aromatase enzyme contributes to spermatogenesis (200). In normal 
breast tissue, the majority of aromatase is produced by the fibroblasts localized in the fatty 
tissue of the breast while adipose cells do not express aromatase gene (201). Increased 
estrogen production, through activity of aromatase enzyme in fibroblasts located adjacent to 
breast cancer mass, enhances proliferation of cancer cells (202). In addition, in breast 
cancer tissue, aromatase is present in both epithelial cancer cells as well as fibroblasts 
located in the extracellular matrix surrounding breast tumor cells (203, 204). Studies have 
shown interaction between fibroblasts and cancer cells. For example, co-culture of the 
fibroblasts with breast cancer cells (MCF7) resulted in higher expression of aromatase in 
fibroblasts through production of stimulatory factors by cancer cells (205). Increased 
aromatase expression in fibroblasts stimulated by cancer cells can lead to higher local 
estrogen production, which in turn increases proliferation of cancer cells in a positive 
feedback loop (203, 204). In addition to estrogen-mediated proliferation, increased 
aromatase expression enhances survival and metastasis of ER+ breast cancer cells. In one 
study, the authors exogenously overexpressed aromatase in ZR75 cell line (ER+) and 
compared their tumorigenic as well as metastatic potential to the parental cells (206). These 
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aromatase overexpressing cells were able to form tumors when implanted into mammary fat 
pad of nude mice without estrogen supplementation suggesting enhanced tumorigenicity. To 
investigate metastatic potential of these cells, the authors injected aromatase 
overexpressing and control cells into the heart of nude mice and examined metastases 
formed in bone. The results showed that aromatase overexpressing cells were capable to 
form metastasis in mandible bone (in 80% of mice) and tibia/femur (in 40% of mice). In 
sharp contrast to this, none of the mice injected with parental cells formed metastasis (206).  
        One mechanism of resistance to anti-estrogen treatment is attributed to alteration in 
aromatase expression. For example, tamoxifen-resistant MCF7 cells were shown to have 
higher aromatase level and activity than parental cells using Western blot and enzyme 
activity assay (207). In this study, treatment with a PI3K inhibitor down-regulated aromatase 
expression, suggesting a possible interaction between PI3K and aromatase. To translate 
these findings, the authors examined aromatase expression by immunohistochemistry in 4 
cases who relapsed after adjuvant tamoxifen therapy and compared those to 4 patients who 
did not relapse at least within 6 years of follow up. Results revealed that recurrent tumors 
had significantly higher percentage of aromatase positive cells compared to non-recurrent 
tumors, 57.5% versus 9.8%, respectively. Taken together, these studies show that 
aromatase enzyme plays a significant role in ER+ breast cancer and that its enhanced 
expression can contribute to resistance to anti-estrogens.  
 
1-5b Androgen receptor and AI resistance 
       Androgen receptor, similar to ER, is a member of the nuclear receptor family and upon 
binding with androgen translocates to the nucleus to bind to the promoter regions of target 
genes (208, 209). Collins and colleagues used immunohistochemistry to examine tissue 
microarray samples of a cohort of invasive breast cancer patients (210). The investigators 
stained 2171 invasive breast cancer tissues for ER, PR, Her-2, cytokeratin 5/6, EGFR, and 
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AR to identify molecular subtype of breast cancer. According to phenotype staining the 
tissues included luminal A (64%), luminal B (15%), basal-like subtype (11%), Her-2 (6%), 
and the rest as unidentified. Overall 77% of all cases were considered positive for AR 
expression (210). Luminal A patients had the highest rate of AR positivity (91% of cases) 
while basal like had the least percentage of AR expression (32% of cases) (210). Several 
studies show the correlation between serum androgen level in postmenopausal women and 
higher rate of breast tumor formation (211, 212).  
          Androgen receptor has been shown to contribute to de-novo resistance to AIs (213). 
In this study, AR played role in resistance through activation of ER pathway as well as 
parallel growth signaling pathway (213). AR overexpression in ER+ cell line (MCF7) resulted 
in increased phosphorylation of IGF-1R receptor and activation of PI3K downstream 
signaling pathway (213). In line with this notion, treatment with an IGF-1R inhibitor 
(Tyrphostin, AG1024) desensitized the cells to anastrozole by inhibiting androgen receptor 
as well as downstream AKT pathway (213). Similarly, AKT inhibitor restored sensitivity to 
anastrozole in AR overexpressing cell line (213).  
        Another mechanism of AR-mediated resistance is linked to its collaboration with ERα 
and activation of ER transcription (213). First, using a proximity ligation assays 
(immunoassay that detects protein-protein interaction using two specific antibodies detected 
by confocal microscopy), the authors found co-localization of ERα-AR in the nucleus of 
resistant cells (213). Next, chromatin immunoprecipitation assay (chip) revealed enrichment 
of AR at the pS2 (a well-known estrogen responsive gene) promoter region upon 
androstenedione treatment (213). In addition, a combination of either an AR antagonist 
(abiraterone) or an ER degrader (fulvestrant) with anastrozole restored sensitivity to AI in 
AR-overexpressing resistant cell lines (213). These experiments suggest that AR and ER 
can collaborate to bypass the effect of aromatase inhibitors. In another study, the 
researchers examined primary and AI resistant recurrent tumors from 21 breast cancer 
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patients using immunohistochemistry (214). Results from this study revealed higher Ki67 
(representative of proliferation) and higher PSA levels (representative of androgen activity) 
and lower ER and PR expression in recurrent tumors (214). In addition, higher AR 
expression and activity were detected in long-term estrogen deprived cell line (T47D-LTED) 
compared to parental cell line (214). These preclinical studies suggest that cancer cells 
adapt to low estrogen environment by increasing AR expression and activity leading to 
expression of the ER target genes in resistant cells in spite of anti-estrogen treatment. 
Additional studies are required to investigate the potential efficacy of anti-androgen 
treatment in AI resistant patients who overexpress AR. For example, one proposed study is 
to randomize ER+ patients who become resistant to AIs into two arms in which one arm 
would receive fulvestrant plus AR antagonist (enzalutamide) based on AR overexpression 
while the other arm would receive fulvetsrant plus placebo and follow up these patients for 
short-term and long-term response. It is worth noting that feasibility of enzalutamide therapy 
in under clinical investigation in early stage AR+ TNBC patients (NCT02750358). 
 
1-5c Her-2 MAPK pathway and AI resistance 
        Aberrant activity of growth signaling pathways is another known mechanism of 
resistance to aromatase inhibitors. In vitro and in vivo studies using acquired AI resistant 
models indicate that cancer cells are able to adapt to low estrogen environment in order to 
survive (215). One such adaptation is escape from ER signaling by activation of growth 
factor signaling pathways (215). Studies in the lab of Dr. Brodie are focused on 
understanding AI resistance using in vitro and in vivo models. Her group has generated 
letrozole-resistant tumors by injecting aromatase overexpressing cell lines into the 
mammary fat pad of ovariectomized mice and treating the tumors with letrozole (216). In 
order to develop resistance, tumor-harboring mice were treated with a low dose (10μg/day) 
of letrozole for 8 weeks followed by a higher dose (100μg/day) for a total period of 37 weeks 
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until the tumors almost doubled in size compared to the initial size (216). They generated in 
vitro cell lines from these tumors and showed that these cells are able to form tumors when 
implanted into nude mice without androstenedione supplementation. This confirms that the 
cells are able to form tumors in the absence of estrogen suggesting resistance to AIs. In 
vitro analysis of these cells using Western blot analysis showed that the level of ERα 
increased at 4 weeks following letrozole treatment but decreases at 28 or 56 weeks of 
therapy when the cells are resistant to letrozole. In contrast, the level of HER-2 as well as 
phosphorylated MAPK increased at 28 and 56 weeks (217) suggesting that resistant cells 
are dependent on Her-2/MAPK pathway rather than ER signaling (217). To further confirm 
dependence of these resistant cells on MAPK pathway, they treated letrozole resistant cells 
and parental controls with increasing concentrations of a MEK inhibitor (U0126) or a MAPK 
Inhibitor (PD98059) (217). Results from this study revealed that only resistant cells respond 
to these inhibitors by decreasing proliferation in a dose-dependent manner (217). In a 
similar study, letrozole resistant cells and tumors responded to HER2 inhibitor (trastuzumab) 
in a dose dependent manner (215). Western blot analysis indicated that trastuzumab 
blocked Her2/MAPK pathway and increased ERα at the protein level. Chip and RT-PCR 
assays revealed that trastuzumab increased ER binding to pS2 gene promoter (a known ER 
responsive gene) as well as increased pS2 mRNA level (215). Moreover, pre-treatment with 
trastuzumab enabled these cells to show exponential growth upon estrogen stimulation 
suggesting these cells become hypersensitive to estrogen (215). Brodie’s lab has also 
generated anastrozole-resistant tumors and found that HER-2/MAPK pathway was not 
activated in these cells (in contrast to letrozole resistant cells) (218). However, they detected 
higher expression of insulin-like growth factor type I receptor β (IGF-R1β) as well as up-
regulation of mTOR and phospho-mTOR rather than HER-2 in this model (218). Using a 
xenograft model system, they showed that the tumors respond to a combination of 
anastrozole and fulvestrant (218). Taken together, results from these studies show that 
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signaling pathways can contribute to AI resistance in a subset of patients and inhibition of 
this pathway may re-sensitize resistant cells to anti-estrogen treatment. Comparison of 
letrozole to anastrozole resistant cells suggests that resistant mechanisms to each individual 
AI could be different and cancer cells may adopt different pathways to survive the pressure 
of antiestrogen treatment. 
 
1-5d PI3K pathway and AI resistance 
        Phosphoinositide 3-kinases (PI3K) is the most frequent signaling pathway that is 
aberrantly activated in human cancers (219). PI3K pathway activation initiates when growth 
factors bind to the specific cell surface receptors of the pathway such as Her-2 or MET 
(220). Upon activation of these receptors, the signal is transmitted through PI3K and 
downstream signal transduction proteins such as AKT and mechanistic target of rapamycin 
(mTOR) (221). Activation of these kinases eventually transmits the signal to the nucleus and 
regulates many hallmarks of the cancer cells such as growth, cell cycle progression, and 
survival (222-224). One mechanism of deregulation of the pathway is through mutation in 
the PIK3Ca (catalytic unit) leading to hyperactivity of the pathway (219). In addition, PI3K 
amplification has been detected in 40% of ovarian cancer patients, and is associated with 
higher level of PI3K (225). Amplification of AKT has been detected in ovarian and breast 
cancer (226). Bellacosa et al examined 132 ovarian cancer and 106 breast cancer tissues 
using southern blot analysis and found AKT2 amplification in 12.1% of ovarian and 2.8% of 
breast tumors (226). Phosphatase and tensin homolog (PTEN), a known cancer suppressor 
gene, negatively controls the pathway and may become inactivated through mutation or 
gene silencing in different cancers (227, 228). Given the significance of this pathway in 
human cancer, several targeted inhibitors have been developed that can be used for 
cancers with deregulation of this pathway.  For example, compounds that can specifically 
target downstream molecule in the pathway (mTORC1) such as everolimus are currently 
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approved by FDA and used in clinic (229, 230). In a phase III study, HR+ patients who 
progressed on anastrozole or letrozole were categorized to exemestane plus everolimus or 
exemestane plus placebo regimen. Results from this study revealed that everolimus 
significantly improved progression-free survival in this population of patients (229). Orally 
available Inhibitors of PI3K such as BKM120 (buparlisib) are another class of inhibitors 
currently being investigated in breast cancer (231). In BELLE-2 trial, HR+ patients who were 
unresponsive to AIs received fulvestrant for 14 days followed by randomization to receive 
fulvestrant alone or fulvestrant plus BKM120. Results revealed that the combination 
treatment increased PFS significantly (but modestly) from 5 months (control group) to 6.9 
months (combination group) (231).  
       The link between PI3K pathway and AI resistance has been investigated in a few 
studies. Miller et al cultured different estrogen receptor positive cell lines over long period of 
time to develop resistant models (known as LTED model). Next, the researchers subjected 
these resistant cells along with their parental counterparts to proteomic analysis (232). LTED 
cells adapted to survive and proliferate in the media deprived of estrogen and thus are 
acceptable model to study AI resistance (232). Comparison of LTED cells with parental 
controls revealed increased activity of mTOR as measured by higher phosphorylation of 
p70/p85 ribosomal protein S6 kinase (p70S6K), a kinase downstream of mTOR (232). 
Higher phosphorylation of AKT was detected in LTED cells suggesting higher activity of 
PI3K-AKT-mTOR pathway in resistant cells (232). In addition, treatment of these LTED cells 
with a dual inhibitor of PI3K and mTOR (BEZ235) resulted in maximum apoptotic rate and 
highest inhibition of proliferation. In contrast, mTOR inhibitor alone (RAD001) or PI3K 
inhibition using RTKs Inhibitors (IGFR or Her-2 Inhibitors) resulted in a moderate 
suppression of cell growth (232). To translate these findings, the authors examined 64 ER+ 
tumors using RPPA analysis and stratified them to PI3K-high and low signatures (232). 
Presence of PI3K activation signature correlated with shorter recurrence in patients who 
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underwent adjuvant therapy with anti-estrogens suggesting the link between PI3K pathway 
and resistance to anti-estrogens (232). In another study, the authors examined the 
combination of PI3K inhibitor and antiestrogen treatment and detected greatest cell death in 
the concomitant treatment condition (233). Individual PI3K inhibition induced less than 20% 
apoptosis in the LTED MCF7 cell lines (233). However, combination of fulvestrant with a 
PI3K inhibitor resulted in almost 80% cell death. Taken together, these studies show that 
PI3K pathway plays role in resistance to AIs and dual inhibition of PI3K and ER pathway can 
be a considered beneficial combination therapy in anti-estrogen resistant ER+ breast 
cancer.  
 
1-5e Cancer stem cells, epithelial to mesenchymal transition and AI resistance  
        Caner stem cells (CSCs) are rare population of pluripotent cells within a tumor with 
self-renewal capacity (234). It is thought that CSCs are resistant to chemotherapy and 
radiation (235, 236). Cancer stem cells are identified in many different cancers such as lung, 
colon, ovary and breast (237-240). Al Hajj et al first described and isolated cancer stem cells 
in breast cancer using flow cytometry for CD44+ CD24−/low Lineage− cells (237). These 
subpopulations of cells were able to generate tumors when as low as 100 cells were 
injected in mice. In addition, these cells formed the bulk of non-stem cells within a newly 
formed xenograft tumors indication their pluripotent potential. Later on, aldehyde 
dehydrogenase (ALDH) was found to be another marker of breast cancer stem cells (241). 
Further studies suggest that ALDH+ breast cancer cells are responsible for drug resistance 
(241). Tanei et al examined tumor tissues prior to and at the end of neoadjuvant 
chemotherapy and found an association between ALDH positivity and resistance to 
chemotherapy. ALDH positive tumors showed significantly lesser pathologic complete 
response (pCR) in response to therapy in comparison to ALDH-negative ones (242).  
         CSCs have the capability of transforming from an epithelial phenotype to a 
 
 
37 
mesenchymal one (known as EMT) and metastasizing to other tissues. Throughout this 
process, epithelial markers such as E-cadherin (CDH1) are attenuated and in contrast 
mesenchymal markers such as Vimentin and N-cadherin are increased (243). As mentioned 
earlier, cancer stem cells have self-renewal and long-term maintenance abilities. These 
capabilities raise the assumption that these cells are able to survive in the metastatic site. 
During the EMT process, highly adherent epithelial cells transform into mesenchymal cells 
with higher migratory and invasive phenotype (244).  
        Several studies show the link between CSCs and invasion/metastasis in breast cancer 
(245, 246). Liu and colleagues generated an invasive gene signature by comparing 
differentially expressed genes in breast cancer stem cells (CD44+ CD24−/low) and normal 
epithelial cells (245). In this study “high invasive signature” correlated with higher metastasis 
and diminished survival (245). In another study, tumor particles isolated from triple negative 
breast cancer patients were implanted into the mammary fat pad in order to track lung 
metastasis (246). Examination of the lung metastatic cells revealed CD44+ cancer stem 
cells. In addition, these cells retained their tumorigenic potential when transplanted in vivo 
suggesting their stemness phenotype (246). In line with these studies, evidence shows the 
link between EMT phenotype and stemness where forced expression of Twist and Snail, two 
genes with cancer stem cell function, in immortalized mammary epithelial cells induced EMT 
and concomitantly shifted the cells toward a cancer stem cell phenotype (higher percentage 
of CD44high CD24low cells in experimental cells compared to control ones) (247). In addition, 
these transformed cells with EMT phenotype showed higher mammosphere formation ability 
in vitro as well as enhanced tumorigenicity in animal models.  
        A few studies have investigated the link between EMT/CSCs and development of AI 
resistance (248). Creighton et al investigated the link between cancer stem cell phenotype 
and letrozole resistance (248). To this end, they generated a CSC signature by combining 
gene expression signature of CD44+/CD24 -/low subpopulation and a signature of 
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mammosphere forming cells. Comparison of post-neoadjuvant samples from 36 ER+ 
patients treated with letrozole to pretreatment samples shows enrichment of this signature 
(248). In addition, gene expression profile of post-letrozole treatment tumors overlapped 
with a claudin-low signature characterized by increased expression of EMT related genes 
(MMP2 & MMP3) and down-regulation of CDH1 (E-cadherin) (248). This suggests an 
enrichment of CSCs and EMT in the letrozole resistant tumors. In a similar study, the 
authors examined cancer stem cell markers in letrozole resistant cells isolated from in vivo 
tumors treated long-term with letrozole. Letrozole resistant cells had higher subpopulation of 
ALDH+ cells compared to sensitive cells (3.9 % vs. 0.6 %) and formed almost two times 
higher mammospheres in vitro (249). At the protein level, letrozole resistant cells had higher 
breast cancer resistant protein (BCRP) level. BCRP is a trans-membrane protein that is 
involved in resistance to multiple chemotherapies and is considered as a marker of stem 
cells (250). Treatment of resistant cells with lapatinib, a HER-2 tyrosine kinase inhibitor, 
resulted in decreased percentage of ALDH+ cells, decreased BCRP level and diminished 
mammosphere formation in vitro suggesting that HER-2 pathway regulates stem cell 
behavior of letrozole resistant cells (249). In addition, letrozole resistant cells show 
increased HER-2 concomitant with decreased ERα level indicating that resistant cells loose 
their dependence on estrogen pathway by adopting a cancer stem cell behavior (249). The 
link between HER2 receptor and cancer stem cell has been discussed in a few studies (251, 
252). For example, Korkaya et al overexpressed HER-2 in normal mammary epithelial cell 
line and showed enhanced mammosphere formation, enriched ALDH+ subpopulation in 
vitro and increased mammary outgrowth with dysplasia when implanted in vivo (251). 
Similarly, overexpression of HER-2 in two different cell lines, MCF7 (ER+) and SUM159 
(triple negative), resulted in higher invasiveness of these cells as assessed by matrigel 
invasion assay. Moreover, the authors detected higher expression of genes associated with 
stem cell behavior such as Notch1, Notch2, and Oct3/4 in SUM159 cells ectopically 
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overexpressing HER-2. In a similar study, tumor-initiating subpopulation of breast cancer 
cells had higher expression of HER-2 (252). Treatment of these HER-2 overexpressing cells 
with trastuzumab resulted in decreased mammosphere formation ability in vitro and tumor 
formation in vivo when serially transplanted into mice suggesting that anti-HER-2 therapy 
can specifically target these HER-2 overexpressing tumor initiating cells (252).  
        In summary, these findings highlight the significance of CSCs and EMT process in 
resistance to AIs. Currently, the studies examining cancer stem cells and resistance to AIs 
are limited and inconclusive. It is not completely clear whether the subpopulation of cells 
that become resistance to AIs are derived stem cells. In addition, the clinical implications of 
CSCs in the context of AI resistance are yet to be determined. For example, anti-CD44 
monoclonal antibody showed efficacy to decrease repopulation of AML cells when 
transplanted into immune-deficient mice and prevented leukemia propagation in serial 
transplantation experiments suggesting that anti-CDK44 antibody is able to target cancer 
stem cells (253). As mentioned earlier, a CD44 cancer stem cell signature is enriched in 
remaining tumors following letrozole treatment (248). Therefore, it is intriguing to study 
whether a combination of anti-stem cell therapies (such as CD44 antibodies) are beneficial 
in combination with aromatase inhibitors.  
 
1-5f Gene alterations/mutations and AI resistance 
        Gene mutations are often detected in human cancers. Some of these mutations are 
detected in early phase of oncogenesis. However, some mutations are found as a response 
to targeted therapies leading to resistance to therapies. The most relevant example of such 
mutation is the BCR-ABL gene mutation leading to resistance to BCR-ABL inhibitor imatinib. 
BCR-ABL is an oncogenic protein detected in CML patients that can be targeted with 
specific kinase inhibitors (254). The discovery of the BCR-ABL inhibitor imatinib has 
dramatically changed the landscape in CML, due to significantly improving overall patient 
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survival (254, 255). However, resistance to imatinib is a great challenge partially attributable 
to mutation in the trans-located gene (256, 257). Another well-known example in this context 
is the secondary mutation in EGFR gene following treatment with its specific inhibitor in non-
small cell lung cancer (NSCLC). NSCLC is a malignant disease of the lung with very poor 
prognosis. EGFR is often overexpressed or mutated in NSCLC and these patients benefit 
from anti EGFR targeted therapy (258). However, secondary mutations in the gene develop 
upon treatment, which limit the effect of targeted therapies (259, 260). Therefore, 
identification of secondary mutations that can cause resistance to targeted therapies is an 
important aspect to consider when these medications are used.  
       A few studies in breast cancer have investigated association between gene mutation 
and response to anti-estrogen treatment. As an example, Veeraraghavan et al detected 
gene rearrangement between ESR1 (gene encoding ERα protein) and CCDC170 (gene 
encoding a protein with unknown function) in 8 out of 200 ER+ breast cancer tumors (261). 
The authors screened a series of BC cell lines and detected this fusion in three ER+ ones 
that were isolated from metastatic patients namely MCF7, HCC1428, and ZR-75-1. They 
further show that introduction of ESR1-CCDC170 into mammary epithelial cell line 
(MCF10A) resulted in higher migration and invasion (assessed by Boyden chamber), 
enhanced cell proliferation, and increased colony formation. Mutant variant of ER was first 
reported by Fuqua et al by examination of 5 tumors isolated from ER-/PR+ BC patients 
(262). ER mutations are rare in primary tumors but more frequent in the metastatic setting 
(148). DNA Sequencing of specimens isolated from patients who progressed while on anti-
estrogen therapy revealed mutation in 14 out of 80 samples. These mutations were mainly 
localized in the ligand-binding domain of estrogen receptor and incorporation of these 
mutant constructs resulted in estrogen-independent activity of mutant ER (148).  
       Another important related aspect in the context of resistance to AIs is to examine 
tumors from treatment-naive patients for mutational patterns that can predict response to 
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treatment. Ellis et al applied a whole genome analysis approach using whole-genome or 
exome sequencing of 77 biopsy samples isolated from ER+ patients to examine correlation 
between mutations and response to treatment. Tissue samples before and after treatment 
with neoadjuvant AIs were examined (263). Cases were considered resistant when Ki67 
positivity remained more that 10% after neoadjuvant treatment with AIs. On average, they 
detected 16.8 mutations in each tumor. Genes encoding for PI3K-α subunit, p53, E-
cadherin, Rb and p27 were among the significantly mutated genes in their samples with 
PI3K being the highest mutated genes (41.3%) followed by p53 (16.1%). Mutation in p53 
correlated with higher Ki67 in both samples before and after neoadjuvant AI therapy (263). 
Combining these mutated genes into pathway analysis and comparison between resistant 
and sensitive cases revealed enrichment of DNA replication, mismatch repair and p53 
signaling in resistant cases (263). Taken together these studies suggest that examination of 
mutations at the DNA level could be beneficial for the selection of specific targeted therapies 
along with anti-estrogen treatment. However, more studies with longer follow up are needed 
in order to validate the clinical significance of these findings and apply therapeutic strategies 
based on available druggable targets that are mutated. 
 
1-5g Gene expression analysis and AI resistance 
        Cancer cells often alter their gene expression profile to tolerate the pressure of 
chemotherapy and other targeted therapies. A few studies have investigated gene 
expression changes upon AI treatment using model systems that are resistant to AIs. 
Chen’s team has established acquired resistance models of aromatase inhibitors by 
culturing aromatase-overexpressing cells in the presence of aromatase inhibitors for a long 
period of time (264). In addition, his lab has generated LTED and tamoxifen resistant cell 
lines (264). In order to identify mechanism of resistance, they performed Affymetrix 
microarrays on these cell lines. Comparison of gene expression changes compared to 
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parental cell lines showed that all the three cell lines resistant to individual AIs (letrozole, 
anastrozole, exemestane) were clustered together in one group but different from tamoxifen 
or LTED clusters suggesting distinct mechanism of resistance (264). Even within the AI 
cluster, the authors found almost 50% similarity between up-regulated or down-regulated 
genes. The top 20 up-regulated genes in resistant cells were categorized as estrogen 
responsive genes suggesting an ER-mediated transcriptional activity in the resistant cells. 
Further molecular analyses using ER luciferase reporter assay and Western blot in resistant 
cells showed constitutive ER transcription activity and phosphorylation of ERα protein (264). 
This is consistent with the notion that combining an ER downregulator (fulvestrant) with an 
AI is beneficial to overcome resistance. Furthermore, Ingenuity Pathways Analysis (IPA) of 
resistant cells compared to their parental cell line revealed enrichment of pathways involved 
in DNA replication, DNA repair, as well as cell cycle control (264). In another similar study, 
the authors established LTED models from 4 different ER+ cell lines including MCF7, ZR75-
1, MDA-361, HCC-1428. Comparison of gene expression profile of LTED versus parental 
cells revealed a total of 86 down-regulated genes and 13 up-regulated genes that were 
similarly altered across all cell lines (265). Next, they examined the correlation between 
LTED signature and response to aromatase inhibitors in tumors isolated from patients 
treated with neoadjuvant letrozole (266). To this end, they assigned “LTED score” to each 
tumor before and after therapy based on the available microarray data of these tumors. 
Results showed that high LTED signature correlated with high Ki67 in post-treatment 
samples as a marker of proliferation. Furthermore, high “LTED signature” correlated with 
poor long-term survival in a separate data set where patients were treated with tamoxifen. 
Taken together, these studies suggest that gene expression profile derived from resistant 
cell lines has clinical implications and can inform response to anti-estrogen treatment. 
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1-6 THE CELL CYCLE AND CANCER 
       Cell cycle is a very orchestrated phenomenon resulting in generation of two daughter 
cells from an individual cell. Each cell goes through multiple phases in order to divide. These 
are known as interphase: a period in which cells grow and replicate their DNA content, and 
Mitosis: when the replicated DNA is separated along with cytoplasm into two daughter cells. 
During interphase the cells go through G1 phase in which the cells metabolically prepare for 
DNA synthesis, S phase the actual duplication of the DNA content, and finally G2 phase 
when the cells prepare for mitosis. In addition, there are checkpoints between cell cycle 
phases when the cells decide to move forward to the next phase considering the internal 
and external stimuli. In addition, normal cells have capacity to pause at the checkpoints with 
any aberration in the natural progression of cell cycle with potential to activate repair 
mechanisms. The most significant checkpoint is at the time of transition between G1 to S 
phase, as the cells are committed to continue through cell cycle and divide after passing this 
checkpoint while no longer rely on external stimulation. Cell cycle progression requires 
appropriate interaction and activity of different proteins known as cyclins and cyclin 
dependent kinases (CDKs) (267) (Figure 3). CDKs are the active components that fuel 
progression of cell cycle and have constant levels throughout different phases of the cell 
cycle. In contrast, cyclins oscillate throughout different phases, form complex with CDKs, 
and initiate their kinase activity. On the other hand, cyclin dependent kinase inhibitors (CKIs) 
inhibit the activity of CDKs through binding with the cyclin-CDK complex (268). Two families 
of CKIs include INK proteins such as p15, p16, p18 and p19 that can inhibit CDK4/6 
kinases. The other family know as Cip/Kip family entails p21, p27 that are responsible to 
inhibit CDK1 and CDK2 kinases (269), (270). G1 checkpoint is mainly regulated by Rb 
protein, a well-known tumor suppressor. Under hypo-phosphorylated state, Rb protein 
keeps E2F transcription factor in the inactive form. Cyclin D CDK4/6 complex initiates 
phosphorylation of Rb protein during the early G1 phase. This phosphorylation is further 
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resumed by cyclin E/CDK2 resulting in inactivation of Rb protein as a tumor suppressor 
gene. Hyperphosphorylated Rb can no longer bind to E2F, releasing it to transcriptionally 
activate genes required for DNA synthesis (271, 272). Expression of Cyclin E as well as 
cyclin A is also affected by E2F transcription factor. As a result of this process, cyclin E level 
increases throughout G1 phase reaching its peak level at the time of G1 to S transition. 
Cyclin E activity is required for initiation of S phase (273). Cyclin A expression continues 
through G2 phase of the cell cycle and replaced by cyclin B during mitosis. In fact, cyclin B 
level peaks at the end of G2 and early mitosis. Cyclin B forms a complex with CDK1 and 
allows the cells to pass G2/M checkpoint and start mitosis (274). Lastly, cyclin B degradation 
is required for the cells to progress out of mitosis. Any defects in this orchestrated process 
can result in abnormal progression of the cell cycle, enhanced proliferation, DNA damage, 
and tumor formation.  
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Figure 3. Cell cycle phases and regulation of cell cycle in human. A single cell passes 
through multiple phases including Gap 1 (G1), DNA synthesis (S), Gap 2 (G2), and Mitosis 
(M) in order to divide. This process is tightly regulated by interaction of complexes including 
cyclin dependent kinases (CDKs), cyclins as binding partners, and CDK inhibitors such as 
p16, p21 and p27. Rb phosphorylation releases E2F allowing gene transcription and 
bypassing the restriction point between G1 and S. 
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Deregulation of cell cycle is a very common phenomenon in many cancers. Alterations in 
many components of cell cycle regulators have been detected in many cancers. For 
example, translocation and amplification of cyclin D is detected in breast cancer patients 
(see section cyclin D and breast cancer). At the protein level, cyclin D is overexpressed in 
breast, GI malignancies, head and neck cancers (275). Cyclin E is deregulated in breast 
cancer as discussed in the next chapters. Alteration of CDKs also can play role in abnormal 
growth of cancer cells. In melanoma, CDK4 mutation results in inability of CKIs to bind and 
inhibit CDK4 leading to proliferation of the cells (276). Rb protein is a well-known cancer 
suppressor gene that is frequently altered in human cancers including breast cancer. Rb 
dysfunction is linked to resistance of breast cancer to tamoxifen (277). Loss of inhibitory role 
of CKIs such as p16 is implicated in oncogenesis. P16 knock out animal models tend to 
develop cancers suggesting the cancer suppressive role of this gene (278). CKIs can be 
inactivated through methylation at the promoter region of the genes, as well as mutations of 
the gene (279). Similarly, loss of p27 in breast cancer is correlated with decreased survival 
(280).  
       In the context of AI resistance, a few studies have shown deregulation of the cell cycle 
in AI-resistant cell lines. These studies are described in detail in chapter 3 of this 
dissertation. Given the significance of cell cycle in cancer, many different CDK inhibitors 
have been developed. Most of these drugs are able to bind to ATP-binding pocket of CDKs 
in a competitive manner and inhibit their activity (281). The initial CDK2 inhibitors that were 
developed did not have specificity to specific CDKs with unknown mechanism of actions. In 
addition, these inhibitors were used in clinical trials without a potential biomarker for patient 
selectivity and therefore resulted in early termination of trials (see CDK2 inhibitors and 
breast cancer section). With promising results from the current CDK4/6 inhibitors, there is a 
great interest in clinical use of these CDK inhibitors in other cancers. The clinical 
development of each of these CDKs is discussed in the next few paragraphs. 
 
 
47 
1-7 CYCLIN D AND CDK4/6 INHIBITORS IN BREAST CANCER  
        The first evidence of cyclin D (previously known as PRAD1) involvement in cancer 
originates from studies performed on parathyroid adenomas (282). In parathyroid tumors, a 
gene rearrangement between an upstream regulatory sequence of parathyroid hormone 
gene and unknown DNA sequence from chromosome 11 was detected (282). Motokura and 
colleagues first cloned PRAD1 cDNA, detected homology of its sequence with other cyclin 
family, and found oscillation through cell cycle phases indicating a cell cycle regulatory 
action (283). The same group found that PRAD1/cyclin D is overexpressed in parathyroid 
and breast tumors (284). Jiang et al identified cyclin D amplification in 25% of human 
esophageal cancers (285). Cyclin D is deregulated in many other tumors such as lung, head 
and neck, and bladder cancer to mention a few (286-288). Schuuring et al examined tissues 
from 226 stage I-III patients and detected amplification of cyclin D region in 16% of these 
patients. Importantly, in this cohort, cyclin D amplification correlated with lymph node 
involvement and poor survival (289). While cyclin D gene amplification is detected in about 
20% of tumors, overexpression is seen in almost half of all BC patients (290). This suggests 
deregulation at the transcriptional and post-transcriptional level. Transgenic animals with 
cyclin D1 overexpression form breast tumors indicating an oncogenic role of cyclin D1 (291). 
While the canonical interaction of cyclin D with CDK4/6 to inactivate Rb protein has been 
accepted as the major contributor of cyclin D in tumorigenesis, other evidence argues a 
CDK4/6 independent function of cyclin D (292, 293). As an example, exogenous expression 
of cyclin D1 in BC cells not only interacted directly with estrogen receptor but also activated 
ER signaling in a CDK4/6-Rb independent manner (292, 293). On the other hand, estrogen 
receptor and Her-2 receptor can induce cyclin D expression indicting interaction between 
cyclin D and these receptors. Moreover, major signaling pathways such as PI3K and MAPK 
can increase cyclin D level at both mRNA and protein levels, as well as phosphorylate CDK4 
protein resulting in cell cycle progression (294). These findings raise the question whether 
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cyclin D can overcome the effect of AIs by activating unliganded ER. Clinical trials including 
ER+ BC patients reveled an important role for cyclin D and CDK4/6 (295, 296). A 
combination of a CDK4/6 inhibitor (palbociclib) with letrozole has shown promising results 
leading to approval of palbociclib combined with letrozole by FDA in advanced ER+ breast 
cancer patients. In the next section of this dissertation, I will review development of CDK4/6 
inhibitors in further detail. 
 
1-7a CDK4/6 inhibitors in breast cancer 
        PD-0332991, also known as palbociclib, is a novel CDK4/6 inhibitor. ER+ cell lines 
showed the highest sensitivity to palbociclib when different subtypes of BC cell lines were 
exposed to the drug (297). In this study, sensitive cell lines (IC50<150nM) had higher level 
of cyclin D1 and Rb1 when gene expression was compared to resistant cell lines 
(IC50>150nM). Mechanistic studies showed that PD diminished phosphorylation of Rb 
protein associated with cell cycle arrest at G1 phase specifically in sensitive cells (297). 
Moreover, PD was shown to have synergistic activity when combined with tamoxifen. 
Sensitivity to palbociclib was further studied using an explant model of breast cancer (298). 
11 out of 13 explants responded to palbociclib as measured by significant decrease in Ki67 
positivity whereas 2 explants did not show decrease in Ki67. In this study, loss of Rb protein 
was linked to insensitivity to palbociclib. Knudson et al examined the gene expression 
changes in MCF7 cell line upon palbociclib treatment and compared the profile with 
estrogen-deprived condition (299). In contrast to estrogen deprivation, palbociclib treatment 
did not affect the ER target genes. However, long-term treatment with palbociclib altered the 
gene expression profile of MCF7 cell line by suppressing the cell cycle regulatory genes 
(299). Analysis of PAM50 genes following palbociclib treatment revealed a shift from 
luminal-B to a luminal-A molecular subtype. Similar gene suppression was detected when a 
xenograft model of MDA-MB-231 cells (triple negative) were treated with palbociclib 
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highlighting the gene alterations induced by palbociclib is not restricted to HR+ breast 
cancer. Taken together, these results suggest that beneficial role of palbociclib in HR+ 
breast cancer patients.  
        To advance the clinical development of palbociclib, a cohort of patients with advanced 
disease were treated with palbociclib (300). In this study, patients received escalating doses 
of palbociclib with three-week on-treatment and one week off-treatment schedule. Based on 
this study, a dose of 125 mg of palbociclib was suggested for the phase II trial. Neutropenia 
was found to be the only significant toxicity in this trial (300). Later on, DeMichele and 
colleagues tested palbociclib in a single-arm phase II trial on 37 advanced BC patients who 
had failed at least two lines of anti-hormonal therapy. A similar dose of 125 mg for three-
week on-treatment regimen was used. Results showed that two patients showed partial 
response to treatment and five patients had stable disease. Neutropenia was detected in 
half of patients, however only one patient developed fever and sepsis. This shows that 
palbociclib is generally a well-tolerated drug while the bone marrow suppression is 
reversible. In fact, in spite of neutropenia most patients were uncomplicated suggesting that 
the bone marrow is still functional (301). As far as biomarkers are concerned, the 
investigators examined tumor tissues for expression of Rb, p16 and Ki67 using 
immunohistochemistry and cyclin D1 amplification using FISH. Surprisingly, no correlation 
was detected between response to treatment with and any of these molecules (301). The 
authors suggest that these biomarkers need to be tested at a larger sample size. In addition, 
other biomarkers such as PI3K pathway or Rb mutation could potentially be involved 
requiring further investigation.  
         PALOMA-1, phase 2 clinical trial, investigated response to letrozole monotherapy or 
letrozole plus palbociclib in postmenopausal ER+ BC patients with advanced disease (296). 
Patients in this study were treatment naïve and were recruited in two different cohorts where 
cohort 1 included only advanced ER positive/Her-2 negative patients and cohort 2 included 
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those with cyclin D amplification and/or p16 loss (296). In cohort 1, palbociclib addition to 
letrozole improved median progression-free survival from 5.7 months to 26.1 months. In 
cohort 2, combination treatment enhanced median progression-free survival from 11.1 
months to 18.1 months. Taken together, addition of palbociclib to letrozole improved median 
progression-free-survival from 10.2 months to 20.2 months (296). The most significant side 
effect was neutropenia (54%) of patients who were treated with both drugs, whereas only 
1% of cases treated in the letrozole arm developed neutropenia. However, addition of 
palbociclib to letrozole did not statistically change overall survival of patients, 33.3 months in 
the letrozole arm versus 37.5 months in the combination group (296). While preclinical 
studies suggest that an intact Rb pathway could be a predictor of response to palbociclib, 
translating such findings to clinical samples is difficult since loss of Rb is uncommon in 
ER+/HER2- breast cancer patients. In addition, it is required to examine whether the level of 
Rb protein could potentially be used as a predictive marker of palbociclib sensitivity. Results 
recently published from the phase III trial (PALOMA-2) also confirmed improved 
progression-free survival in patients who received palbociclib plus letrozole in comparison to 
placebo plus letrozole arm (295). In this phase III trial, 666 ER positive/Her-2 negative 
patients were randomized to receive letrozole or letrozole plus palbociclib. Analysis of the 
data revealed that addition of palbociclib increased progression-free survival by 
approximately fourteen months. Although neutropenia was detected in a majority of patients 
who received combination treatment (79.5%), febrile neutropenia was only found in 2% of 
patients. These results confirm the clinical benefit of palbociclib found in previous phase II 
trial and signifies role of cell cycle regulatory proteins such as cyclin D and CDK4/6 play in 
breast cancer. In the PALOMA-3 study, a total of 521 advanced ER positive/Her-2 negative 
patients with prior relapse or progression on endocrine therapy were assigned to receive 
either fulvestrant and placebo or fulvestrant in combination with palbociclib on a 3-week on 
and 1-week off treatment schedule for palbociclib (302). Most patients recruited in this study 
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were post-menopausal patients (79.3%). Results revealed that patients who received 
palbociclib-fulvestrant regimen had longer median progression-free survival compared to 
those who were treated with fulvestrant alone, 9.2 months versus 3.8 months, respectively 
(302). Grade 3 and 4 neutropenia was detected in 62% of patients who received palbociclib-
fulvestrant treatment but most patients were uncomplicated and did not require 
discontinuation of therapy.  
        In addition to palbociclib, two other CKD4/6 inhibitors are under development; one by 
Lilly known as abemaciclib (LY2835219) and the other one by Novartis company ribociclib 
(LEE011). Ribociclib is another CDK4/6 inhibitor that can prevent phosphorylation of Rb and 
induce cell cycle arrest. Radet et al tested ribociclib on a panel of neuroblastoma cell lines in 
vitro and xenograft tumors and showed that ribociclib induced cell cycle arrest and delayed 
tumor growth (303). Mechanistic analysis by Western blot revealed that ribociclib decreased 
phosphorylation of Rb protein at S780 as early as 6 hours. In addition, ribociclib decreased 
mRNA level of FOXM1, a transcription factor recently found to be a target of CDK4/6 
pathway, in the sensitive cell lines. In addition, ribociclib showed antitumor activity in 
xenograft models alone or in combination with other agents such as MEK inhibitor (304). A 
phase I trial studied ribociclib in a cohort of patients with advanced malignancy (18 BCs) 
(305). Similar to palbociclib treatment, most patients received a 3-week on and 1-week off 
treatment with neutropenia being the most common side effect. Results from a recent phase 
III trial shows the efficacy of ribociclib in combination with letrozole in advanced ER+ breast 
cancer patients (306). In this multi-center study, post-menopausal patients with advanced or 
metastatic disease were randomized to receive either letrozole (daily) in combination with 
ribociclib (21 out of 28-day cycle) or letrozole plus placebo as control arm (306). Results 
from this study showed than ribociclib significantly delayed the progression of breast cancer 
when combined with letrozole (306). Overall response was significantly higher in the 
combination group compared to letrozole-alone treated patients (52.7% VS 37.1%, 
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respectively). Other studies combining ribociclib with endocrine therapies such as tamoxifen 
in premenopausal women (MONALEESA-7 NCT02278120) and fulvestrant in 
postmenopausal women (NCT02422615) are currently undergoing.  
        The third CDK4/6 inhibitor under clinical investigation in this class is abemaciclib. 
Pantaik and colleagues have recently published results of a study using abemaciclib as 
monotherapy which included fourty seven BCs (307). Unlike the other two CDK4/6 
inhibitors, patients received continuous daily or twice a day regimens. Results from this 
study revealed that abemaciclib is generally safe when dosed continuously. More 
importantly, overall response was detected in almost one third of breast cancer patients 
(307). Bone marrow suppression and high-grade neutropenia are less commonly detected 
with abemaciclib compared to palbociclib and ribociclib. However, abemaciclib is associated 
with higher fatigue and diarrhea. Examination of breast cancer tumors from HR+ patients 
treated with abemaciclib showed that the drug was able to inhibit proliferation of breast 
cancer as measured by decreased Ki67 (308). One important aspect of abemaciclib is the 
detection of the drug in the CSF when animal models where examined suggesting that it can 
pass the blood brain barrier. In fact, abemaciclib increased survival of rats harboring 
orthotopic brain tumors (309). This raises the question whether abemaciclib could be 
effective in treating brain metastasis. Besides breast cancer, preclinical models show 
promising results with abemaciclib in mutant BRAF melanoma and glioblastoma (309, 310). 
While the use of CDK4/6 inhibitors in breast cancer has gained a lot of attention recently, 
CDK2 inhibitors are still not well studied. In the next section, the role of CDK2 in breast 
cancer and development of specific inhibitors are discussed in further detail.  
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1-8 CYCLIN E AND CDK2 INHIBITORS IN BREAST CANCER 
        Cyclin E, an important regulator of cell cycle, is deregulated in many human cancers. 
Overexpression of cyclin E is detected in different cancers such as stomach, breast, ovary, 
to mention a few. Immunohistochemistry staining of cyclin E showed overexpression of 
cyclin E in gastric adenocarcinoma in comparison to adenomas (311). In addition, in gastric 
tumor tissues, the level of cyclin E expression correlated with increased proliferation as 
measured by Ki67 using IHC (311). Lindhal and colleagues examined cyclin E expression 
using immunohistochemistry in 270 breast cancer patients with known p53 status (312). 
Cyclin E status was divided into three categories based on the percentage of positive cells 
in IHC; low (less than 4%), intermediate (5-49%), or high (more than 50% positivity) (312). 
Patients with high cyclin E staining tumors had more frequent point mutations, deletions and 
insertions in p53 as well as decreased survival (312). Comparison of BC cell lines (including 
MCF7, T47D, MDA-MB 231, and MDA-MB 436) to normal mammary epithelial cells (70N 
and 76N) revealed overexpression of different cyclins such as cyclin E in breast cancer cells 
(313). Amplification of cyclin E is detected in breast cancer cell line (MDA-MB-157 cell line) 
compared to normal mammary epithelial cells (76N) using southern blot analysis (313). In 
addition, comparison of these two cell lines using northern blot and Western blot analyses 
revealed one similar mRNA in both cell lines (2.1 kb) but three different overexpressed 
“cyclin E (-like)” bands exclusively in cancer cell line suggesting modification at the post 
translational level (313). Further studies using Western blot analysis revealed presence of 
cyclin E isoforms in breast cancer tumor tissues but not normal breast tissue samples (314). 
Several studies using both cell culture as well as animal models in our lab have focused on 
understanding the mechanism by which low molecular weight cyclin E (LMW-E) is produced. 
In one such study flag-tagged cyclin E constructs were introduced into different cell types; 
two normal breast cell lines and two BC cell lines (MDA-MB-157, MDA-MB-436) followed by 
examination of cyclin E expression using Western blot (315). Results indicated generation of 
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LMW-E forms exclusively in the cancer cells suggesting higher activity of cyclin E 
processing in breast cancer cells. Moreover, cancer cells showed higher cyclin E and CDK2 
kinase activities. Western blot analysis using antibodies against flag tag showed cyclin E 
expression suggesting that the cleavage occurs at the N-terminal of the protein because flag 
tag was located at the C terminal of the protein. These findings propose that cancer cells 
activate a protease system that gives the cells capacity to cleave cyclin E into LMW-E 
isoforms. 
        Elastase is a member of serine proteases that is able to cleave full length cyclin E into 
LMW-E forms. Five different isoforms of cyclin E are generated in tumor cells (Figure 4). 
Four of these isoforms are formed by elastase, which is able to cleave full-length cyclin E 
(Figure 4). Western blot analysis showed production of the two doublets at 45 KD (EL2)/44 
KD (EL3) collectively considered as trunk 1 (T1) and 35 KD (EL5)/33 KD (EL6) collectively 
considered as Trunk 2 (T2). The last isoform (EL4) is produced through an alternate start 
site (Figure 4). Mull et al showed that phosphorylation of cyclin E is required for generation 
of LMW-E forms (316). Our lab has applied a mutagenesis approach to alter the 
phosphorylation site of cyclin E in order to further study the generation of these LMW-E 
forms. Results from this approach showed that EL2 band represent the phosphorylated form 
of EL3 and similarly EL5 band is phosphorylated form of EL6 at T395 (Figure 4).  
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Figure 4. Generation of low molecular weight cyclin E in breast cancer. Full length 
cyclin E (EL1, referred to as EL in this dissertation) is cleaved by the activity of the elastase 
enzyme at indicated sites generating two truncated proteins (EL3 and EL6). These two 
isoforms can be phosphorylated at T395 site representing a higher band on Western blot 
(EL2 and EL5). These truncated proteins (T1 and T2) are considered LMW-E isoforms of 
cyclin E and are mainly localized in the cytoplasm. EL4 is a 40 KD protein produced from an 
alternate start site. 
Adapted by permission from Macmillan Publishers Ltd: Oncogene, Mull, B. B., J. Cox, T. 
Bui, and K. Keyomarsi. 2009. Post-translational modification and stability of low molecular 
weight cyclin E. Oncogene 28: 3167-3176, copyright 2009, License Number 
4222210891922 
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        To further study the biologic role of LMW-E, EL and LMW-E constructs were 
overexpressed in insect cells separately along with CDK2 expressing vector (317). Kinase 
assay showed that LMW-E constructs induced higher CDK2 kinase activity compared to EL. 
This increased kinase activity is partially related to higher binding affinity of LMW-E forms 
with CDK2 as examined by immunoprecipitation assay. In addition, although LMW-E and EL 
both showed similar binding pattern to p21 and p27, LMW-E kinase activity was less 
affected by these inhibitors indicating resistance of LMW-E to endogenous inhibitors (Figure 
5). It is worth noting that LMW-E forms are able to sequester endogenous inhibitors away 
from EL. This increased kinase activity was similarly detected in breast cancer cell lines and 
tumor tissues. To investigate the differential activity of EL versus LMW-E, in vitro translated 
forms of both proteins were mixed with cell extracts of breast cancer cells (MDA-MB-157), 
pulled down with antibody and subjected to CDK2 Western blot and kinase assays (318). 
Results from this experiment revealed that EL and LMW-E have the capability to bind to 
CDK2 and induce kinase activity. Of particular note, addition of cyclin E increased 
phosphorylated active form of CDK2 and resulted in higher CDK2 kinase activity (Figure 5). 
In another similar study, EL and LMW-E constructs (both T1 and T2) were overexpressed in 
ER+ cell line (MCF7) followed by assessment of kinase activity in these cells (319). 
Comparison of LMW-E overexpressing clones to EL ones revealed higher cyclin E-
associated and CKD2 kinase activities in LMW-E overexpressing cells. Taken together, 
these studies suggest that LMW-E can bind to CDK2 and is biologically active. However. 
LMW-E isoforms are resistant to p21 and p27 inhibitors highlighting the specific behavior of 
LMW-E. 
        Biologic significance of LMW-E goes beyond increasing CDK2 and cyclin E kinase 
activities. Studies in our lab have shown that in contrast to full length cyclin E, LMW-E 
isoforms are mainly localized to the cytoplasm. Subcellular localization of cyclin E was 
assessed in a panel of different cell lines including immortalized mammary epithelial cells as  
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Figure 5. LMW-E is more hyperactive than EL and is mainly localized in the 
cytoplasm. Low molecular weight cyclin E (LMW-E), compared to full length cyclin E (EL) is 
mainly localized in the cytoplasm, have higher CDK2 kinase activity, is resistant to 
endogenous cyclin dependent kinase inhibitors (P21, P27), and is less affected by F box 
protein (Fbw7). 
Adapted from Cancer Res, 2009, 69: 2817-2825, Delk, N. A., K. K. Hunt, and K. Keyomarsi, 
altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent 
kinase 2 complex formation and proteasomal regulation, with permission from AACR. 
License number 4222220357990 
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well as breast, ovarian and osteosarcoma cell lines (320). Fractionation and Western blot 
analyses revealed LMW-E expression exclusively in the cancer cells with higher localization 
in the cytoplasm. Cytoplasmic cyclin E component is able to bind to cytoplasmic CDK2 and 
is active as measured by its kinase activity. To confirm localization of LMW-E, a protein 
complementation assay with tagged cyclin E (or LMW-E) and CDK2 was used which 
revealed localization of LMW-E mainly in the cytoplasm or perinuclear membrane. In 
contrast to this, full-length cyclin E was mainly localized in the nucleus. This specific 
localization prevents the LMW-Es to be degraded by F box protein which normally 
ubiquitinate and target full length cyclin E for degradation in the nucleus. These specific 
LMW-E features enable these isoforms to be more stable than the full-length cyclin E. These 
experiments suggest that LMW-E is more hyperactive than EL cyclin E contributing to its 
biologic significance in breast cancer.  
        Several other studies have shed light on the significance of cyclin E in breast cancer 
patients.  Cyclin E status was first examined in tissue samples isolated from breast cancer 
patients. To this end, expression of cyclin E and cyclin D were examined in extracts isolated 
from breast cancer as wells as normal adjacent tissues. Results revealed abnormal 
expression of cyclin E in 8 out of 9 patients exclusively in breast cancer tissue but not the 
normal breast tissue (321). In comparison, cyclin D overexpression was seen only in 2 out of 
9 patients. Cyclin E deregulation was associated with higher stage and grade but was 
independent of proliferation (PCNA level by Western blot). To further explore the role of 
cyclin E in the early phase of breast cancer, tumor tissues containing in situ carcinoma (128 
samples) and invasive tumor (177 samples) from a cohort of stage I/II breast cancers were 
stained with cyclin E antibody (322). Cyclin E was considered positive when more than 5% 
positive cells (intensity >1) were detected in each specimen. This analysis revealed cyclin E 
overexpression in almost one third of in situ carcinoma, one third of invasive tumors, as well 
as 45% of normal breast epithelial cells adjacent to tumor tissue. Staining with γH2AX 
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revealed high percentage of DNA damage (77% of samples) in cyclin E overexpressing 
normal breast epithelial cells suggesting that cyclin E overexpression is (1) real and (2) 
induces genomic instability in normal cells. In addition to overexpression, abnormal 
cytoplasmic localization of cyclin E was detected in both breast cancer tissues and breast 
cancer cells. These results suggest that cyclin E deregulation is an early process during 
breast cancer formation and occurs through both overexpression and altered subcellular 
localization. In another study, cyclin E status was examined in frozen tissue samples of 395 
breast cancer patients using Western blot and immunohistochemical analysis (323). EL or 
LMW-E levels were defined as low or high in comparison to normal breast tissue. Statistical 
analysis showed that patients with high levels of full-length cyclin E and LMW-E had poor 
overall and disease-specific survival than those with low levels. In a similar fashion, patients 
with high cyclin E expression, as per IHC, in their breast tumor had poor survival. In addition, 
when cyclin E was examined in stage I-III patients, higher cyclin E level in each stage 
correlated with poor survival from breast cancer. Our lab has recently published the use of 
immunohistochemistry as a feasible method to identify cytoplasmic cyclin E in breast cancer 
tumors (324). Examination of tumor tissues from 1676 breast cancer patients (stage I-III) 
revealed that 40% of patients expressed cyclin E exclusively in the cytoplasm representing 
the LMW-E expression (324). Moreover, the majority of patients with cytoplasmic cyclin E 
expression were also positive for cytoplasmic p-CDK2 (85.1%). On the other hand, almost 
80% of patients who were negative for cytoplasmic cyclin E staining were also negative for 
cytoplasmic phospho-CDK2 indicating that abnormal expression of cyclin E in breast cancer 
tumor deregulates cell cycle by activation of CDK2. More importantly, patients with 
cytoplasmic expression of cyclin E and p-CDK2 in their tumors had higher histologic grade 
and worse prognosis compared to patients who stained negative for these two markers 
(324). Similar to this study, cytoplasmic cyclin E was detected in almost 40% of patients with 
inflammatory breast cancer (IBC) (325). IBC is an aggressive type of BC often with poor 
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response to chemotherapy and poor prognosis indicating that novel therapies are urgently 
needed for this subtype of breast cancer (326). In vitro analysis using IBC cell lines in our 
lab has shown that IBC cell lines are very sensitive to dinaciclib and meriolin 5, two potent 
CDK2 inhibitors (see CDK2 inhibitor section) (325). Mechanistic studies showed that 
dinaciclib induced apoptosis in IBC cell lines as measured by percentage of annexin V 
positive cells, cleaved caspase 3, and cleaved poly ADP ribose polymerase (PARP) 
(indicators of apoptosis) (325). In addition, a combination of dinaciclib given prior to DNA 
damaging agents such as epirubicin and carboplatin showed synergistic activity in IBC cells 
through enhancing DNA damage (325). These results suggest that cyclin E/CDK2 pathway 
is a potential target to be considered in the treatment of IBC patients. Prognostic value of 
cytoplasmic cyclin E is not subtype dependent (327). Cytoplasmic staining of cyclin E 
correlated with LMW-E forms detected by Western blot when 152 tumor samples were 
examined (327). Examination of tissue samples from 2494 patients including all molecular 
subtypes from four different cohorts revealed that cytoplasmic staining correlated with poor 
survival and its prognostic value was superior to all clinical variables as well as Ki67 (327). 
Taken together, these results show the significance of cyclin E as a prognostic marker and 
suggest that targeting LMW-E/CDK2 has potential therapeutic value in patients with 
cytoplasmic expression of cyclin E.  
        To interrogate the tumorigenic activity of LMW-E, Duong et al introduced LMW-E and 
EL in hMEC cells and showed that only the LMW-E harboring cells were able to form tumors 
(328). Serial transplantation of these LMW-E expressing cells in vivo showed enrichment of 
EMT phenotype by downregulating endothelial markers (E-cadherin) while upregulating 
mesenchymal and stem cell markers N-cadherin, Twist, and Slug. LMW-E expressing cells 
showed higher migratory ability compared to EL cells when subjected to a scratch assay. 
Expression of LMW-E in hMECs almost doubled the subpopulation of CD44high/CD24low cells 
(Marker of CSCs) as compared to EL. Moreover, serial transplantation of LMW-E cells was 
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associated with enrichment of the CD44high/CD24low subpopulation. Additionally, LMW-E 
expressing cells formed more and bigger mammospheres in vitro and showed higher ALDH 
activity as two characteristics of CSCS. To further study the significance of LMW-E in breast 
cancer, transgenic animal models of LMW-E and EL cyclin E were generated (329). In this 
model, the LMW-E and EL transgenes were expressed under the MMTV promoter. 
Examination of the mammary gland in ten-day-old lactating mice revealed abnormal 
morphology of the alveolar cells (variable size nuclei) specifically in the LMW-E expressing 
model. Longer follow up of the mice for tumor formation showed higher incidence of 
mammary tumor in LMW-E expressing animals than the EL ones, 25% versus 8.3% of mice, 
respectively. More importantly, LMW-E transgenic mice harbored higher metastasis rate 
(25%) with a mean latency of 17.2 months. Lungs were the main sites of metastasis in these 
animals. Mechanistic studies showed that LMW-E did not induce proliferation or 
chromosomal instability in this transgenic model.  However, loss of the wild-type p53 allele 
increased mammary tumor formation and decreased latency suggesting the cooperation 
between LMW-E and p53 for carcinogenesis. These studies highlight the significance of 
cyclin E in driving mammary tumor formation and metastasis in animal models. 
        Using animal models, our lab has also shown that LMW-E-mediated mammary tumor 
formation requires the activity of CDK2 within the mammary tissues. To address this, 
transgenic animals with CDK2 deficient background were generated (330). CDK2-deficient 
mice showed decreased branching morphology of the breast tissue at an early stage. 
Longer follow up of the animals revealed that LMW-E expression under MMTV promoter 
induced tumor formation in CDK2+/+ or CDK2+/- mice with latency between 16 to 19.5 
months. In contrast, CDK2 deficient mice (CDK-/-) did not form any tumors within a two-year 
follow up. In a similar fashion, pharmacologic inhibition of CDK2 by two different CDK2 
inhibitors (roscovitine and meriolin 5) delayed mammary tumor formation in LMW-E 
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expressing mice and improved survival of these mice. Taken together, these results 
highlight targeting CDK2 as a potential therapeutic strategy in LMW-E expressing tumors. 
        The significant role of LMW-E in breast cancer raises the question whether targeting 
cyclin E could have potential therapeutic role. To explore this, inducible model systems of 
LMW-E and EL in ER positive MCF7 cells were generated. Using this system, our lab has 
examined the differential kinetics of EL and LMW-E over time (331). Comparison of LMW-E 
versus EL expressing cells showed that LMW-E does not alter rate of proliferation compared 
to EL. However, LMW-E expression was associated with enhanced cyclin E associated 
kinase activity and higher chromosomal instability including higher chromosomal breaks, 
fusions and polyploidy. Next, our lab planned to find specific inhibitors that can target LMW-
E expressing cells. Roscovitine that targets CDK2 was not effective to inhibit LMW-E 
inducible cells individually (IC50 15µM), however, a combination of roscovitine followed by 
doxorubicin showed synergistic activity in LMW-E inducible MCF7 cells. This sequential 
combination also showed synergistic activity in a triple negative cell line with high 
endogenous level of LMW-E (MDA-MB-436). The potential efficacy of roscovitine combined 
with doxurubicin was further explored in TNBC. As mentioned earlier, TNBC tumors do not 
express hormone receptors nor Her-2 receptor and thus will not respond to targeted 
therapies against these receptors. In a recently published study, our lab has shown that 
roscovitine alone induces higher G2-M arrest specifically in p53 mutant TNBC cells (332). 
Similar to the previous study in inducible MCF7 cells, administration of roscovitine before 
doxorubicin showed synergistic cell killing in TNBC cells. This sequential combination 
induced apoptosis in 30% and 45% of MDA-MB-157 and MDA-MB-468 cell lines (TNBC cell 
lines), respectively. In terms of mechanism, this combination increased doxorubicin-induced 
DNA damage as measured by γH2AX foci and phospho-H2AX expression. Additionally, the 
sequential combination of roscovitine with doxorubicin controlled tumor growth and 
improved survival of mice implanted with triple negative breast cancer cells.  
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        Further studies show the link between cyclin E and response to platinum-based 
therapy in ovarian cancer. Cyclin E, p27 level, and cyclin E associated kinase activity were 
measured in 75 tumor tissues isolated from ovarian cancer patients who underwent 
chemotherapy with platinum based drugs (333). In this sample set, cyclin E level did not 
correlate with cyclin E associated kinase activity. However, cyclin E associated kinase 
correlated with clinical response to platinum based therapy. Mechanistically, higher cyclin E 
kinase activity resulted in higher inactivation of Rb protein through hyper-phosphorylation 
leading to higher S phase entry and thus more susceptibility to platinum chemotherapy. 
Taken together, these studies suggest that LMW-E is a potential biomarker to select 
patients who would benefit from cyclin E/CDK2 targeting drugs.  
 
1-8a CDK2 Inhibitors in breast cancer  
        Cell cycle deregulation is a common process during tumorigenesis. Therefore, targeting 
cell cycle component by specific CDK inhibitors is a potential therapeutic approach. CDK 
inhibitors are small molecule inhibitors that can bind to CDKs and inhibit their kinase 
activities (281). Flavopiridol was a first generation of CDK inhibitor that reached clinical 
trials, but was not able to be developed into a marketed drug because of toxicity profile. 
Flavopiridol can inhibit different CDKs including CDK1/2, CDK4/6, CDK7 and CDK9 (334). 
Flavopiridol induced G1/G2 cell cycle arrest when two cell lines (MCF-7 and MDA-MB-246) 
were challenged (334). In addition, flavopiridol was induced cell death in bladder cancer cell 
lines at a concentration as low as 50nM as measured by increased annexin V positive cells 
(335). Flavopiridol went into a phase I trial on a cohort of 34 patients with advanced disease 
(2 BC patients) (336). Neither of these two breast cancer patients responded to this 
treatment regimen (336). Results from another study using flavopiridol in combination with 
docetaxel in breast cancer patients were not sufficiently promising to support further drug 
development. This was due to the high rate of toxicity such as neutropenia in the majority of 
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patients (337). Similar to previous studies using flavopiridol most patients experienced 
fatigue and diarrhea, 82% and 64% respectively. However, in colorectal cancer, flavopiridol 
reached to a phase II study which was not further pursued due to lack of objective response 
and toxicities such as diarrhea (21% of patients) and fatigue (11%) (338). Similarly, 
flavopiridol did not reach beyond phase II in malignant melanoma (339) or androgen 
insensitive metastatic prostate cancer patients (340).  
        Another first generation CDK2 inhibitor that was advanced into clinic is known as 
roscovitine (seliciclib) (341). In vitro analysis of roscovitine using ER+ MCF7 cell line 
revealed both G2 arrest as well as apoptosis (342). Furthermore, anti-proliferative activity of 
roscovitine was enhanced when the cells were concomitantly treated with tamoxifen (342). 
Antitumor activity of roscovitine was examined in a xenograft model of breast cancer using 
MCF-7 cells implanted in the subcutaneous tissue of nude mice (343). Results revealed that 
roscovitine or doxorubicin induced almost 50% tumor regression individually compared to 
vehicle treated mice (343). However, a combination of both drugs induced almost 70% 
tumor shrinkage in this model. Mice treated with concomitant treatment showed higher areas 
of necrosis with diminished proliferating cells in the remaining tumors in comparison to 
single treatments (343).  In a phase I study, 21 patients (none had breast cancer) with 
different tumors were treated with roscovitine at a dose range from 100 mg to 800 mg twice 
daily (344). None of treated patients showed objective response to roscovitine but 8 out of 
21 patients had stable disease on treatment (344). Nausea, fatigue and electrolyte 
abnormalities were detected in patients who were treatment with roscovitine. In general, 
these two inhibitors lacked specificity against CDKs with possible off-target effects resulting 
in toxicities when used clinically.  
        Dinaciclib is the next generation CDK2 inhibitor (IC50 1nM) with potential to inhibit 
others CDKs such as CDK1 or CDK9 but at higher IC50 values (345). In addition, dinaciclib 
can block DNA replication at very low nanomolar range. Mechanistic studies using 
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increasing concentrations of dinaciclib on A2780 cells (Human ovarian carcinoma cell line) 
indicated that dinaciclib inhibited phosphorylation of Rb protein (S801/811) at a 
concentration as low as 6nM and induced cleavage of PARP (marker of apoptosis) at 12nM. 
Furthermore, in vivo studies using xenograft model of A2780 showed antitumor activity of 
dinaciclib with only 5% body weight loss when maximum dose (48 mg/kg) was used. The 
authors detected a decrease in the neutrophil and reticulocyte counts at day 6 following 
therapy which was reversible at day 13. Dinaciclib efficacy has also been tested in triple 
negative cell lines. Dinaciclib has apoptotic activity in TNBC specifically in those with MYC 
overexpression. Furthermore, dinaciclib induced tumor regression in xenograft tumors 
derived from two TNBC cell lines (MDA-MB-231 and HCC-3153) (346). These preclinical 
studies suggest that dinaciclib is a valuable drug to be tested in breast cancer patients. 
        The clinical efficacy of dinaciclib has been investigated in different studies. Results of a 
phase I study including 3 patients with BC indicated general safety of dinaciclib (347). 
Patients were treated with increasing concentration of dinaciclib (range from 0.33 to 14 
mg/m2) once every week for three weeks followed by one week of recovery. Results of this 
study indicated that 10 out of 48 patients showed prolonged stable disease and confirmed 
that the drug is well tolerated. To advance clinical development of dinaciclib, a cohort of BC 
patients with history of chemotherapy failure were categorized to treatment with dinaciclib or 
capecitabine. The trial was stopped since lower time to progression was detected in the 
dinaciclib arm (median 2.7 months) compared to the capecitabine arm (median 4.1 months) 
(348). However, antitumor activity was reported in 2 out of 7 ER+ breast cancer patients. 
47% of patients on dinaciclib treatment showed significant drop in neutrophil count and 21% 
showed significant decrease in the total number of leukocytes. Another study using 
dinaciclib plus epirubicin in a cohort of metastatic TNBC was terminated early due to severe 
neutropenia in spite of growth factor use suggesting that this combination modality is not 
satisfactory for TNBC patients (349). Therefore, studies using dinaciclib in breast cancer are 
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very preliminary and inconclusive. However, promising results have been detected in other 
cancers as discussed in the next paragraphs suggesting that the drug could be potentially 
tested in more clinical trials including breast cancer patients.  
        Dinaciclib has shown promise in hematologic malignancies and is further studied in 
lung cancer. Dinaciclib at those of 12 mg/m2 was administered IV at days 1,8, and 15 within 
a 28-day cycle for lymphoma patients (350). Most patients tolerated a few cycles of 
treatment using such dose while adjustment in dose (decrease to 10mg/m2) was required for 
two patients. The authors reported clinical response in some of these highly pretreated 
patients. In patients with refractory or relapsed CLL, a combination of dinaciclib (started at 
7mg/m2 and increased to 10 mg/m2 in further cycles) with rituximab was well tolerated (351). 
A more recent study reported administration of different concentrations of dinaciclib (a range 
from 7mg/m2 to 17 mg/m2) to 52 refractory or relapsed CLL patients with at least 4 previous 
treatments. Dose limiting toxicity was set as 17 mg/m2 and was further tested in an 
expansion study. Response was detected in 54% of CLL patients with administration of 
dinaciclib as monotherapy (352). A phase II study compared the efficacy of dinaciclib 
(50mg/m2) with erlotinib, a standard of care EGFR inhibitor used in advanced NSCLC, in a 
cohort of pretreated non-small cell lung cancer patients. Although dinaciclib was well 
tolerated, it did not improve time to progression in comparison to erlotinib suggesting that it 
is not effective as single agent therapy for these patients (353). Taken together, the studies 
using dinaciclib in human cancers show that it is fairly well tolerated drug. However, 
appropriate selection of patients and dosing are required to identify patients who would 
benefit from dinaciclib treatment. Using cyclin E as a predictive biomarker of response could 
be a feasible approach to identify and select patients. Additionally, a combination of 
dinaciclib with AIs may have beneficial role in ER+ patients with abnormal cyclin E pathway.  
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1-9 GAP IN KNOWLEDGE  
        Approximately 75% of all breast cancer patients express hormone receptor on the 
surface of their tumors requiring anti-hormonal therapies. Resistance to anti-estrogen 
therapies develops overtime during treatment as patients are often treated for five years. In 
the neoadjuvant setting only half of patients showed objective response to letrozole (190). In 
addition, the majority of BC patients with metastatic disease show resistance to these drugs 
(187). As discussed earlier, different mechanisms have been implicated in resistance to anti-
estrogens including aromatase inhibitors. Studies have shown that Her-2 is overexpressed 
upon resistance to aromatase inhibitors. However, theoretically only a minority of patients 
would express both ER and Her-2 receptor on the surface of their tumors and thus would 
benefit from the dual inhibition of these receptors. In addition, resistance to Her-2 targeted 
therapies develops as mentioned earlier (33). Aberrant activity of signaling pathways can 
contribute to resistance to hormonal therapies. For example, different clinical trials have 
investigated the beneficial role of mTOR inhibition in HR positive breast cancer patients 
(229, 354). Among these however, everolimus is the only signal transduction-targeting drug 
that has gained FDA approval to reverse resistance to endocrine therapy in BC patients with 
advanced disease (229). Further novel therapies are urgently needed to tackle against 
resistance to AIs. Recent clinical trials combining CDK4/6 inhibitors with letrozole have 
shown promising results indicating the significance of G1 cell cycle component in promoting 
breast cancer (295). Cyclin E is deregulated in breast cancer and abnormal cyclin E 
expression has prognostic value (323). LMW-E isoforms are specifically generated in cancer 
cells and deregulate cell cycle by enhancing G1 to S transition. However, the significance of 
cyclin E deregulation in patients treated with aromatase inhibitors is not yet studied. The 
goals of this study are to investigate the correlation between cytoplasmic cyclin E and 
response to AI in HR+ BC patients, investigate resistance mechanisms to AIs, and 
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determine whether CDK2 inhibitors such as dinaciclib (as binding partner of cyclin E) may 
be successful in reversing resistance to AIs.  
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CHAPTER 2: CYTOPLASMIC CYCLIN E MEDIATES RESISTANCE TO AROMATASE 
INHIBITORS  
2-1 INTRODUCTION  
        The majority of breast cancer patient harbor tumors that express hormone receptors 
(70-80% of all patients) (2, 3). These patients harbor tumors with ER or PR expression and 
may benefit from the anti-estrogen treatments including aromatase inhibitors, tamoxifen, or 
fulvestrant (128-132). Aromatase inhibitors are considered as the first line treatment in post-
menopausal BC patients. Clinical studies have shown superiority of AIs to tamoxifen in post-
menopausal patients (187,188). However, some patients show de novo resistance to these 
medications and oftentimes tumors relapse in spite of initial response after long-term 
treatment with aromatase inhibitors (187,193). In spite of numerous studies aimed at 
understanding the biology of such resistance, current combination treatments are not 
completely successful to eradicate tumors resulting in progression of the disease. 
        Multiple mechanisms have been discussed in the literature contributing to resistance to 
these hormonal therapies. Examples of these alternative mechanisms include increased 
aromatase expression (207), alteration of ER expression including epigenetic silencing or 
mutation of the gene (148), independent activation of ER through growth factor signaling 
pathway (169,170), induction of ER transcription by androgen receptor (213), 
overexpression of growth factor receptors such as Her-2, and activation of intracellular 
cascades such as MAPK and PI3K (217). In addition to these mechanisms, there is new 
evidence on the role of cell cycle regulators in resistance to aromatase inhibitors. For 
example, AI resistant cells show abnormal expression of aurora kinase A and B (mitotic cell 
cycle regulator) or polo-like kinase 1 (G2 phase regulator) and respond to aurora or polo-like 
kinase inhibitors (355, 356). Results from combination of CDK4/6 inhibitor (palbociclib) with 
letrozole revealed improved median progression-free-survival in HR+ postmenopausal 
patients diagnosed with advanced stage (296). These results confirm the significance of cell 
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cycle targeted therapy in HR+ breast cancer patients. However, further studies are needed 
to identify biomarker of response to CDK4/6 inhibitors. 
        Cyclin E is a major regulator of G1/S checkpoint and is deregulated in many 
malignancies including breast cancer (311). Studies in our lab have shown that cyclin E is 
cleaved into oncogenic LMW-E specifically in the cancer cells but not normal breast cells 
(314, 315). In comparison to full length cyclin E, LMW-Es are biologically hyperactive, bind 
more tightly to its kinase partner CDK2, are resistant to endogenous inhibitors of cyclin 
dependent kinases, and are mainly localized to the cytoplasm of the breast cancer cells 
(317, 319, 320). More importantly, examination of cyclin E status in tissue samples of 395 
BC patients using Western blot analysis showed correlation between cyclin E and poor 
survival. Subcellular localization of LMW-E in the cytoplasm as detected by 
immunohistochemistry assay also enables identification of patients who express LMW-E in 
their tumor tissues (324). The majority of these patients with cytoplasmic cyclin E expression 
also showed phosphorylated CDK2 expression in the cytoplasm associated with higher 
histologic grade and worse prognosis (324). Animal models using LMW-E expression 
hMECs showed that only LMW-E but not full-length harboring cells are capable to generate 
tumors in vivo (328). Moreover, serial transplantation of these LMW-E expressing cells 
resulted in enrichment of cancer stem cells (331). Given the important role of cyclin E and 
CDK2 pathway, combination treatments including inhibitors of CDK2/cyclin E pathway may 
have beneficial role in breast cancer.  
        Combination of a CDK2 inhibitor (dinaciclib) with epirubicin or carboplatin has 
synergistic activity in IBC cell lines (325). Similar synergistic activity has been detected when 
combining roscovitine with doxorubicin in preclinical models using ER+ MCF7 cell line or 
triple negative cell lines (332). In preclinical animal models, dinaciclib was able to regress 
xenograft tumors derived from triple negative cell lines (346). Although clinical studies using 
dinaciclib combination in breast cancer are limited and preliminary, promising results have 
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been observed in hematologic malignancies (350) (351). Considering the important function 
of LMW-E in BC, we propose that targeting this pathway with CDK inhibitors such as 
dinaciclib is a potential combination therapy that needs to be considered along with 
aromatase inhibitors. Therefore, we hypothesize that LMW-E expression deregulates 
cell cycle and mediates resistance to aromatase inhibitors. To address this hypothesis, 
we examined three different aims in this study: 
1) Determine response to neoadjuvant AIs in post-menopausal BC patients with or without 
LMW-E expression  
2) Investigate mechanism of resistance to aromatase inhibitors using LMW-E inducible 
model system  
3) Determine LMW-E medicated response to letrozole in xenograft model of hormone 
receptor positive breast cancer    
 
2-2 MATERIALS and METHODS 
2-2a Cell lines and cell culture 
        We purchased ER+ cell lines (MCF7& T47D) from the American Type Cell Culture 
Collection (ATCC, Manassas, VA). Aromatase overexpressing MCF7 cells were cultured as 
previously described (357). Briefly, we cultured the cells in Dulbecco’s modified Eagle 
medium (DMEM)(Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Flowery Branch, GA) and G418 purchased from Teknova 
(Hollister, CA) at 600μg/ml concentration. We generated cyclin E inducible MCF7Ac1 cells 
using transcripts expressing full-length cyclin E, LMW-E, or empty vector and maintained 
them in DMEM supplemented with 10% tetracycline-free FBS, 600 μg/ml G-418, and 4 
μg/ml blasticidin from InvivoGen (San Diego, CA). T47D cells were cultured as previously 
described in minimum essential medium alpha modification from Sigma-Aldrich (St. Louis, 
MO) supplemented with sodium pyruvate (1 mM), non-essential amino acids (0.1 mM), L-
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glutamine (2 mM), and HEPES (0.01 M) (358). Full-length and LMW-E expressing T47D 
cells, previously generated in our lab, were maintained in the same media as T47D but 
supplemented with 200 μg/ml of G418. All plates were kept in incubators at 37° C containing 
6.5 % CO2 with fresh media being replaced every 2-3 days. Cell lines were tested for 
mycoplasma and if positive, treated accordingly with plasmocin (InvivoGen, San Diego, CA) 
until eradication before using them for experiments. 
 
2-2b Cyclin E expression model system 
        We generated cyclin E inducible system in MCF7Ac1 cells and cyclin E stable system 
in T47DAc1 cells. For this purpose, we transfected 293T cells with a vector containing 
tetracycline repressor and blasticidin-resistance cassette (pBMN-BSR-TetR) to generate 
viral particles harboring Tet repressor gene. Next, MC7Ac1 cells were infected with the viral 
particles and cells were screened with blasticidin 48 hours after infection. We performed 
Western blot analysis to confirm expression of Tet repressor. We repeated the same 
infection using cyclin E constructs harboring TetO upstream of full-length, LMW-E, or empty 
vector expression vector and selected the cells using puromycin 1 μg/ml (InvivoGen, San 
Diego, CA). Generation of cyclin E constructs (CMV-TetO-Cyclin E) are described 
elsewhere (359). Cells were plated in small quantity to allow single colony growth. Next, we 
picked and expanded single colonies, harvested cells with or without doxycycline, and 
confirmed cyclin E expression in the individual colonies using Western blot analysis. At least 
two colonies for each cyclin E isoform were selected to perform our experiments. Colonies 
that were leaky or non-inducible were excluded. We used the same protocol and infected 
T47D LMW-E and vector control cells with viral particles harboring human aromatase 
construct and a blasticidin resistant cassette (Clone ID: PLOHS_ccsbBEn_06078, 
ORFeome core at MD Anderson). Western blot analysis was performed to confirm 
aromatase expression. 
 
 
73 
2-2c CDK2/Rb knock down experiments 
        In order to knock down Rb or CDK2, we first transfected 293T cells with constructs 
harboring shRNA targeting CDK2 or Rb fused with GFP. We next infected inducible 
MCF7Ac1 cells with viral particles and sorted GFP+ cells using flow cytometry 48 hours after 
infection. To maximize knock down efficiency, we repeated the sorting process followed by 
Western blot analysis to confirm efficient knock down. Multiple independent shRNA 
constructs were used and two clones with the best knock down efficiency were selected for 
further experiments. shRNA constructs were purchased from shRNA core facility at MD 
Anderson Cancer Center, CDK2 (Clone ID: V3LHS_637569 and V3LHS_637573) or Rb 
(Clone ID: V2LHS_130606 and V3LHS_340825). 
 
2-2d Proliferation and cell viability assays  
        To measure proliferation, we deprived the cells of estrogen for four days before each 
experiment. To remove estrogen from media, we added dextran-coated charcoal (Sigma-
Aldrich, St. Louis, MO) to tetracycline-free FBS followed by shaking overnight at 4°C and 
filtration the next day to remove charcoal. This process removes most of the estrogen from 
the FBS. Next, we cultured the cells in phenol red-free improved minimum essential medium 
(IMEM; Corning, Corning, NY) supplemented with 10% of tetracycline-free charcoal-treated 
FBS for 4 days before each experiment. We plated equal number of inducible MCF7Ac1 
cells in 6-well plate and exposed for twenty four hours to doxycycline at a concentration of 1 
ng/ml in order to induce cyclin E followed by drug treatment. Fresh media containing drug 
and doxycycline was replaced every 48 hours. Control conditions containing only vehicle 
without doxycycline were included for each experiment. At the end of experiment, we 
washed the cells with cold phosphate-buffered saline (PBS) followed by trypsinization to 
detach the cells and counting using an automated cell counter (Biorad, Hercules, CA) or 
Coulter Counter (Z series; Beckman Coulter, Brea, CA). To measure proliferation of 
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aromatase overexpressing T47D cells, we deprived the cells from estrogen by culturing 
them in phenol red-free MEM (Corning, Manassas, VA) supplemented with 10% charcoal 
dextran-stripped FBS (Gemini, Sacramento, CA) for four days. Next, we measured 
proliferation of the cells by counting cell number after treatment with aromatase inhibitors for 
three days. Androstenedione was purchased from Sigma-Aldrich (St. Louis, MO) and 
dissolved in ethanol as vehicle and maintained at 4°C. We purchased both AIs from Sigma-
Aldrich (St. Louis, MO) and diluted them in ethanol. We measured cell viability using a high 
throughput survival assay described previously (331). We deprived the cells from estrogen 
for four days as explained earlier and plated equal number of cells in 96-well plate. The next 
day, we changed media to an estrogen-deprived media with or without doxycycline to induce 
cyclin E expression in inducible cells. Next, we treated the cells with or without 
androstenedione and AIs for a total of 12 days. Fresh media containing drugs was replaced 
every other day. At the end of the experiment, we washed the cells in PBS, stained them 
with crystal violet, washed the cells again to remove extra crystal violet, solubilized the cells, 
and finally measured absorbance at 590 nm using an Epoch spectrophotometer (BioTek, 
Winooski, VT). For dinaciclib and palbociclib treatment, we deprived inducible cells of 
estrogen, challenged with/without doxycycline, treated with palbociclib or dinaciclib, followed 
by culture in drug-free media until analysis at day 12.  
 
2-2e Cell cycle analysis 
       To analyze cell cycle, we deprived the cells of estrogen for 4 days and plated 1 × 106 
cells followed by treatment as indicated in each figure. Following drug treatment at indicated 
date, we washed the cells in cold PBS, harvested them and maintained the cells in 70% 
ethanol at 4°C overnight. Next, we centrifuged the cells, removed ethanol, washed them 
with PBS, and maintained them in PBS solution containing 0.5% Tween-20 and bovine 
serum albumin, 20μg/mL ribonuclease A, and 10 μg/mL PI overnight to stain the cells. We 
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then incubated the cells at 37oC for an hour, filtered them to avoid pellet formation, and 
subjected a minimum of 10000 cells to flow cytometry analysis at MD Anderson flow 
cytometry facility as previously described (360).  
 
2-2f Western blot analysis and in vitro kinase assay 
       Following drug treatment, we washed the cells with PBS, trypsinized the cells to 
separate them from the plates, neutralized trypsin using the same volume of inhibitor, and 
centrifuged to precipitate the pellet. Next, we washed the cells twice in ice-cold PBS and re-
suspended them in the same volume of phosphatase/protease inhibitor, sonicated 
(Sonicator XL; Misonix Inc) followed by ultracentrifugation to clear the lysate. We determined 
total concentration of protein in each sample using the Bradford assay. We loaded equal 
amount of protein on SDS-polyacrylamide gel and subjected them to electrophoresis at 120 
V, followed by overnight transfer to Immobilon P membrane (Millipore) at 35 V at 4°C. The 
next day, we stained the membrane with ponceau for 5 minutes, de-stained with 5% acetic 
acid for visualization of protein, washed in TBST, and blocked the membrane in BLOTTO 
milk at room temperature. We incubated the membrane with primary antibodies for 2 hours 
and appropriate secondary antibodies for 1 hour at room temperature with multiple washes 
in between. Primary antibodies used for this assay included cyclin E (HE12; Santa Cruz 
Biotechnology, Santa Cruz, CA), CDK2 (Santa Cruz Biotechnology), pCDK2 (Cell Signaling 
Technology, Danvers, MA), Rb (BD Pharmingen, San Jose, CA), pRb (S807/811; Cell 
Signaling Technology), CDK4 (BD Pharmingen), CDK6 (Santa Cruz Biotechnology), 
aromatase (Biorad), actin (Millipore, Billerica, MA), and vinculin (Sigma-Aldrich). Secondary 
antibodies were goat anti-mouse or goat anti-rabbit immunoglobulin conjugated with 
horseradish peroxidase (Pierce, Rockford, IL). After the final wash, we developed the 
membranes using a Renaissance chemiluminescence system (Perkin Elmer Life Sciences, 
Inc., Boston, MA) according to the manufacturer’s instructions. 
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2-2g Aromatase activity assay 
       To measure aromatase activity, we used an in vivo assay using radiolabelled 
androstenedione as the substrate. To this end, we deprived the aromatase overexpressing 
inducible cells of estrogen for four days, plated them into 6-well plates and challenged the 
cells with or without doxycycline (1ng/ml) for 24 hours to induce cyclin E expression. The 
next day, we treated the cells with 100nM of radiolabelled androstenedione (PerkinElmer, 
Waltham, MA) with different concentrations of letrozole for 4 hours. Next, we collected 1ml 
of the media containing radiolabelled H2O and mixed with 2 ml of chloroform. We removed 
any extra steroid by treating the upper aqueous phase with 2.5% charcoal for 30 minutes, 
centrifuged each sample for 10 minutes at 2000 g, and measured radioactivity using a liquid 
scintillation analyzer. To normalize radioactivity in each sample, we measured protein 
concentration using the Biorad assay following solubilizing the remaining cells in each well 
by 0.5M NaOH and adjusted the activity to the level in each well.  
 
2-2h Real-time PCR  
        We extracted RNA from cells at the end of treatment experiments using the RNeasy kit 
(QIAGEN, Hilden, Germany) following the instructions of the manufacturer. RNA from each 
sample (2 μg per sample) was reverse-transcribed to generate cDNA using the cDNA 
synthesis kit (Applied Biosystems, Foster City, CA). We subjected each sample to 
quantitative PCR analysis using SYBR Green Master Mix (Applied Biosystems) and 
normalized the value to the level of GAPDH expression. Primers used were as following:  
pS2 F 5'-GTACACGGAGGCCCAGACAGA 
pS2 R 5'-AGGGCGTGACACCAGGAAA 
Progesterone F 5'-ACCCGCCCTATCTCAACT 
Progesterone R 5'-AGGACACCATAATGACAGCCT 
GAPDH F 5'-ACCCAGAAGACTGTGGATGG 
 
 
77 
GAPDH R 5’-CTGGACTGGACGGCAGATCT 
 
2-2i Establishment of xenograft model 
        We developed a xenograft model systems representing aromatase inhibitor treatment 
by injecting aromatase-overexpressing inducible MCF7 cells into mammary fat pads of 4-6-
week-old female nude mice. We purchased animals from the colony of the Department of 
Experimental Radiation Oncology at MD Anderson and performed ovarian removal surgery 
before cell injections. Since these mice are deficient in androstenedione production, we 
supplemented them with subcutaneous androstenedione pellets in the neck (7.5 mg/pellet, 
60-day release; Innovative Research of America, Sarasota, FL). We harvested aromatase 
overexpressing inducible cells, centrifuged them with final wash in PBS, diluted to 50% 
Matrigel (Corning, Tewksbury MA), and maintained on ice before injection (100 μl per 
injection). We measured tumors using calipers twice a week starting from the time that 
tumors reached a measurable size. We randomized the mice to treatment arms such that 
there were no differences between initial tumor volumes (150 mm3). We diluted letrozole in 
hydroxypropyl cellulose (vehicle, Sigma-Aldrich, St. Louis, MO) and supplemented drinking 
water with doxycycline in the experiment arms (1 mg/ml plus 5% sucrose) to induce cyclin E 
expression throughout the treatment period. We randomized the mice to treatments; vehicle, 
vehicle plus doxycycline, letrozole (10 μg/day, 5 days per week), or letrozole plus 
doxycycline until the end of the experiment when we sacrificed the mice and collected 
tumors for Western blot and immunohistochemistry assays.  
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2-2j Patient data 
        We collected data from a cohort of newly diagnosed ER+ postmenopausal patients 
(stage II & III) who were recruited as part of The American College of Surgeons Oncology 
Group (ACOSOG)-Z1031 study (361). Core biopsy was performed initially to diagnose 
breast cancer and to ascertain hormonal status and Her-2 expression (Her-2 negative 
patients were included). Patients were randomized to receive neoadjuvant treatment with 
AIs for 16-18 weeks before undergoing tumor resection. All patients who participated in the 
study signed an informed consent approved by the Institutional Review Board and in 
accordance with federal and institutional guidelines. We also obtained IRB approval at MD 
Anderson for this study. Paraffin-embedded tumor tissues following neoadjuvant treatment 
were obtained from the pathology bank at MD Anderson Cancer Center and used for 
immunohistochemistry analysis. Further clinical information is provided in the result section 
of this chapter.  
 
2-2k Immunohistochemistry staining and scoring system 
        Immunohistochemistry analysis and scoring system were performed as previously 
described. We cut 5-μm-thick sections from xenograft tumors or patient samples, de-
paraffinized, and rehydrated the slides by immersing them in Histoclear (National 
Diagnostics), alcohol series (100%, 90%, 70% for 5 minutes each), PBS (5 minutes), and 
ddH2O (5 minutes). We immersed the slides in Vector antigen unmasking solution for 20 
minutes at 90°C and 20 minutes at room temperature to retrieve antigens. We washed the 
slides in ddH2O three times (5 minutes each), soaked them in 3% hydrogen peroxidase 
(diluted in methanol) for 15 minutes at room temperature followed by incubation with goat 
blocking serum for 1 hour at room temperature in order to block endogenous peroxidase 
and nonspecific binding. We washed the slides in PBS at room temperature 3 times (5 min 
each) and incubated with primary antibodies in a humid chamber at 4°C overnight. Primary 
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antibodies used in this analysis included polyclonal cyclin E (Santa Cruz Biotechnology), 
polyclonal pCDK2 (Thr160; Cell Signaling Technology), and monoclonal Ki67 (MIB-1; Dako, 
Carpinteria, CA). The next day, we washed the slides in PBST (0.1% Tween-20 in PBS) and 
incubated them with biotinylated secondary antibodies in a humidified chamber for 30 
minutes at room temperature. At the end of incubation, we washed the slides in PBST three 
times (5 minutes). We incubated the slides in ABC solution from Vectastain Elite ABC Kit 
(Vector Labs, Burlingame, CA) for 30 minutes followed by washing three times in PBS (5 
minutes each) and two times in ddH2O (5 minutes each). We next developed the slides by 
incubating the slides in DAB substrate and washed the slides in ddH2O. We counterstained 
the slides with Mayer’s hematoxylin for 10 seconds followed by washing under tap water. 
We immersed the slides in serial ethanol (70%, 90%, 100%) for 5 minutes each and in 
Histoclear for two times (5 minutes each) in order to rehydrate and cover-slipped with 
Permount. We scored cyclin E and pCDK2 staining as previously described in our lab (362). 
To this end, we determined the intensity of staining independently both in the nucleus and 
cytoplasm of the cells. We assigned the staining pattern into four different categories: 0 
represent without any detectable staining, 1 represent weak staining, 2 represent moderate 
staining, and 3 shows strong staining. Tumors with no staining or only nuclear staining were 
considered as LMW-E negative. However, tumors were considered LMW-E positive if they 
showed cytoplasmic-alone or combination of cytoplasmic and nuclear pattern. To determine 
pCDK2 staining we combined two different scores assigned by the intensity of the staining 
(0 to 3) and the percentage of positive cells (0 to 6) for a total score 18. Any tumor tissue 
with score above 6 was considered as positive for pCDK2 expression. The scaling system 
for percentages included: 0 = 0%, 1 = 1-5%, 2 = 6-10%, 3 = 11-25%, 4 = 26-50%, 5 = 51-
75%, and 6 = 76-100% and for intensity included: 0: no staining, 1: weak staining, 2: 
moderate staining, and 3: strong staining. To determine the percentage of Ki67 positivity, we 
counted three different regions of each tumor and counted at least 200 cells in each area 
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and calculated the average positivity in each tumor.   
 
2-2l Statistical analysis  
        We repeated all in vitro experiments in triplicate and used two-sided T test to perform 
pairwise comparisons using Prism software 6th version (Prism, San Diego, CA). P<0.05 was 
considered statistical significance. The period between performing surgery until any 
recurrence from breast cancer was defined as recurrence-free interval and estimated using 
the Kaplan-Meier method. We censored cases with death from other medical conditions or 
those with secondary malignancies. We compared recurrence-free survival and other 
parameters such as Ki67 staining, PEPI score, or LMW-E status using long-rank test.  
 
2-3 RESULTS  
2-3a LMW-E informs poor response to neo-adjuvant AIs in HR+ breast cancer patients 
       To examine the correlation between LMW-E and clinical response to aromatase 
inhibitors, we determined cyclin E status in a cohort of patients who underwent neoadjuvant 
AI therapy as part of the Z1031 trial. These patients (n=73) were randomized to receive 
aromatase inhibitors for a period of 16-18 weeks before undergoing surgery at MD 
Anderson Cancer Center. Clinical data and pathologic features are summarized in table 3. 
We excluded 11 patients due to lack of follow up ultrasound or unavailable post-treatment 
tissue samples (Figure 6). Post-treatment tissue samples isolated at the time of surgery 
were subjected to immunohistochemistry analysis using cyclin E antibody to determine 
cytoplasmic versus nuclear staining pattern of cyclin E protein. We stratified each tumor into 
LMW-E positive if the tumors scored positive for cytoplasmic staining of cyclin E as we have 
previously shown that LMW-E localizes mainly to the cytoplasm of breast cancer cells (320, 
324). We detected cytoplasmic staining of cyclin E (LMW-E expression) in 32 out of 65 
(49%) of breast cancer tumor tissues (Figure 7A). Waterfall plot showed that patients with 
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the maximum shrinkage of tumor during neoadjuvant therapy were mainly in the LMW-E 
negative category (Figure 7B). In contrast, LMW-E expressing tumors were significantly 
correlated with higher remaining tumor volume and lymph node involvement at diagnosis 
(Figure 7, C and D). Moreover, long-term follow up of these patients showed higher relapse 
from breast cancer in patients who express LMW-E in their tumors (Figure 7E). Other 
studies have shown the link between PEPI score (a combination of tumor size, lymph node 
status, Ki67 and ER status) and risk of relapse in the neoadjuvant setting (152). We 
detected higher PEPI score in patients who express LMW-E in their tumors compared to 
those with no LMW-E expression (Figure 7F). 
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Figure 6: Remark diagram indicating HR+ post-menopausal patients who were 
included to study cyclin E status as part of the (ACOSOG)-Z1031 trial. 
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Figure 7: LMW-E correlates with lack of response to neoadjuvant aromatase 
inhibitors. (A) Representative immunohistochemistry staining using cyclin E antibody 
showing four different phenotypes based on the pattern of cytoplasmic (C) compared to 
nuclear (N) staining (B) waterfall plot indicating percent change in tumor size after 16-18 
weeks of neoadjuvant AI treatment in patients with LMW-E positive (red) and negative 
(green) tumors (C) comparison of change in tumor size between the two groups in panel B 
(D) lymph node involvement in ER+ postmenopausal patients with LMW-E positive and 
negative tumors (E) recurrence-free survival in ER+ patients with LMW-E positive and 
negative tumors (F) comparison of preoperative endocrine prognostic score (PEPI) in ER+ 
patients with or without LMW-E expression  
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       We further investigated the significance of LMW-E binding partner, CDK2, in mediating 
resistance to neoadjuvant aromatase inhibitor. To this end, we stained tissue samples from 
the same patients using phospho-CDK2 antibody and dichotomized tumors into phospho-
CDK2 negative or positive based on intensity and the percentage of positive cells. Statistical 
analysis showed correlation between LMW-E and cytoplasmic phospho-CDK2 in tumor 
samples (Figure 8, A and B). Cytoplasmic phospho-CDK2 expression correlated with 
diminished response to neoadjuvant aromatase inhibitors (Figure 8C). Finally, we 
interrogated the significance of Ki67 as a tumor proliferation marker in predicting response 
to AIs. In these samples, no correlation was detected between post-treatment Ki67 level and 
relapse-free survival (Figure 8D). Taken together, these results suggest that LMW-E and 
phospho-CDK2 status can inform response to AIs in the neoadjuvant setting. 
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Figure 8: Cytoplasmic phospho-CDK2 correlates with LMW-E expression and lack of 
response to aromatase inhibitors. (A) Representative immunohistochemistry staining of 
remaining tumors following neoadjuvant aromatase inhibitor treatment using cyclin E and 
phosphoCDK2 (pCDK2) antibody (B) Correlation between LMW-E and cytoplasmic 
phosphoCDK2 expression in tissue samples after neoadjuvant treatment with aromatase 
inhibitors (C) Percent change in tumor size after neoadjuvant AI therapy in patients with or 
without pCDK2 expressing tumors (D) Comparison of relapse rate between patients with 
Ki67-high versus Ki67-low tumors following neoadjuvant treatment with aromatase 
inhibitors.  
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Table 3: characteristics of ER+ postmenopausal patients treated with neo-adjuvant 
aromatase inhibitors (AIs) at MD Anderson Cancer Center 
 
 
Factor 
 
Number (%) 
Age at diagnosis (years): 
Median (range) 
 
64 (47-84) 
Neoadjuvant AIs 
Anastrozole   
Letrozole 
Exemestane 
 
26 (35.6) 
24 (32.9) 
23 (31.5) 
Lymph node status  
Positive   
Negative 
 
30 (41.1) 
43 (58.9) 
Adjuvant chemotherapy 
Yes 
No 
 
28 (38.4) 
45 (61.6) 
Radiation therapy 
Yes 
No 
 
56 (76.7) 
17 (23.3) 
Stage 
I 
II 
III 
IV 
 
0 (0) 
50 (68.5) 
23 (31.5) 
0 (0) 
Estrogen receptor 
Positive  
Negative 
 
73 (100) 
0 (0) 
Progesterone receptor 
Positive 
Negative 
 
66 (90.4) 
7 (9.6) 
Her-2 receptor 
Positive 
Negative 
 
0 (0) 
73 (100) 
Subtype 
Ductal carcinoma 
Lobular carcinoma 
Mixed ductal and lobular 
Mucinous 
Unspecified 
 
45 (61.6) 
14 (19.2) 
12 (16.4) 
1 (1.4) 
1 (1.4) 
Recurrence/metastasis 
Positive 
Negative 
 
7 (9.6) 
66 (90.4) 
Cyclin E staining 
Cytoplasmic positive (LMW-E) 
Cytoplasmic Negative (No LMW-E) 
Unavailable samples 
 
32 (43.8) 
33 (45.2) 
8 (11) 
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2-3b LMW-E expression overcomes inhibition of proliferation by aromatase inhibitors  
       In order to study the mechanism of LMW-E mediated resistance to aromatase inhibitors, 
we developed a model system using aromatase overexpressing MCF7 cells to inducibly 
express cyclin E. In this model system, individual clones are able to express full length or 
LMW-E isoforms only upon exposure to doxycycline (1ng/ml) (Figure 9A). Moreover, cyclin 
E expression was independent of aromatase expression as shown in the Western blot 
analysis (Figure 9A). We used empty vector (not able to express cyclin E) and GFP 
inducible cells as control for our experiments. In order to detect the effect of aromatase 
activity, we challenged aromatase-overexpressing cells (control) to estrogen deprivation 
followed by androstenedione treatment. We detected enhanced proliferation by 2.5 fold 
compared to estrogen deprivation condition (Figure 9B). This suggests that the cells are 
able to generate estrogen through conversion of supplemented androstenedione by 
aromatase activity inside the cells. This process represents steroid production in 
postmenopausal patients in whom androgen precursors are converted to estrogen by the 
activity of aromatase enzyme. Treatment of these cells with AIs (letrozole or anastrozole) in 
addition to androstenedione inhibited androstenedione-induced proliferation in a dose 
dependent manner (Figure 9, B and C).  
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Figure 9: Aromatase inhibitors inhibit androstenedione-induced proliferation. (A) 
Example of Western blot analysis showing aromatase and cyclin E using aromatase 
overexpressing cells. Aromatase overexpressing MCF7 cells infected with viruses to 
inducibly express empty vector (EV), full-length cyclin E (EL), or LMW-E isoforms (T1 or T2) 
upon doxycycline challenge (1 ng/ml). (B, C) Aromatase-overexpressing MCF7 cells 
(control) were deprived of estrogen for 4 days followed by treatment with androstenedione 
(AD; 25nM) with/without letrozole (LET) or anastrozole (ANA) with indicated concentrations. 
Cell proliferation was assessed after three days by counting cell numbers. *p < 0.05, **p < 
0.01, ***p < 0.001; unpaired t test. 
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        In order to examine response to LMW-E, we exposed inducible cells to doxycycline 
followed by treatment with aromatase inhibitors and assessed proliferation at two different 
short-term or long-term assays (3-day and 12-day experiment, respectively). For the 3-day 
experiment, the cells were exposed to doxycycline for one day to induce the transgene and 
then treated with AIs with/without doxycycline and AIs (letrozole or anastrozole) for three 
days. The cell proliferation assay showed that only LMW-E expression enabled the cells to 
overcome letrozole or anastrozole inhibition (Figure 10, A and B). Full-length and control 
(empty vector) cells showed inhibition of proliferation when exposed to letrozole or 
anastrozole (Figure 10, C and D).  
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Figure 10: LMW-E but not full-length cyclin E overcomes AI-mediated inhibition of 
proliferation. (A, B) Proliferation of LMW-E-inducible cells (T1 and T2) cultured in the 
absence of estrogen for 4 days, induced with/without doxycycline (Dox) for 24h and exposed 
to 25nM of androstenedione and/or 1μM of letrozole (LET) or 1μM of anastrozole (ANA). 
Cells were counted after 3 days of treatment. (C, D) Proliferation of empty vector (EV) or full-
length cyclin E (EL) inducible cells cultured and treated as in A and B. *p < 0.05, **p < 0.01; 
unpaired t test 
 
  
AN
A 
1u
M
D
O
X+
 A
N
A
AD
+A
N
A
D
O
X+
AD
+A
N
A
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
**
*
C
e
ll	
n
u
m
b
er
	
LMW-E	T1	
AN
A1
uM
D
O
X+
AN
A1
uM
AD
+A
N
A1
uM
D
O
X+
AD
+A
N
A1
uM
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
**
*
C
el
l	n
u
m
b
e
r	
LMW-E	T2	
A
C
e
ll	
n
u
m
b
e
r	
T1 inducible
Ve
hi
cl
e
D
O
X+
V
eh
icl
e
AD
D
O
X+
AD
LE
T
1u
M
D
O
X+
L
ET
1u
M
AD
+L
ET
1u
M
D
ox
+A
D
+L
ET
1u
M
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
**
*
LMW-E	T1		
T2		
C
el
l	n
u
m
b
e
r	
EXP29A-MCF7Ac1 T2C33 response to LET
Ve
hi
cl
e
D
O
X+
V
eh
icl
e
AD
D
O
X+
AD
LE
T
1u
M
D
O
X+
L
ET
1u
M
AD
+L
ET
1u
M
D
ox
+A
D
+L
ET
1u
M
0
1×105
2×105
3×105
4×105
5×105
C
e
ll
 n
u
m
b
e
r
**
*
LMW-E	T2		B
AN
A1
uM
D
O
X+
AN
A1
uM
AD
+A
N
A1
uM
D
O
X+
AD
+A
N
A1
uM
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
NS
	EL	
C
e
ll	
n
u
m
b
e
r	
Empty	vector	
EXP 28A Empty Vector C2 LET
Ve
hi
cl
e
D
O
X+
V
eh
icl
e
AD
D
O
X+
AD
LE
T
1u
M
D
O
X+
L
ET
1u
M
AD
+L
ET
1u
M
D
ox
+A
D
+L
ET
1u
M
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
C
e
ll	
n
u
m
b
e
r	 EV	
EL Letrozol
Ve
hi
cl
e
D
O
X+
V
eh
icl
e
AD
D
O
X+
AD
LE
T
1u
M
D
O
X+
L
ET
1u
M
AD
+L
ET
1u
M
D
ox
+A
D
+L
ET
1u
M
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
NS NSC
e
ll	
n
u
m
b
er
	 EL	
C
AN
A1
uM
D
O
X+
AN
A1
uM
AD
+A
N
A1
uM
D
O
X+
AD
+A
N
A1
uM
0
1×105
2×105
3×105
C
e
ll
 n
u
m
b
e
r
NS
C
e
ll	
n
u
m
b
er
	 EV	
D
 
 
91 
        Next, we extended these experiment by challenging the cells in a 12-day survival 
assay. To this end, we challenged the inducible cells and their parental control cells with 
estrogen deprivation followed by treatment with doxycycline and AI treatment. Results 
showed that 50% inhibitory concentration of letrozole was approximately 15-fold higher 
when LMW-E was expressed suggesting resistance to letrozole (Figure 11, A and B). In 
sharp contrast to LMW-E, overexpression of full length cyclin E or empty vector cells did not 
significantly affect response to letrozole under similar treatment condition to LMW-E (Figure 
11, C and D).  
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Figure 11: LMW-E but not full-length cyclin E improves survival of cells treated with 
letrozole. (A, B) LMW-E inducible cells were deprived of estrogen for four days, challenged 
with/without doxycycline for 24 hours and treated with androstenedione plus letrozole 
(increasing concentrations), followed by assessment of cell viability at day 12. (C, D) empty 
vector (EV) and full-length inducible cyclin E (EL) cells treated and assesses as in A and B.  
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2-3c LMW-E overcomes cell cycle inhibition of aromatase inhibitors   
        In order to understand mechanism of response to cyclin E induction, we assessed cell 
cycle when cells were treated with AIs under induced or un-induced conditions. For these 
experiments, we deprived the cells of estrogen, challenged with/without doxycycline in order 
to induce the transgene and treated with androstenedione and letrozole (or anastrozole) for 
three days. Flow cytometry analysis of the control cells revealed that androstenedione 
increased S phase percentage of the cells with concomitant decrease in G1 phase 
(compare second bar to first one) (Figure 12A). These cells respond to increasing 
concentration of AIs by arresting in G1 phase as shown by increase in G1 and decrease in 
S phases of cell cycle (Figure 12, A and B). Anastrozole or letrozole were both able to 
significantly inhibit S phase at 1μM concentration (Figure 12, A and B). We challenged 
inducible cells to the same concentration of AIs and assessed their cell cycle profile in the 
presence of absence of LMW-E. Results indicated that LMW-E expression overcome S 
phase inhibition of AIs (Figure 12, D and E). This response is attributed to LMW-E 
expression but not doxycycline, as doxycycline did not modulate response to AIs in control 
(empty vector) cells (Figure 12 C).  
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Figure 12: LMW-E expression overcomes AI-mediated cell cycle arrest. (A, B) 
Aromatase overexpressing MCF7 cells (control) were deprived of estrogen for total of four 
days and treated with androstenedione (AD, 25nM) and increasing concentrations of 
letrozole (LET) or anastrozole (ANA) followed by assessment of G1 and S phases by flow 
cytometry analysis. (C, D, E) empty vector (EV) or LMW-E inducible cells (T1 and T2) were 
estrogen deprived for four days, challenged with/without doxycycline for 24 hours, and 
treated with androstenedione (AD) with/without letrozole (LET) or anastrozole (ANA) at 1μM 
concentration. Cell cycle analysis was done following AI therapy at day 3. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001; unpaired t test.  
D
LMW-E	T1	
C
el
ls
	in
	S
	p
h
as
e
	(
%
)	
T2C33 
C
e
ll
s
 i
n
 S
 p
h
a
s
e
 (
%
)
T2
C3
3 v
eh
icl
e
T2
C3
3 D
Ox
+ v
eh
icl
e
AD
DO
X+
AD LE
T1
DO
X+
LE
T 1
AD
+L
ET
1
DO
X+
AD
+L
ET
 1
0
5
10
15
20
25
30
***
*
***
****
**
nsLMW-E	T2	
C
el
ls
	in
	S
	p
h
as
e
	(
%
)	
T1C2 
T1
C2
 ve
hic
le
T1
C2
 D
OX
+V
EH
IC
LE T1
C2
 A
D
T1
C2
 D
OX
+A
D
T1
C2
 LE
T 1
UM
 A
LO
NE
T1
C2
 D
OX
+L
ET
 1U
M
T1
C2
 A
D+
LE
T 1
UM
T1
C2
 D
OX
+A
D+
LE
T 1
UM
0
5
10
15
20
25
30
C
e
ll
s
 i
n
 S
 p
h
a
s
e
 (
%
)
***
**
*
**
*
C
el
ls
	in
	S
	p
h
as
e	
(%
)	
C
el
ls
	in
	S
	p
h
as
e	
(%
)	
E
AN
A
AN
A 
DO
X+
AD
+A
NA
AD
+A
NA
 D
ox
+
0
5
10
15
20
25
30
T1C2 cell cycle ANA
C
e
ll
s
 i
n
 S
 p
h
a
s
e
 (
%
) **
*
LMW-E	T1	
AN
A
AN
A 
DO
X+
AD
+A
NA
AD
+A
NA
 D
ox
+
0
5
10
15
20
25
30
T2 S phase ANA
C
e
ll
s
 i
n
 S
 p
h
a
s
e
**
NS
LMW-E	T2	
C
EVC2 S phase
C
e
ll
s
 i
n
 S
 p
h
a
s
e
 (
%
)
EV
C2
 Ve
hic
le
EV
C2
 D
OX
+ V
eh
icl
e
EV
C2
 A
D
EV
C2
 D
OX
+A
D
EV
C2
 LE
T 1
 um
 al
on
e
EV
C2
 D
OX
+L
ET
1u
M
EV
C2
 A
D+
LE
T1
uM
EV
C2
 D
OX
+A
D+
LE
T1
uM
0
5
10
15
20
25
30
EV	
A
C
el
ls
	in
	G
1
	p
h
as
e	
(%
)	
C
el
ls
	in
	S
	p
h
as
e	
(%
)	
G
0
G
1
 P
h
a
s
e
  
p
e
rc
e
n
ta
g
e
Ve
hic
le AD
 
AD
+L
ET
 0.
1u
M
AD
+L
ET
 1u
M
AD
+L
ET
 10
uM
0
20
40
60
80
*****
S
 P
h
a
s
e
 p
e
rc
e
n
ta
g
e
Ve
hic
le AD
 
AD
+L
ET
 0.
1u
M
AD
+L
ET
 1u
M
AD
+L
ET
 10
uM
0
10
20
30
**** ****
C
el
ls
	in
	S
	p
h
as
e	
(%
)	
S
 P
h
a
s
e
 p
e
rc
e
n
ta
g
e
Ve
hic
le AD
 
AD
+A
NA
 0.
1u
M
AD
+A
NA
 1u
M
AD
+A
NA
 10
uM
0
10
20
30
**** ***B
C
el
ls
	in
	G
1	
p
h
as
e	
(%
)	
G
0
G
1
 P
h
a
s
e
  
p
e
rc
e
n
ta
g
e
Ve
hic
le AD
 
AD
+A
NA
 0.
1u
M
AD
+A
NA
 1u
M
AD
+A
NA
 10
uM
0
20
40
60
80
*** *
 
 
95 
2-3d LMW-E overcomes cell cycle inhibition through up-regulation of G1 regulators. 
        To further study mechanism by which LMW-E bypasses the activity of aromatase 
inhibitors, we collected cell lysates from inducible cells and subjected them to Western blot 
analysis. Treatment of cells with androstenedione increased the level of G1 cell cycle 
regulators such as CDK2, pCDK2, Rb, and phospho-Rb proteins (lane 1 and 3, figure 13, A 
and B). Letrozole addition blocked induction of the aforementioned G1 regulators (lane 3 
and 7 figure 13, A and B). These findings are in line with G1 arrest following AI treatment as 
detected in our cell cycle analyses. However, LMW-E expression rescued AI-mediated 
inhibition by up-regulation of CDK2, pCDK2, and phosphorylated Rb protein (lane 1 and 2, 7 
and 8, figure 13, A and B). Similar findings were detected under treatment with anastrozole 
treatment. In vitro kinase assay also confirmed that letrozole inhibited CDK2 kinase activity 
while LMW-E overcome such inhibition (Figure 13C). These results show that LMW-E 
expressing cells have inactivated Rb protein as a tumor suppressor and thus are unable to 
arrest at G1 phase by either estrogen deprivation or aromatase inhibitor treatment. 
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Figure 13: LMW-E bypasses aromatase inhibitor inhibition through up-regulation of 
G1 cell cycle regulators. (A, B) LMW-E inducible MCF7AC1 cells were deprived of 
estrogen for 4 days, challenged with/without doxycycline for 24 hours followed by treatment 
as shown with androstenedione (AD; 25nM) with/without letrozole (LET; 1μM) or anastrozole 
(1μM) for three days. Western blot analysis was performed with antibodies as shown. (C) 
LMW-E (T2) cells were treated as in A, Cell lysates were immunoprecipitated (IP) using 
antibody against CDK2 followed by analysis of kinase activity using specific CDK2 substrate 
(GST-Rb). 
 
 
         
LMW-E	T1	
LMW-E	T1	
    Lanes   1   2   3   4   5  6   7   8 
LMW-E	T1	A
8	
B LMW-E	T2	 LMW-E	T2	
    Lanes   1   2   3  4  5  6  7  8   
 
C LMW-E	T2	
 
 
97 
We also validated our results using aromatase overexpressing T47D cell line that stably 
express LMW-E (T2) isoform (Figure 14A). Similar to MCF7 cells, we found that treatment 
with letrozole inhibited androstenedione-medicated proliferation (Figure 14B). However, 
LMW-E (T2) expression bypassed AI-mediated inhibition of proliferation and cell cycle arrest 
(Figure 14, C and D).  
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Figure 14: LMW-E expression bypasses AI-mediated inhibition of proliferation and 
cell cycle arrest in T47D cell line. (A) Representative Western blot analysis of aromatase 
overexpressing T47D cells that stably express empty vector (EV) or LMW-E (T2) isoform of 
cyclin E (B) Cell proliferation of aromatase overexpressing T47D-empty vector (EV) cells 
deprived of estrogen for 4 days followed by treatment with androstenedione (AD; 25nM) plus 
increasing concentrations of letrozole (LET) for 3 days. (C) Cell proliferation of empty vector 
(EV) or LMW-E (T2) cells deprived of estrogen for 4 days and treated with AD (25nM) 
with/without letrozole (1μM) for 3 days (D) S-phase percentage of empty vector and LMW-E 
(T2) expressing T47D cells treated as in C with letrozole or anastrozole (ANA) at 1 μM 
concentration. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired t test. 
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2-3e LMW-E-mediated resistance to aromatase inhibitors is reversible 
        To examine reversibility of LMW-E-mediated resistance, we challenged inducible 
MCF7AC1 cells with doxycycline to express LMW-E and then removed doxycycline followed 
by assessment of proliferation and cell cycle. To this end, we collected cell lysates before 
and after induction of LMW-E as well as every day following doxycycline removal for 7 days. 
Western blot analysis at different time intervals revealed that the level of LMW-E initiated to 
drop after 1 to 2 days of doxycycline removal and subsequent to that the levels of other G1 
regulators (such as CDK2, pCDK2, Rb and pRB) decreased at a later time (Figure 15A). 
Proliferation assay indicated the cells that were induced initially followed by doxycycline 
withdrawal (DOX removal) responded to letrozole similarly to the cells that were never 
induced (Dox –ve) (Figure 15B). In contrast, LMW-E expressing cells continued to show 
significantly higher proliferation when treated with letrozole (DOX +ve) (Figure 15B). Cell 
cycle analysis of LMW-E inducible cells under similar condition showed that doxycycline 
removal inhibited S-phase under letrozole treatment similar to un-induced cells (Figure 15C).  
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Figure 15: LMW-E-mediated resistance to AIs is reversible. (A) Representative Western 
blot analysis of LMW-E (T2) MCF7-AC1 cells deprived of estrogen for 4 days, challenged 
with/without doxycycline and treated with androstenedione (AD) plus letrozole throughout 
the experiment. Doxycycline was withdrawn from the media after induction; cell lysates were 
collected every day for 7 days and subjected to Western blot analysis. (B) MCF7A1C1 
LMW-E (T2) cells were cultured in estrogen-deficient media and treated as in A followed by 
counting cell numbers at indicated times. (C) LMW-E inducible cells were estrogen deprived, 
induced and treated as in A and B and subjected to cell cycle analysis at indicated days. 
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2-3f LMW-E mediated resistance to aromatase inhibitors is CDK2/Rb dependent 
       To further explore the role of cell cycle regulators downstream of LMW-E that contribute 
to resistance to AIs, we down-regulated CDK2 or Rb independently and examined response 
to treatment. We knocked down Rb and CDK2 using two independent shRNAs (Figure 16A) 
and examined response to letrozole under un-induced or induced conditions using Western 
blot analysis and flow cytometry analysis. Western blot analysis showed that under Rb-
knockdown condition, the cells respond to LMW-E by induction of CDK2 and pCDK2 (Figure 
16B). However, in contrast to scramble cells, LMW-E induction failed to induce Rb or 
phospho-Rb when CDK2 was downregulated (Figure 16B). Moreover, knockdown cells did 
not show enhanced S phase entry upon LMW-E expression as compared to scramble cells 
(Figure 16C). Collectively, our findings show that LMW-E mediated resistance is at least 
partially dependent on CDK2 to phosphorylate Rb allowing the cells to bypass G1 phase.  
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Figure 16: LMW-E mediated resistance is CDK2/Rb dependent: (A) Western blot 
analysis indicating downregulation of CDK2 or Rb in LMW-E (T2) inducible cells using two 
independent shRNAs. (B) Representative Western blot analysis of LMW-E (T2) inducible 
cells knocked down with shRNA targeting CDK2, Rb, or scramble (control), deprived of 
estrogen for 4 days, challenged with/without doxycycline (1ng/ml) for 24 hours, and treated 
with/without androstenedione (AD; 25nM) and letrozole (LET, 1 µM) for 3 days. (C) 
Comparison of S-phase percentage of LMW-E (T2) inducible cells, knocked down with 
shRNA, treated similarly to (B) and subjected to flow cytometry analysis. Results for two 
independent shRNAs are shown and compared to scramble. **p < 0.01, ***p < 0.001. 
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2-3g Tumors with LMW-E expression do not respond to letrozole  
        To determine responsiveness of LMW-E expressing tumors to AIs, we developed a 
model system by injecting inducible cells into mammary fat pad of 4-6 week-old nude mice. 
These mice were ovariectomized before the experiment and supplemented with 
androstenedione pellets that provide the precursor for estrogen production by the 
aromatase-overexpressing cancer cells. We randomized the mice to different treatments 
such that there were no differences in the average volumes at the initiation of therapy 
(average 150 mm3). Four treatment arms were considered; two control arms (vehicle and 
vehicle plus doxycycline) and two experiment arms (letrozole and letrozole plus 
doxycycline). Letrozole was injected subcutaneously and doxycycline was supplemented to 
drinking water throughout the experiment. We euthanized the mice and harvested tumors at 
the end of experiment when tumors reached the maximum size in the control arm (45 days). 
Tumor measurements revealed that letrozole treatment induced tumor shrinkage only when 
LMW-E was not expressed (Figure 17, A and B). In contrast, LMW-E expressing tumors 
showed continuous tumor growth in spite of letrozole treatment (Figure 17, A and B). The 
two control lines of the experiment showed similar tumor growth throughout the experiment 
(Figure 17, A and B). In addition, we collected cell lysates from the harvested tumors and 
subjected them to Western blot analysis using antibodies targeting G1 cell cycle regulators. 
Results confirmed LMW-E expression in tumors of the animals that received doxycycline 
(lanes 3,4,7,8 Figure 17C). Letrozole treatment decreased CDK2 and pCDK2 levels in 
tumors compared to vehicle treated mice (lanes 1,2 VS 5,6 Figure 17C). However, LMW-E 
expression rescued such letrozole-mediated inhibition by up-regulating CDK2 and pCDK2 
levels (Figure 17C). Immunohistochemistry analysis revealed cyclin E expression in the 
cytoplasm of the tumor cells when exposed to doxycycline representing LMW-E expression 
in these tumors (Figure 17D). LMW-E expression corresponded with higher cytoplasmic 
pCDK2 levels in tumors as well as higher proliferation as measured by Ki67 level (Figure 17, 
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D and E). Collectively, these in vivo experiments suggest that LMW-E expression make the 
tumors unresponsive to letrozole treatment.  
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Figure 17: LMW-E tumors are unresponsive to letrozole. (A) All nude mice were 
ovariectomized and injected with aromatase overexpressing MCF7AC1-T2 inducible cells in 
their mammary fat pad. All animals were supplemented with androstenedione pellets, and 
randomized to treatment arms; vehicle (hydroxypropyl cellulose) (n = 7), vehicle plus 
doxycycline (Dox) (n = 7), subcutaneous letrozole (LET; 10 μg/day; n = 9), or letrozole plus 
doxycycline (n = 6). Doxycycline (1 mg/ml) was added to drinking water to express LMW-E 
in the tumors. Tumor measurements were performed twice a week and tumor volumes were 
compared. (B) Representative tumors harvested from mice treated as in A at the end of the 
experiment. (C) Representative Wb indicating expression of cyclin E, CDK2, and pCDK2 in 
xenograft tumors (two tumors for each treatment arm) isolated from xenografts treated as in 
A. (D) Representative immunohistochemistry analysis of tumors isolated from mice treated 
as in A and stained with cyclin E, CDK2, and Ki67 antibodies. Three tumors from each 
treatment arm are shown. (E) Comparison of quantitative Ki67 levels from xenograft tumors 
isolated from mice treated as in A. percentage of Ki67 value for each tumor was measured 
by counting 200 cells from three different areas of each tumor and the average is shown for 
each arm. *p < 0.05, **p < 0.01. 
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        Studies have shown that constitutive activity of ER pathway or increased expression of 
aromatase enzyme contributes to resistance to anti-estrogens (207, 264). We performed an 
in vivo aromatase assay and quantitative PCR analysis to test whether these alternative 
pathways contribute to LMW-E mediated resistance in our model system. Results revealed 
that aromatase activity is inhibited by only by letrozole in a dose-dependent manner but not 
LMW-E (Figure 18A). In addition, quantitative PCR analysis of two main ER target genes 
(progesterone receptor and pS2) showed that the expressions of these two genes are only 
regulated by androstenedione or letrozole but not LMW-E (Figure 18, B and C). Our findings 
suggest that LMW-E regulates response of AIs mainly through deregulation of cell cycle.  
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Figure 18: LMW-E expression does not alter aromatase activity or ER mediated gene 
expression. (A) LMW-E (T2) MCF7AC1 cells were deprived of estrogen for 4 days, 
exposed to doxycycline for 24 hours, treated with letrozole for 4 hours and subjected to an 
aromatase activity assay using radio-labelled androstenedione as a substrate. (B, C) 
Quantitative PCR analysis of LMW-E inducible cells (T2), deprived of estrogen for 4 days, 
challenged with doxycycline (1ng/ml) for 24 hours, and treated with/without androstenedione 
(AD; 25nM) and letrozole (LET; 1 µM) for 3 days. Real-time RT-PCR analysis was 
performed using primers targeting progesterone receptor (PgR) and pS2 genes. ***p < 
0.001. 
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2-3h Dinaciclib but not palbociclib can inhibit proliferation of LMW-E expressing cells  
        The FDA has recently approved Palbociclib for advanced ER+ breast cancer patients in 
combination with AIs or Fulvestrant (363). We asked whether pharmacologic inhibition of 
cyclin dependent kinases by palbociclib or dinaciclib is effective to reverse LMW-E mediated 
resistance. Western blot analysis of T2 inducible cells indicated that LMW-E expression 
increased CDK2, and pCDK2 while it did not affect expression of CDK4 or CDK6 (targets of 
palbociclib) (Figure 19A). In addition, LMW-E expression increased CDK2 kinase activity 
while the activity of CDK4 kinase remained unchanged (Figure 13C and 19B). Next, we 
assessed responsiveness of the LMW-E expressing cells to dinaciclib and palbociclib using 
a survival assay. To this end, we estrogen deprived the cells for four days before the 
experiment and treated them with increasing concentrations of either dinaciclib or palbociclib 
under estrogen deprived condition and in the presence or absence of doxycycline. Cell 
survival analysis at day 12 revealed that LMW-E expressing cells were responsive to 
dinaciclib (Figure 19D), but unresponsive to palbociclib (Figure 19C). In contrast, full-length 
cyclin E did affect response to either dinaciclib or palbociclib (Figure 19, E and F). These 
results indicate that dinaciclib is a beneficial therapeutic strategy for the LMW-E cells 
compared to palbociclib. 
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Figure 19: LMW-E expressing cells respond to dinaciclib. (A) Representative Western 
blot analysis of LMW-E inducible cells deprived of estrogen, challenged with/without 
doxycycline (1 ng/ml) for 24 hours, and treated with/without androstenedione (AD; 25 nM) 
plus letrozole (LET; 1 µM) for three days using antibodies as indicated. (B) Representative 
kinase assay of LMW-E T2 cells treated as in A, cell lysates were immunoprecipitated with 
CDK4 antibody and subjected to kinase assay using CDK2 substrate (GST-Rb). (C, D) 
Representative results of cell viability assay using MCF7AC1-LMW-E (T2) inducible cells 
deprived of estrogen for 4 days, challenged with/without doxycycline (throughout 
experiment) and treated with palbociclib (6 days) or dianciclib (4 days). Drugs were removed 
afterwards and media was changed to drug-free estrogen-deprived media until the end of 
the experiment at day 12.  (E, F) Representative results from cell viability assay of full-length 
(EL) inducible MCF7Ac1 cells deprived of estrogen, induced, and treated with palbociclib or 
dinaciclib similar to C and D.   
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2-4 DISCUSSION  
       Two different forms of resistance are observed in BC patients who are treated with AIs; 
primary (de novo) resistance and secondary (acquired) resistance. In the primary resistance 
model, approximately 20% of patients show tumor proliferation is spite of anti-hormone 
therapy (193). On the other hand, acquired resistance develops overtime when patients are 
treated for a long period of time with AIs (132). In this study, we have examined primary 
resistance to AIs using in vitro and in vivo models as well as tumors isolated from patients 
undergoing neoadjuvant AI treatment. Our results indicate correlation between LMW-E 
expression and lack of response to neoadjuvant AIs. Patients who express LMW-E have 
higher chance of relapse from breast cancer. Our in vitro model system showed that AIs 
inhibited proliferation, induced G1 cell cycle arrest by decreasing CDK2, pCDK2, Rb and 
phospho-Rb levels. However, expression of LMW-E increased CDK2 activity and inactivated 
Rb protein allowing the cells to bypass G1 checkpoint. In line with these experiments, 
xenograft tumors with LMW-E expression were unresponsive to letrozole treatment.  
       Our models propose that deregulation of cell cycle is an initial process leading to 
activation of other signaling pathways that allow the cells to escape from AI treatment. For 
example, AI resistant cell lines show higher expression of aurora kinase A and B (two major 
regulators of M phase of cell cycle) and are more sensitive to aurora kinase inhibitors (355). 
These resistant cells were able to arrest at G2/M phase of cell cycle when treated with 
inhibitors of aurora kinase (355). Similarly, inhibition of PLK1 (a kinase involved in G2/M 
transition) inhibited proliferation of resistant cells and induced cell death in vitro (356). 
Moreover, combination of PLK1 inhibitor with fulvestrant showed synergistic activity in vivo 
(356). These studies suggest that cell cycle targeted therapies are valuable to be 
considered in combination with aromatase inhibitors.  
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       Results from recent clinical trials confirm the beneficial role of combination of cell cycle 
inhibitors with aromatase inhibitors. The combination of palbociclib with AIs in advanced 
HR+ BC patients has improved progression-free- survival (295, 296). A recently published 
study showed that palbociclib combined with anastrozole improved complete cell cycle 
arrest as defined by Ki67 less than 2.7% (364). However, anti-proliferative effect of 
palbociclib required continued treatment with palbociclib (364). In vitro studies suggest that 
the cells adapt to short-term (3 day) palbociclib treatment by sustained cyclin E2 expression 
and phosphorylation of Rb protein (365). This adaptation resulted in cell cycle progression 
through activity of CDK2. Moreover, examination of palbociclib resistant cells (long-term 
palbociclib treated cells) revealed cyclin E amplification as well as cyclin E1 overexpression 
at protein level in resistant cells (365). Consistent with these findings, our results indicate 
that deregulation of cyclin E pathway through LMW-E generation induce resistance to 
palbociclib. LMW-E expression results in higher CDK2 activity, inactivation of Rb protein 
through hyperphosphorylation of the protein. Therefore, the cells are not further arrested at 
cell cycle in spite of upstream inhibition of CDK4/6 by palbociclib.   
       Recently published data on patients treated with neo-adjuvant AIs revealed that patients 
who were resistant to aromatase inhibitors also showed poor response to chemotherapy 
(193). This suggests that additional therapies are needed for this subpopulation of patients. 
Our results show that breast cancer cells that are resistant to aromatase inhibitors respond 
to a CDK2 inhibitor dinaciclib. Sequential combination of a CDK2 inhibitor (roscovitine) 
followed by doxorubicin induced cell death in vitro and controlled tumor growth in vivo using 
TNBC cell lines (332). It is worth noting that such combination did not affect HMEC cells in 
vitro and was not toxic in animal models (332). A phase one study tested the combination of 
dinaciclib (starting dose of 20 mg/m2) followed by epirubicin treatment in 9 patients 
diagnosed with advanced breast cancer (349). However, this study was terminated due to 
toxicity of this combination including neutropenic fever, syncope and lower doses were not 
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further investigated (349). In hematologic malignancies, dinaciclib has reached an advanced 
level (366). In a phase III study, refractory chronic lymphocytic leukemia (CLL) patients 
received only dinaciclib (dose range 7 to 14 mg/m2 within each cycle) for a total of 12 
cycles. Overall response rate was detected in 40% of patients and the most common 
adverse effects included neutropenia (35%) and thrombocytopenia (20%) of cases (366). 
Monotherapy using dinaciclib was tested in relapsed multiple myeloma patients. Results of 
this study defined and the maximum tolerated dose of dinaciclib as 50 mg/m2 (higher than 
combination study in breast cancer) (367). In this phase 1/2 study, approximately 10% of 
patients showed partial response to dinaciclib treatment (367). Taken together, we propose 
that dinaciclib is a valuable drug to be considered in combination of aromatase inhibitors in 
HR+ breast cancer patients. 
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CHAPTER 3: CELL CYCLE DEREGULATION IN ACQUIRED RESISTANCE TO 
AROMATASE INHIBITORS  
3-1 INTRODUCTION  
       Escape from growth suppressors is one of the hallmarks of cancer. Therefore, inhibiting 
cell cycle dependent kinases could be a potential therapy against cancer cells. A few studies 
have shown the link between cell cycle deregulation and AI resistance (355, 356). Using a 
compound screen including 195 kinase inhibitors that can exclusively inhibit proliferation of 
AI resistant cells, Hole et al found aurora kinase A and B as potential targets (355). Western 
blot analysis indicates that AI resistant cells had higher aurora A and B kinase levels 
compared to parental cells. Aurora kinases are cell cycle regulatory proteins playing major 
role during mitosis (368). Functionally, aurora kinase A is involved in centrosome maturation 
and separation of chromosomes and aurora kinase B regulates cytokinesis (368, 369). Up-
regulation of aurora kinases is found in different cancers such as ovary, breast and thyroid 
cancers (106, 370, 371). Knockdown of Aurora kinases by siRNA or treatment with two 
aurora kinase inhibitors (Alisertib and Danusertib) resulted in higher inhibition of proliferation 
and G2/M arrest in AI resistant cells compared to parental cells. Results from this study 
suggest that a combination of aurora inhibitors with an anti-estrogen could be potentially 
effective to reverse AI resistance (355). In a similar study, the authors used two ER+ LTED 
models (MCF7 and HCC1428) and screened them with a library of inhibitory RNA that can 
target 720 different kinases. They measured output based on inhibition of cell viability as 
well as decreased ER activity in an ERE luciferase reporter assay. This screen detected 
polo-like kinase 1 (PLK1), a kinase overexpressed in G2 phase of the cell cycle, as the top 
target (356). LTED cells had higher PLK1 both at mRNA and protein level compared to 
parental cells and higher PLK1 mRNA level correlated with higher Ki67 in post-letrozole 
treated tumors isolated from 10 patients. Furthermore, inhibition of PLK1 by siRNA or by two 
different inhibitors in LTED cells suppressed proliferation, decreased ER transcriptional 
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activity, and induced apoptosis as measured by PARP cleavage and p-Histone H2AX. 
Lastly, a combination of fulvestrant with PLK-1 inhibitor (Volasertib) showed synergistic 
effect using both cell culture and animal model. 
       Dynamic alterations in cell cycle regulatory genes along with ER, PR and Her-2 
receptors have been detected in AI resistant cells (372). Expression levels of these markers 
were examined using two LTED model systems generated from parental MCF7 and BT474 
cell lines using IHC and qRT-PCR (372). Results revealed a dynamic pattern of ER 
expression throughout a 10 month culture in the absence of estrogen (372). They detected 
decreased expression of ER during the first 2-8 weeks of estrogen deprivation with re-
expression after 10 months both at mRNA and protein level. In contrast to this, In BT474 cell 
line ER level did not change during the first 8 weeks but decreased only after 10 months. 
However, consistent decrease in PR level was detected throughout estrogen deprivation in 
both cell lines (372). Comparison of microarray gene expression profile of these LTED cells 
at multiple time points revealed the highest down-regulation in genes that regulate cell cycle 
at an early phase (2 days and 6 weeks) with reversible expression pattern at a later phase 
(10 months). This suggests a concomitant dynamic change in the level of ER and genes that 
regulate cell cycle and further suggests that targeting components of cell cycle using 
available targeted therapies could be an effective strategy in resistant cells. A summary of 
studies showing the link between cell cycle and resistance to antiestrogens is shown in table 
4. 
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Table 4- Studies indicating a link between cell cycle components and resistance to 
anti-estrogens 
List of Genes Applied Model 
system 
Type of Anti-
estrogen resistance 
Reference 
Aurora kinase A and 
B 
Letrozole resistant 
MCF7 
Exemestane resistant 
MCF7 
Letrozole and 
Exemestane 
(355) 
Polo-like kinase 1 MCF7-LTED 
HCC1428-LTED 
Aromatase inhibitors (356) 
Cyclin B2, cyclin D2 
CDK6, CDC25C 
MCF7-LTED 
BT474-LTED 
Aromatase inhibitors (372) 
Rb protein Xenograft from Rb-
knockdown MCF7 & 
Rb-knockdown T47D 
Tamoxifen (373) 
Rb protein Tumor tissues from 
tamoxifen treated 
patients 
Tamoxifen (277) 
Phospho-CDK2 Letrozole resistant or 
tamoxifen resistant 
MCF7 
Letrozole &  
Tamoxifen 
(374) 
Cyclin E Transient 
overexpression of 
LMW-E 
Letrozole (357) 
Cell cycle signature Gene expression 
from AI resistant 
MCF7 vs parental 
Aromatase inhibitors (264) 
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3-1a Role of CDK2/Rb pathway in AI resistance 
        Cdk2-Rb pathway is the major regulator of cell cycle. The association between 
CDK2/Rb pathway and resistance to anti-estrogens has been the focus of a few studies 
(277, 373). Bosco and colleagues studied the link between Rb and tamoxifen resistance. 
Using Rb knock down cells, they show that ER+/Rb knocked down cells show higher 
proliferation in vitro. In addition, xenograft tumors generated from Rb knock-down cells 
become insensitive to tamoxifen therapy (373). In line with these findings, Rb dysfunction in 
patient samples is also linked to tamoxifen resistance (277). Lehn and colleagues examined 
tumor tissues from 500 post-menopausal breast cancer patients with or without adjuvant 
tamoxifen therapy (277). Rb dysfunction phenotype was detected in 17% of cases where 
Ki67 staining was high but phospho-Rb staining was low suggesting that these patients 
have either lost Rb or have a mutation in the gene. The role of CDK2 in breast cancer and 
its significance in resistance to AIs is not well studied. In one study, the authors generated 
letrozole and tamoxifen resistant derivatives of MCF-7 cell lines and found higher phospho-
CDK2 to CDK2 ratio in resistant cells (374). Treatment of these resistant cells with 
roscovitine decreased proliferation of cells, induced cell cycle arrest at G1 (letrozole 
resistant) or G2/M (tamoxifen resistant) phase of the cell cycle (374). Western blot analysis 
showed that roscovitine decreased phospho-CDK2 (T160), phospho-Rb (S795) and ERα 
levels. More importantly, roscovitine decreased tumor volume when these resistant cells 
were incorporated subcutaneously into nude mice. This study suggests that tamoxifen and 
letrozole resistant cells respond to roscovitine. However. It is important to mention that the 
concentration of roscovitine in this study was very high (20-30 μM). Another study in our lab 
using transient overexpression of LMW-E in MCF7 cells shows that the cells are able to 
bypass cell cycle arrest following letrozole treatment when LMW-E was overexpressed 
(357). However, the effect of LMW-E was abrogated when the cells were treated with a 
CDK2 inhibitor, roscovitine. Collectively, these finding implicate the role of LMW-E/CDK2 
 
 
117 
pathway in breast cancer suggesting that further studies are needed to explore the potential 
benefit of CDK2 inhibitors specifically in patients with LMW-E expressing tumors.  
 
3-2 MATERIALS and METHODS  
3-2a Generation of resistant cell lines:  
        We have developed two different model systems to study mechanism of acquired 
resistance to aromatase inhibitors. In the first model, we exposed aromatase overexpressing 
cells (MCF7AC1) to increasing concentration of individual AIs for at least 10 months before 
analysis. To this end, the cells were cultured in phenol-red free DMEM and charcoal-dextran 
treated FBS (Corning, Corning, NY) throughout the process and supplemented with AD 
(25nM) (Sigma-Aldrich (St. Louis, MO) and increasing concentrations of either anastrozole 
or letrozole (Sigma-Aldrich, St. Louis, MO). We maintained the cells in media containing the 
maximum tolerated concentration of the AIs (5uM) during the experiments. To generate 
control cells in parallel with AI resistant cells, we only supplemented the cells with AD 
(25nM) without addition of AIs. In addition, we generated another model by depriving the 
cells of estrogen for a long period of time (at least 9 months). This model system is known 
as long-term estrogen deprived model system (LTED), mimics acquired resistance to AIs, 
and is used in the literature to study acquired resistance to aromatase inhibitors. To study 
dynamics of changes in cell cycle profile of the cells, we froze and examined cells at 
different time points during the estrogen deprivation process. 
 
3-2b Cell proliferation and viability assay  
        To examine proliferation, equal number of cells were plated in 6-well plate and treated 
as indicated on each figure for three days. At the end of the experiment, we washed the 
cells in PBS, trypsinized, and counted using an automated cell counter (Biorad, Hercules, 
CA). For cell viability assay, we used the same HTSA assay as described in previous 
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chapter. Briefly, equal number of cells were plated in 96-well plates and allowed the cells to 
attach. Next, we treated the cells for a specific period of time with each drug as indicated on 
each figure, removed the drug, and cultured the cells in drug-free media to complete a 12-
day experiment. At the end of the experiment, we washed the cells using PBS, stained them 
with crystal violet, solubilized using the solubilizing solution, and measured density using a 
plate reader (Biotek, Winooski, VT).  
 
3-2c Cell cycle analysis  
        To study the cell cycle profile of the cells, we treated AI-resistant cells with different 
concentrations of AIs as indicated for three days and subjected them to cell cycle analysis 
as described in the previous chapter. To this end, we washed the cells in cold PBS, 
collected cells and maintained in 70% ethanol overnight at 4°C. The next day, the cells were 
precipitated by centrifugation, ethanol was removed and the cells were washed in PBS twice 
followed by centrifugation. Cells were stained with propidium iodide (10 μg/mL), 0.5% 
Tween-20, ribonuclease A (20 μg/mL) diluted in bovine serum albumin overnight at 4°C, 
incubated at 37oC and subjected to cell cycle analysis at MD Anderson Flow Cytometry 
core. To examine cell cycle profile of the LTED cells, we cultured cells that were frozen at 
different time points simultaneously, stained the cells similar to the condition described for 
AI-resistant cells, and subjected them to cell cycle analysis.  
 
3-2d Western blot analysis  
        AI resistant and LTED cells were treated as indicated on each figure. At the end each 
experiment, we washed the cells in PBS, harvested using trypsin, washed in cold PBS, and 
precipitated pellets by centrifugation. Cell pellets were lysed by addition of same volume of 
RIPA lysis buffet to the pellets followed by several occasional vortexing and ultra 
centrifugation for 45 minutes. We collected supernatant and measured protein level using 
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the Biorad assay. Thirty five microgram of protein was loaded on each lane of SDS-
polyacrylamide gel and subjected to electrophoresis followed by overnight transfer to 
immobilon P membrane (Millipore) at 35V in cold room (4°C). The next day, the membrane 
was blocked in BLOTTO milk for 30 minutes at room temperature and incubated with 
individual primary antibodies for 2 hours followed by multiple cycles of washes in TBST. 
Next, the membranes were incubated with appropriate goat anti-mouse or goat anti-rabbit 
secondary antibodies conjugated with horseradish peroxidase (Pierce, Rockford, IL) for 1 
hour at room temperature. After several wash cycles, we developed the membranes using a 
Renaissance chemiluminescence system (Perkin Elmer Life Sciences, Inc., Boston, MA) 
using the provided instructions of the company. Primary antibodies used for this assay 
included cyclin E (HE12), CDK2, and CDK6 (Santa Cruz Biotechnology, Santa Cruz, CA), 
phospho-CDK2 (Cell Signaling Technology, Danvers, MA), P21 (EMD Millipore, Billerica, 
MA), P27 (BD Biosciences, San Jose, CA), Rb and CDK4 (BD Pharmingen, San Jose, CA), 
pRb (S807/811; Cell Signaling Technology), aromatase (Biorad), actin (Millipore, Billerica, 
MA), and vinculin (Sigma-Aldrich).  
 
3-2e Scratch assay  
        LTED cells were cultured on 6-well plates and were maintained in incubator in order to 
form monolayers. Next, the cells were scratched with capturing the image of the monolayer. 
Plates were maintained in incubator followed by recapturing of the images at indicated times 
to measure the gap between the two layers.  
 
3-2f Establishment of xenograft model system  
        To assess tumorigenic potential of the cells, LTED and AI-resistant cells were injected 
into mammary fat pad of nude mice followed by examination of mammary tissue for tumor 
formation. To this end, 4-6 week-old nude mice were purchased from animal facility at 
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Experimental Radiation Oncology department of MD Anderson Cancer Center and were 
ovariectomized in order to deplete any endogenous source of estrogen. These animals were 
not supplemented with any exogenous source of androgen or estrogen to assess 
tumorigenicity under hormone independent condition. One week after recovery from 
surgery, 5×106 cells (parental MCF7 or LTED) were harvested, mixed with matrigel (1:1 
ratio) and injected into mammary fad pad (100ul total volume) followed by examination of 
mammary fat pad for tumor formation. In a similar experiment, we examined experimental 
metastasis model using LTED, LET-R and parental cells. To this end, 1×106 cells were 
injected via tail vein into 4-6 week female nude mice. The mice were sacrificed 30-40 days 
after injection, and lungs and liver tissues were collected for examination of metastasis.  
 
3-3 RESULTS  
3-3a Development of acquired resistance model to aromatase inhibitors  
        In order to characterize our model system, we challenged the cells that we cultured in 
the presence of AIs as well as the control counterpart to increasing concentration of both 
letrozole or anastrozole and assessed cell proliferation and survival. Cell proliferation 
analysis after 3-day treatment revealed that long-term cultured cells show significantly 
higher proliferation when challenged with either anastrozole or letrozole (Figure 20, A and 
B). In addition, a 12-day survival assay showed that long-term anastrozole-treated cells can 
tolerate 20 times higher concentration of the drug compared to control cells (IC50 4 M VS 
0.2 M, respectively) (Figure 20C). Similarly, long-term letrozole treated cells showed higher 
IC50 value when challenged with letrozole in a 12-day experiment (0.9 M VS 0.02 M 
respectively) (Figure 20D). These experiments suggest that long-term treated cells are 
resistant to individual aromatase inhibitors, further entitled as anastrozole resistant (ANA-R) 
or letrozole resistant (LET-R) cells in this chapter.  
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        To assess proliferation of LTED cells, we cultured LTED cells that had been frozen at 
different times simultaneously and measured cell proliferation after three days of culture in 
the estrogen-deprived media. Results indicated a trend toward higher proliferation overtime 
suggesting that the cells have adapted to estrogen deprivation situation (Figure 20E). We 
next injected LTED and control cells into mammary fat pad of nude mice and assessed 
tumor formation. These mice were ovariectomized before cell injection without any 
exogenous hormone supplementation throughout the experiment. Examination of mammary 
fat pad revealed that 12 out of 18 sites injected with LTED cells formed tumors (Figure 20F). 
In sharp contrast, none of the mammary fat pads injected with control cells formed tumors 
after two weeks. These experiments suggest estrogen-independent tumorigenesis in LTED 
cells. 
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Figure 20: Establishment of aromatase inhibitor resistance and LTED models. Long-
term anastrozole or letrozole treated cells and their control counterparts were deprived of 
estrogen and treated with androstenedione (AD 25nM) and anastrozole (1μM) or letrozole 
(1μM) followed by counting cell numbers after three days (A, B). Long-term drug treated 
cells were derived of estrogen and treated with androstenedione and increasing 
concentrations of individual AIs followed by cell viability assay at day 12 (C, D).  Parental 
and LTED cells, frozen at different times, were cultured simultaneously and assessed for cell 
proliferation by counting cell number after 3 days (E). Mice were ovariectomized and 
received an injection in mammary fat pad using LTED or parental cells and assessed for 
tumor formation at indicated times (F).  
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3-3b Deregulation of cell cycle in acquired resistance to aromatase inhibitors  
        To further investigate the mechanism of acquired resistance to AIs, we used available 
databases generated from the resistant cells and subjected them to Gene Set Enrichment 
Analysis (GSEA) analysis to identify the profile of resistant cells compared to sensitive cell 
lines (264). Results from our analysis revealed enrichment of cell cycle regulatory genes in 
the resistant cell lines indicating that cell cycle deregulation could be an important regulator 
of resistance (Figure 21A). To further characterize deregulation of cell cycle, we subjected 
our resistant cells and their control counterparts to cell cycle analysis. To this end, 
anastrozole and letrozole resistant cells as well as control cells were subjected to estrogen 
deprivation followed by treatment with AD and different concentrations of AIs. Cell cycle 
analysis revealed that control cells arrest at G1 upon treatment with AIs in a concentration 
as low as 0.1 μM (Figure 21, B and C). In contrast, the AI resistant cells failed to arrest in G1 
cell cycle upon treatment with the drugs. To further study the role of cell cycle, we compared 
G1 cell cycle regulatory proteins in resistant and control cell line using Western blot analysis. 
Results indicated that control cells responded to anastrozole by decreasing CDK2, Rb and 
phospho-Rb levels while these regulators remain unchanged in resistant cells (Figure 21 D). 
Collectively, our findings suggest that cell cycle deregulation is a key process in 
development of resistance to AIs. 
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Figure 21: Cell cycle is deregulated in acquired AI resistant cells. GSEA analysis 
indicating enrichment of genes regulating cell cycle checkpoint and phases in LTED cells 
compared to parental cells (A). Cell cycle analysis of AI-resistant and control cells deprived 
of estrogen for three days and treated with androstenedione (25nM) and increasing 
concentration of anastrozole (ANA,μM) or letrozole (LET,μM) for three days followed by cell 
cycle analysis (B, C). Western blot analysis of anastrozole resistant and control cells 
deprived of estrogen for three days and treated with increasing concentration of anastrozole 
with similar doses as in C (D).   
 
 
 
 
 
A	
D	
LET-R	Control	
Co
ntr
ol 
AD
 25
nM
co
ntr
ol 
AD
+L
ET
0.1
co
ntr
ol 
AD
+L
ET
0.5
co
ntr
ol 
AD
+L
ET
1
co
ntr
ol 
AD
+L
ET
2
LE
T-R
 A
D 
25
nM
LE
T-
R 
AD
+L
ET
0.1
LE
T-
R 
AD
+L
ET
0.5
LE
T-
R 
AD
+L
ET
1
LE
TR
 A
D+
LE
T2
0
20
40
60
80
100
C
e
ll
 c
y
c
le
 d
is
tr
ib
u
ti
o
n
 
SUBG1
G0/G1
S
G2/M
B	
LET(μM)	
Co
ntr
ol 
AD
 25
nM
co
nt
ro
l A
D+
AN
A0
.12
5
co
ntr
ol 
AD
+A
NA
0.5
co
nt
ro
l A
D+
AN
A1
co
nt
ro
l A
D+
AN
A2
AN
A-
R 
AD
 25
nM
AN
A-
R 
AD
+A
NA
0.1
25
AN
A-
R 
AD
+A
NA
0.5
AN
A-
R 
AD
+A
NA
1
AN
A-
R 
AD
+A
NA
2
0
20
40
60
80
100
C
e
ll
 c
y
c
le
 d
is
tr
ib
u
ti
o
n
 
SUBG1
G0/G1
S
G2/M
Control	 ANA-R	
C	
ANA(μM)	 ANA(μM)	
 
 
125 
3-3c Estrogen deprived cells show deregulated cell cycle pattern and respond to cell 
cycle inhibitors  
        To further study mechanism of cell cycle deregulation in AI resistant cells, we examined 
cell cycle profile of LTED cells at different intervals during estrogen deprivation process over 
both short-term (4 day) and long-term (5-9 months) culture. LTED cells that were frozen at 
different times were cultured simultaneously and subjected to cell cycle analysis. Results 
indicated that cells respond to short-term estrogen deprivation by arresting at G1 phase of 
the cell cycle compared to control cells, which is reversed after long-term derivation (Figure 
22A). Western blot analysis using the cell lysates collected from LTED cells at different 
intervals revealed that short-term estrogen deprivation decreased G1 regulatory proteins 
such as CDK2, Rb, phospho-Rb (Figure 22B). However, the levels of the aforementioned 
regulators increased significantly when they adapt to a low estrogen situation (5-7 months) 
(Figure 22B). In addition, examination of aromatase in the LTED cells showed increased 
level of aromatase in the resistant cells. ERα also showed a dynamic change in level along 
with cell cycle regulators. To further study the contribution of cell cycle regulation in AI 
resistance, we treated LTED and control cells with two cell cycle targeted therapies 
dinaciclib (CDK2 inhibitor) and MLN8237 (Aurora-A kinase inhibitor) and assessed cell 
viability using the HTSA survival assay. Results showed that LTED cells respond to these 
inhibitors as least at a similar dose to parental cells suggesting that these medications can 
be considered beneficial under context of AI resistance (Figure 22C). Our results presented 
in previous chapter showed that expression of LMW-E results in deregulation of cell cycle 
allowing the cells to bypass inhibition of aromatase inhibitors. In our LTED models we 
observed the generation of LMW-E as an acute response to estrogen deprivation (4-day) 
and after long-term estrogen deprivation (5-7 Months). In addition, using transgenic animal 
models of cyclin E, our lab has shown have LMW-E expressing tumors have higher invasive 
and metastatic potential (329). We asked whether LMW-E expressing LTED cells have 
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higher migratory potential compared to control cells. To this end, we used a scratch assay to 
compare the ability of control and LTED cells to fill the gap indicating their migratory 
potential. Results showed that LTED cells show higher migration compared to parental cell 
line at two different intervals of measurement (24h and 48h). Taken together, results from 
LTED model also suggest that deregulation of cell cycle, through up-regulation of G1 
regulators or generation of LMW-E, is associated with development of resistance.  
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Figure 22: Deregulation of cell cycle is associated with estrogen independence. LTED 
cells frozen at different time intervals were cultured simultaneously in estrogen-deprived 
media and subjected to cell cycle analysis (A). Western blot analysis of LTED cells at 
indicated times, cell lysates were analyzed by Western blot using antibodies as shown (B). 
Cell viability assay indicating sensitivity of LTED and control cells to CK2 inhibitor (dinaciclib) 
and Aurora-A kinase inhibitor (MLN8237). Cells were pleated in 96-well plates in estrogen-
deprived media, treated with indicated doses for 72h followed by culture in drug-free media 
until assessed at day 12 (C). Scratch assay comparing percentage of wound closure at 24h 
or 48h following scratch induction using LTED and control cells, representative image is 
shown (D).  
 
 
MC
F7
4 D
ay
s
5-
6
 M
o
nt
h
s
8-
9
 M
o
nt
h
s
0
20
40
60
80
100
C
e
ll
 c
y
c
le
 d
is
tr
ib
u
ti
o
n
 
SUBG1
G0/G1
S
G2/M
LTED	P 				Estrogen	deprived	media	
4day		1m				3m			5m			7m	P	
CDK2	
ERα	
Phospho-Rb	
Cyclin	E	
Ac n	
Aromatase	
Rb	
A	 B	
 
 
128 
        To further explore cell cycle deregulation in AI resistant cells, we subjected our AI 
resistant cells and control cells to treatment with/without AIs and examined major G1 cell 
cycle regulators in this model. Results indicated that in control cells, treatment with AIs 
decreased CDK2, phospho-CDK2, Rb, phospho-Rb, and p21 protein levels while cyclin A, 
CDK4, CDK6, and p27 remained either unchanged or elevated. In contrast, AI resistant cells 
did not show decrease in protein level of CDK2, phoospho-CDK2, Rb or phospho-Rb 
proteins upon drug treatment. Protein levels of CDK4, CDK6 and p27 increased in letrozole 
resistant cells upon treatment similar to control cells while CDK4 and p27 levels decreased 
in anastrozole resistant ones. Next, we asked whether ER or other signaling pathways such 
as PI3K contribute to deregulation of cell cycle machinery in AI resistant cells. To this end, 
cell lysates were collected from control and AI resistant cells following treatment with 
Fulvestrant (ER down regulator) or PI3K inhibitor (GDC0941) and subjected them to 
Western blot analysis (Figure 23B). Results indicated that Fulvestrant decreased Rb and 
phospho-Rb levels in both control and AI resistant cells while the levels of cyclin E and 
cyclin D were generally unaffected. In a similar fashion, inhibition of PI3K pathway resulted 
in down-regulation of Rb and Phospho-Rb suggesting that these two inhibitors could be 
beneficial in AI resistant cells by inhibiting Rb pathway. 
 
 
 
 
 
 
129 
 
 
  
Figure 23: Cell cycle regulatory proteins are altered in AI resistant cells. 
Representative Western blot comparing level of cell cycle regulators in AI resistant or control 
cells treated with vector, anastrozole (ANA 1 M), or letrozole (LET 1 M) for three days 
followed by Western blot analysis using antibodies as indicated on the figure (A). 
Representative Western blot indicating level of cell cycle regulators in control, anastrozole 
resistant cells (ANA-R), or letrozole resistant (LET-R) ones (B). Cells were treated with 
Vehicle (DMSO and methanol), Fulvestrant (1μM) or PI3K inhibitor (GDC0941, 1μM) for 24 
hours and followed by Western blot analysis.  
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3-4 DISCUSSION  
        In this study, we aim to understand mechanism of acquired resistance to aromatase 
inhibitors by focusing on cell cycle using two different model systems; LTED and cells that 
become resistant through long-term culture with AIs. Using these two model systems, we 
have shown that in contrast to control cell, resistant cells have deregulated cell cycle profile 
as they fail to arrest at G1. Specifically, we showed that resistance cells have higher levels 
of CDK2, Rb, phospho-Rb and LMW-E (LTED model) associated with deregulated cell cycle 
in comparison to sensitive cell lines. Our results presented in previous chapter indicated that 
LMW-E expression bypasses AI-mediated inhibition through a CDK2 dependent manner in a 
de novo setting. We further showed that inhibition of CDK2 by dinaciclib reverses resistance 
to AIs (de novo model). This signifies that targeting LMW-E/CDK2 pathway could also be a 
potential target in the acquired resistant setting. In fact, xenograft tumors derived from 
letrozole resistant cell lines showed response to roscovitine (CDK2 inhibitor) further 
supporting this hypothesis (374). 
        Using Western blot analysis on LTED cells derived from MCF7 cell line we indicated a 
dynamic change in the expression of ERα throughout estrogen deprivation process. In the 
acute phase the cells respond to estrogen deprivation by decreasing ER expression, 
however eventually ER expression returns to baseline following a few months of estrogen 
deprivation. These results are in line with previous studies using Immunohistochemistry and 
qRT-PCR to show down-regulation of ER in the acute phase of estrogen deprivation 
following up-regulation after 10 months (372). Evidence from patients treated with 
aromatase inhibitors indicates that these dynamic changes are also seen in tumor tissues 
isolated from breast cancer patients (375). Miller et al used microarray analysis on tumor 
tissues taken before and after 2 weeks of neo-adjuvant letrozole therapy and found 91 
down-regulated genes as a response to AI therapy mainly clustered in cell cycle progression 
category (375). One possible explanation for the acute response could be that the cells 
 
 
131 
switch dependence from ER pathway to other mitogenic pathways such as PI3K/AKT 
signaling pathway. For example, Her2 and ERBB3, as two tyrosine kinase receptors that 
active PI3K/AKT pathway, are up-regulated in letrozole resistant cells (376). In addition, 
treatment of xenograft tumors with an ERBB3 inhibitor (Seribantumab) delayed development 
of resistance to letrozole indicating dependence of tumors on this signaling pathway in 
response to AIs. On the other hand, up-regulation of ER level after long-term estrogen 
deprivation phase may suggest that the tumors enter a hypersensitive state in which they 
respond to very low levels of circulating estrogen in the plasma. This raises the question 
whether restart of anti-estrogen therapy after a gap of therapy in resistant condition may be 
beneficial in patients. In fact, letrozole resistant xenograft tumors showed a significant 
response to letrozole after a cycle of being taken “off” treatment suggesting that this could 
be a potential treatment strategy (377).  
        Studies using MCF7 cell line have shown that expression of ERα is synchronized with 
different phases of cell cycle suggesting a cell-cycle regulated process (378). In addition, 
exogenous expression of cyclin D even in the absence of estrogen is able to induce ER 
transcriptional activity (292). In vitro studies using immunoprecipitation assays showed direct 
association between cyclin D and ERα (292). On the other hand, in ER positive breast 
cancer cells, estrogen induces expression of cyclin D (379). In order to study the interaction 
between ERα and cell cycle under AI resistant condition, we treated resistant cells with 
Fulvestrant to down-regulate ER and subsequently detected down-regulation of G1 cell 
cycle regulators. This suggests that the beneficial effect of Fulvestrant in AI resistant setting 
could partially be attributed to cell cycle inhibition. 
        Our results indicated generation of LMW-E with higher migratory potential in LTED cells 
compared to the control cell line. Using mammary epithelial cells our lab has indicated that 
expression of LMW-E enriches cancer stem cell population upon serial transplantation and 
is linked with invasion. In addition, transgenic animals with LMW-E expression in mammary 
 
 
132 
tissues was linked with higher mammary tumor formation and metastasis (359). Our findings 
in LTED cells fit well with previous reports indicating up-regulation of EMT genes in LTED 
model (372). In addition, gene expression analysis of post-letrozole treated tumors revealed 
upregulation of mesenchymal markers such as VIM and MMP2 and enrichment of the 
cancer stem cell phenotype (248). These data suggest that the role of LMW-E and its 
significance in invasion and metastasis during the development of AI resistance needs 
further investigation. Experiments are undergoing to study biologic significance of LMW-E 
using cyclin E knock out model system in LTED cells.  
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CHAPTER 4: CONCLUSIONS, FUTURE DIRECTIONS  
4-1 MAJOR FINDINGS 
        HR positive breast cancer constitutes the majority of breast cancer patients, thus anti-
hormonal therapy is considered as an effective strategy for these patients. Aromatase 
inhibitors are currently considered as the standard of therapy in HR+ post-menopausal 
patients. However, resistance to these therapies develops and is considered a significant 
treatment challenge. Cyclin E is deregulated in breast cancer patients and correlates with 
poor survival. Thus, we hypothesized that expression of cyclin E contributes to development 
of resistance to aromatase inhibitors. The data presented in this dissertation addresses the 
following questions:  
1- Could Cyclin E be applied as a predictive marker of response to aromatase inhibitors in 
HR positive patients? 
        Immunohistochemistry staining of pre and post-treatment with neoadjuvant AIs 
revealed cytoplasmic staining of cyclin E, representing LMW-E, in about 50% of tumors. 
Additionally, LMW-E expression was associated with diminished tumor response (higher 
volume of remaining tumor), higher lymph node involvement, and increased breast cancer 
relapse. Examination of tumor tissues for phospho-CDK2 revealed direct correlation 
between expression of cytoplasmic phospho-CDK2 and cytoplasmic cyclin E as well as 
diminished response to AIs. 
2- Would the deregulation of cell cycle by LMW-E affect response to aromatase inhibitors in 
vitro? 
        Treatment with aromatase inhibitors was able to inhibit AD-induced proliferation and 
induce cell cycle arrest. In contrast, LMW-E expression enhanced proliferation of the cells in 
spite of AI treatment, bypassed cell cycle arrest, increased CDK2, phospho-CDK2, Rb, and 
phospho-Rb levels. 
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3- Is the effect of LMW-E/CDK2 pathway on response to aromatase inhibitors reversible? 
        One important feature of our system is its inducibility, where we can turn off cyclin E 
induction (deinduced) and examine response to AIs. Western blot analysis revealed that 
CDK2, phospho-CDK2, Rb and phosphor-Rb levels decreased after LMW-E expression is 
switched off. In addition, cell cycle analysis of these cells indicated that while LMW-E 
expressing cells showed significantly higher S phase, deinduced cells showed similar cell 
cycle pattern as uninduced cells. Moreover, down-regulation of CDK2 or Rb independently 
abrogated LMW-E medicated resistance to AIs suggesting that CDK2 inhibitors are potential 
therapies for LMW-E expressing tumors.  
4- Does LMW-E regulate response to aromatase inhibitors in xenograft tumors?  
        Letrozole treatment significantly induced tumor regression in xenograft tumors derived 
from aromatase overexpressing MCF7 cells. However, LMW-E expressing tumors showed 
significantly higher tumor volume when treated with letrozole. LMW-E expression in tumors 
was associated with higher expression of cytoplasmic CDK2 and Ki67 expression. 
5- Is dinaciclib or palbociclib effective to reverse LMW-E medicated resistance to AIs?  
        CDK2 level and CDK2 kinase activity increased upon LMW-E expression while CDK4 
level remained unchanged. In addition, LMW-E expressing cells responded to dinaciclib but 
not palbociclib.   
 
4-2 LIMITATIONS OF THE STUDY  
        One limitation of the current study is the overexpression of aromatase inside the breast 
cancer cells, whereas the main source of aromatase in women is peripheral tissues such as 
adipose tissue. In this model system, we deprived the cells of estrogen and provided them 
with androstenedione (estrogen precursor) that can be converted to estrogen by the activity 
of aromatase. While this system differs from the status of aromatase production in post-
menopausal women, it recapitulates the same phenomenon. Our data clearly show that the 
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cells respond to androstenedione and subsequently to letrozole or anastrozole treatment. In 
addition, clinical trials have confirmed similar results originally generated from this pre-
clinical model system indicating that it is a clinically relevant model (380).  
 
4-3 FUTURE DIRECTIONS  
        Our results indicated that LMW-E expression bypassed AI inhibition in vitro through 
deregulation of cell cycle. In addition, examination of tumor tissues from patients who 
received AIs in the neoadjuvant setting revealed that cyclin E and phospho-CDK2 
expression could predict response to AIs. LMW-E expression in tumors correlated with 
higher volume of remaining tumor, lymph node involvement, as well as higher relapse from 
breast cancer throughout the long-term follow up. Our in vitro results using cyclin E inducible 
model revealed that LMW-E mediated resistance is reversible by switching off cyclin E 
expression (doxycycline removal) or down-regulation of CDK2. In addition, LMW-E 
expressing cells responded to dinaciclib suggesting that targeting CDK2 is a potential 
therapy for LMW-E expressing tumors. One potential application of this project is to further 
investigate dinaciclib (or other clinically relevant CDK2 inhibitors) in animal models and in 
early phase clinical trials. We established a xenograft model of cyclin E expressing tumors 
using aromatase overexpressing cell line and indicated that LMW-E expressing tumors are 
unresponsive to letrozole. It is necessary to test whether dinaciclib can inhibit tumor growth 
in these LMW-E expressing tumors. Another strategy is to interrogate response to AIs after 
switching off LMW-E expression by removing doxycycline from the drinking water. It is 
speculated that LMW-E expressing tumors would shrink in response to combination of AI 
treatment and dinaciclib. In addition, we anticipate that tumors would regress when LMW-E 
is turned off upon doxycycline removal. 
        Another therapeutic application of this project is to use dinaciclib in early phase clinical 
trials for patients with LMW-E expressing tumors. Preoperative treatment with AIs in 
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selected ER+ breast cancer patients is a feasible approach to study response to treatment 
and identifying markers of resistance (190, 191). This alternative treatment approach has 
increased the chance of breast conservative treatment in HR+ post-menopausal patients 
with stage II/III disease (193, 381). Using this approach, we propose that patients with early 
resistance to AIs who express LMW-E be treated with dinaciclib in the neoadjuvant setting 
to assess tumor response before undergoing surgery. Analysis of the data from ACOSOG 
Z1031B trial revealed that only two out of 35 patients who were defined as resistant to neo-
adjuvant AIs (Ki67>10%) experienced pathologic complete response when underwent neo-
adjuvant chemotherapy suggesting that these patients were resistant to chemotherapy. 
Using immunohistochemistry analysis, we detected LMW-E expression in approximately 
50% of ER+ post-menopausal patients who received neoadjuvant AIs at MD Anderson 
Cancer Center as part of the Z1031 trial indicating that majority of these patients may be 
considered candidates for dinaciclib treatment. Dinaciclib as monotherapy has been shown 
to be safe and generally well tolerated in clinical trials (347, 350). Combination of dinaciclib 
with epirubicin, however was found to be toxic in TNBC patients (349). Further studies are 
required to study the efficacy of dinaciclib combined with AIs specifically in patients with 
LMW-E expressing tumors.  
        Another potential application of our findings that needs further investigation is use of 
dinaciclib in patients who are unresponsive or develop resistance to palbociclib. Addition of 
palbociclib to letrozole has shown to increase progression-free survival in HR+/Her2-
negative breast cancer patients (295, 296). In a case series study, we have shown 
unexpectedly rapid progression of breast cancer within four months upon discontinuation of 
palbociclib treatment indicating that alternative treatments are required (382). In addition, 
overexpression of cyclin E1 level through gene amplification has been detected in breast 
cancer cells that developed resistant to palbociclib in vitro (365). These results are in line 
with our findings that LMW-E expressing cells are unresponsive to palbociclib but respond to 
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dinaciclib (chapter 2). Thus, dinaciclib can be used in patients who progress on palbociclib 
or alternatively with palbociclib to prevent development of resistance to palbociclib.  
        In the third chapter of this project, we focused on understanding the mechanism of 
resistance to aromatase inhibitors in the acquired setting. To this end, we generated two 
model systems: LTED and ER+ cells that developed resistance to individual aromatase 
inhibitors in vitro. Further experiments are still undergoing using these two model systems in 
our lab, however our current data suggest deregulation of cell cycle in the acquired resistant 
setting. These two model systems are valuable tools to further explore resistant 
mechanisms to aromatase inhibitors.  
        Our preliminary results in the LTED model system showed higher tumorigenic potential 
of LTED cells when transplanted into mammary fat pad and higher migration potential in 
vitro. These results are in line with another study indicating higher invasion in LTED model 
system (383). Of particular note, we detected generation of LMW-E in the LTED cells 
compared to parental cells. In transgenic animal models, overexpression of LMW-E in the 
mammary tissue correlated with increased tumor formation and higher metastasis (329). In 
addition, in bladder cancer cell lines and human tissue samples, expression of LMW-E was 
associated with invasive phenotype and poor survival (384). Therefore, it is intriguing to 
study invasive potential of resistant cells using in vitro assays and an experimental model of 
metastasis through injection of resistant cells into tail vein followed by examination of 
metastatic sites (undergoing experiments). One experimental approach to address the 
significance of cyclin E in our model system is to knock out cyclin E using the Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) system (ongoing 
experiment) followed by examination of biologic effects using specific assays such as 
proliferation, invasion and metastasis. This system has been established in our lab and 
consists of two components including a guide RNA (gRNA) that can be designed to 
specifically recognize cyclin E sequence and a non-specific endonuclease (Cas9) that will 
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cut the specific sequence. This approach will help us investigate significance of cyclin E by 
knocking out cyclin E in experimental models.  
        Another field of research that needs further investigation is the role of CSC in mediating 
resistance to AIs. CSCs exist as a subpopulation of tumor cells with self-renewal capacity 
that can survive the pressure of chemotherapy or radiation (235, 236). In one study, 
examination of post-letrozole treatment tumors revealed enrichment of CSCs (248). One 
possible theory in the context of HR+ breast cancer is the existence of a subpopulation of 
ER-ve cells with stem cells features that are less dependent on estrogen to survive. These 
cells may silent ER expression upon treatment in order to survive anti-estrogen treatment. 
Indeed, in vitro analysis revealed that AI resistant cells showed higher Her-2 expression and 
treatment of resistant cells with anti-Her-2 therapy decreased population of cancer stem 
cells (249). In line with this, we detected a dynamic change in the expression of ERα 
throughout estrogen deprivation process reaching a nadir at 1 month after estrogen 
deprivation in LTED cells (see chapter 3). Therefore, understanding the role of cancer stem 
cells and targeting specific pathways that contribute to resistance could have therapeutic 
implication. Of particular note, we detected LMW-E expression in the LTED model that may 
play role in stem cell behavior of these cells. Introduction of LMW-E but not full length cyclin 
E into the hMEC doubled cancer stem cell population (CD44high/CD24low) and resulted in 
tumorigenicity when injected in vivo (328). Moreover, serial transplantation of the cells in 
vivo enriched the population of CSCs indicating the link between LMW-E and cancer stem 
cell phenotype. Therefore, the role of LMW-E in the mediating resistance to AIs needs 
further investigation.  
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4-4 SIGNIFICANCE  
        Almost 75% of all breast cancer patients express hormone receptor and thus require 
hormonal therapy. Aromatase inhibitors are considered the first line therapy in hormone 
receptor positive patients who already reached menopause. However, resistance to AIs is 
considered as a clinical challenge in treatment. In addition, specific biomarkers of response 
are required to identify resistant patients in the early phase of treatment. Herein, we show 
that cytoplasmic expression of cyclin E (LMW-E) and phospho-CDK2 can identify a subset 
of patients that are resistant to aromatase inhibitors. In addition, our results show that 
targeting CDK2 by dinaciclib is a potential therapeutic strategy to inhibit LMW-E expressing 
tumor cells providing evidence that dinaciclib has therapeutic implication in HR+ patients 
with LMW-E expressing tumors.  
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